Zkem 2 2013

. . .
SHEI Ternopil State Medical University

by I. Ya. Horbachevsky of MPH of Ukraine
Achievements of Clinical
and Experimental Medicine
Scientific and Practical journal
2(19) / 2 0 13
:
. .
. .
. .
. .
. .
. .
. .
. .
. .
. .
:
. . ()
. . ()
. . ()
. . ()
. . ()
. . ()
. . ()
. . ()
. . ()
. . ()
. . ()
. . ()
. . ()
. . ()
. . ()
. . ()
. . ()
. . ()
. . ()
. . ()
.. ()
. . (-)
. . ()
. . ()
. . ()
. . ()
. . ()
. . ()

(- )
2003 .
2 .
:
16983-5753 29.06.2010 .

. 1-05/3
14.04.2010 . ( , , ). Google Scholar.
:

. .
:

, 1
. , 46001
.:
(0352) 434956
(0352) 431133
: (0352) 524183
e-mail: journaltdmu@gmail.com

. .
( 5 29.10.2013 .)
.
.

.
.
, 1, . , 46001,

.
.
.
.
.
.
.
.
30.10.2013. 6084/8.
Pragmatica.
. . . . 34,64. .-. . 34,96.
600. . 13.

. .
, 1, . , 46001,
. 2013. 2

. . , . . , . .

I. M. Fushtey, O. V. Soloviov, Ye. V. Sid
STRUCTURAL HEART REMODELING IN ATRIAL FIBRILLATION PATIENTS ....................................................................... 12
. . , . . , . . , . .
-
-
. V. Abramov, . N. Karnaukh, . V. elnykova, H. I. Bessarab
FUNCTIONAL STATE OF LEU-ENKEPHALINERGIC SYSTEM OF HYPOTALAMIC ARCUATE NUCLEI
IN THE COURSE OF STREPTOZOTOCIN-INDUCED DIABETES IN RATS ..................................................................... 18
. .

H. V. Lykhatska
ASPECTS OF DIAGNOSIS OF ACID DISEASES .................................................................................................................. 21
. .

P. R. Selsky
SUBSTANTIATION OF EFFICIENCI TEST EXAMINATION AS AN IMPORTANT STAGE OF PREPARATION OF HIGHLY
QUALIFIED DOCTOR ..................................................................................................................................................... 24
. . , . .

N. V. Banadyha, Ya. V. Rohalska
MICROLEMENTS BALANCE IN CASE OF IRON-DEFICIENCY ANAEMIA IN CHILDHOOD ................................................. 2 8
. . , . . , . . , . .
, NO-

T. I. Bondarchuk, N. B. Panasyuk, L. P. Biletska, O. Ya. Sklyarov
CHANGES OF LIPID PEROXIDATION PROCESSES, NO-SYNTHASE SYSTEM AND ARGINASE ACTIVITY
IN PANCREAS OF RATS UNDER THE STRESS CONDITION ......................................................................................... 32
. . ,. . , . .

P. O. Vavrukh, Ya.Ya. Bodnar, H. P. Vavrukh
FEATURES OF CARDIOINTERVALOGRAPHY WITH CARDIOMYOPATHY UNDER CONDITIONS OF ENDOTOXEMIA ........ 35
. .

-
O. Ya. Vanchuliak
DIAGNOSTICS OF ACUTE CORONARY INSUFFICIENCY BY MEANS OF THE METHOD OF THE STATISTICAL
MULLER MATRIX ANALYSIS OF THE POLYCRYSTAL MYOSIN NETWORKS OF THE MYOCARDIUM ......................... 38
. . , . . , . .

O. P. Venher, O. Ye. Smashna, Yu. I. Mysula
INFLUENCE OF COGNITIVE DEFICIT ON SOCIAL FUNCTIONING OF PATIENTS WITH PARANOID SCHIZOPHRENIA
AND DIFFERENTIAL APPROACH TO ITS PHARMACOLOGICAL CORRECTION ............................................................ 43
. .

O. M. Vynohradova
USE OF MODERN ANTIMICROBIAL AND ANTI-INFLAMMATORY TOPICAL PREPARATIONS IN THE TREATMENT
OF INFLAMMATORY PARODONTIUM DISEASES ........................................................................................................ 47
. . , . .

O. V. Voytovych, O. M. Kamyshnyi
EFFECTS OF ANTHROPOGENIC POLLUTION ON MUCOSAL IMMUNITY ......................................................................... 5 0
. . , . .

P. A. Hasyuk, N. Ya. Kovtun
ULTRASTRUCTURAL ENAMEL AND DENTINE FEATURES OF HUMAN PREMOLARS ....................................................... 54
. .
-

N. O. Hevkalyuk
CLINICAL AND LABORATORY STUDY OF EFFICIENCY LICORICE ROOT IN THE TREATMENT OF INFLUENZA
STOMATITIS IN CHILDREN ........................................................................................................................................... 57
. 2013. 2
. . , . .

I. Ye. Herasymyuk, Yu. M. Havryshchuk
FEATURES OF BRAIN CIRCULATION IN RATS IN NORM ................................................................................................... 6 2
. . , . .

I. Ye. erasmiuk, T.I. Romaniuk
MORPHOLOGICAL AND FUNCTIONAL STUDY OF POLISORB PREPARATION AS EFFECTIVE MEANS
OF FIRST AID IN CASE OF CORNEAL ALKALI BURNS .................................................................................................. 6 8
. .

S. M. Heryak
CYTOKINE PROFILE IN PREGNANT WOMEN WITH METABOLIC SYNDROME .................................................................. 73
. . , . .

O. Yu. Huminska, N. A. Rykalo
PROSPECTS OF QUERTIN USE UNDER CONDITIONS OF CHRONIC DRUG HEPATITIS IN IMMATURE RATS ............. 76
. .

T. V. Huranych
CHANGES OF INDEXES OF LIPID METABOLISM IN RATS WITH HYPOTHYROID DYSFUNCTION
ON THE BACKGROUND OF COMBINED DEFICIENCY OF IODINE AND COPPER AND OPTIMIZATION
OF THEIR CORRECTION ............................................................................................................................................... 79
. . , . . , . .

2
K. M. Duda, B. V. Vons, I. M. Klishch
FEATURES OF CURRENT FREE RADICAL PROCESSES AND ANTIOXIDANT SYSTEM IN EXPERIMENTAL ACUTE
PARODONTITIS ON THE BACKGROUND TYPE 2 DIABETES ....................................................................................... 84
. . , . .
,
,
I. P. Katerenchuk, O. V. Mokhnachov
MORPHOLOGICAL AND FUNCTIONAL CHARACTERISTIC OF THE MYOCARDIUM IN PATIENTS ON ARTERIAL
HYPERTENSION COMBINED WITH UNSTABLE ANGINA, OBESITY AND DISTURBANCIES OF PURINS METABOLISM ... 9 0
. . , . . , . .

S. A. Kashchenko, O. N. Morozova, O. M. Petizina
RELATIONSHIP BETWEEN PARAMETERS OF SMALL INTESTINE PEYERS PATCHES RATS AFTER CORRECTION
BY IMUNOFAN OF IMMUNOSUPPRESSIVE STATE ..................................................................................................... 94
. . , . .

A. O. Kovalchyk, V. V. Demyanchuk
EFFECTIVENESS OF COMBINED USE OF ABSORBENT POLYURETHANE AND PRIMARY WOUND COVERAGE DURING
REALIZATION OF EARLY SURGICAL TREATMENT OF PATIENTS WITH BURN INJURIES. ........................................... 9 6
. .

M. F. Kovryha
HYSTOSTEREOMETRIC DESCRIPTION OF MYOCARDIUM IN CASE OF TOXIC LESION ............................................... 100
. .

M. A. Kolishetska
CONDITION OF PROOXIDANT AND ANTIOXIDANT SYSTEM IN THE LUNGS OF GUINEAS PIGS IN THE EARLY
PERIOD OF FORMATION OF EXPERIMENTAL BRONCHIAL ASTHMA ....................................................................... 103
. .

H. I. Korytskyi
CURRENT STATE OF ENDOCRINOLOGICAL SERVICES IN TERNOPIL REGION .............................................................. 106
. .

O. Ye. Kopacz
FEATURES GEMODYNAMIC LIVER DISORDERS IN THE DYNAMICS OF MECHANICAL INJURIES OF VARYING
SEVERITY WITH CHRONIC INTOXICATION OF COPPER AND ZINC SALTS ................................................................ 110
. 2013. 2
. . , . .

L. T. Kotlyarenko, O. Yu. Ruzhytska
MORPHOFUNCTIONAL FEATURES OF JEJUNUM HEMOMICROCIRCULATION IN EXPERIMENTAL ANIMALS
POISONED BY CADMIUM CHLORIDE ......................................................................................................................... 114
. . , . . , . .

A. S. Kubayev, A. A. Abdukadyrov, Sh. Sh. Yusupov
PECULARITIES OF RHINOMAXILLARY COMPLEX IN ADULT PATIENTS WITH UPPER MICROGNATHIA ......................... 117
. . , . .

R. D. Levchuk, I. M. Deykalo
ROLE LIPID PEROXIDATION AND ANTIOXIDANT DEFENSE IN THE PATHOGENESIS OF SMALL INTESTINE WALL
DEMAGE IN THE DYNAMICS OF CRANIO-SKELETAL INJURY .................................................................................... 120
. . , . . , . .
-

N. Ye. Lisnychuk, I. Ya. Demkiv, O. V. Chykhyra
ANTIOXIDANT PROTECTION FACTOR AS EFFECTIVE INDICATOR OF PRO AND ANTIOXIDANT PROCESSES IN
EXPERIMENTAL CARCINOGENESIS AND ITS SORPTION CORRECTION .................................................................. 124
. . , . .

L. M. Malanchuk, L. O. Krasnjanska
ARGUMENTATION OF USE OF METABOLIC IMMUNOMODULATOR IN EXPERIMENTAL-INDUCED ENDOMETRIOSIS
IN RATS ....................................................................................................................................................................... 127
. . , . .

V. P. Martsenyuk, D. V. Vakulenko
OPTIMIZATION APPROACH FOR THE STUDY OF MICROVASCULAR OF BRANCHING NODES ...................................... 131
. . , . .

N. V. Matsko, Yu. I. Bondarenko
H. PYLORI INFECTION IN THE DEVELOPMENT AND COURSE OF DISEASE PARODONTIUM TISSUES
IN THE GASTRODUODENAL ULCERS .......................................................................................................................... 137
. . , . .
-
, -
D. I. Merlyev, A. A. Hudyma
FEATURES PROOXIDANT ANTIOXIDANT STATE OF CORTICAL LAYER OF KIDNEY UNDER SKELETAL,
CRANIAL TRAUMATIC INJURIES AND THEIR COMBINATION .................................................................................... 140
. .
,

L. V. Nykolyshyn
INTERRELATION BETWEEN THE INDEXES OF THYROID SYSTEM, MICROELEMENT BALANCE AND ANTIOXIDANT
DEFENSE IN RATS WITH HYPOTHYROID DYSFUNCTION ON THE BACKGROUND OF COMBINED DEFICIENCY
OF IODINE AND SELENIUM AND IN CONDITIONS OF CORRECTION .......................................................................... 143
. . , . . , . .
-

. K. Onufrovych, R. V. Fafula, D. Z. Vorobets
STATE OF THE GLUTATHIONE ANTIOXIDANT SYSTEM OF SPERMATOZOA AT EXCRETORY TOXIC FORM OF MEN
INFERTILITY ................................................................................................................................................................. 148
. . , . . , . .

, ,

N. H. Ryndina, P. H. Kravchun, M. M. Mishyna
INDICATORS OF FERROKINESIS AS PROGNOSTIC MARKERS OF QUALITY OF LIFE IN ANEMIC PATIENTS WITH
CHRONIC HEART FAILURE COMBINED WITH CHRONIC KIDNEY DISEASE AND THEIR DYNAMICS UNDER
THE INFLUENCE OF THERAPEUTIC CORRECTION .................................................................................................... 152
. . , . . , . . , . . , . .

. . Savchuk, S. I. Klymnyuk, .V. Pkryshko,Yu. M. Andreychyn, N. . Krasiy
SOME FEATURES OF STOMATOPHARYNX MICROBIOCENOSIS IN PATIENTS WITH INFLUENZA AND SARS ............. 155
. 2013. 2
. .
IN VITRO

O. V. Sadlyak
SPECIFIC OF THE SYNTHESIS OF ENDOTHELICYTES OF NITROZOGLUTATION IN VITRO UNDER CONDITIONS
OF THE MODELING CHRONIC IMMUNOCOMPLEXEMI ............................................................................................. 159
. .

P. A. Sas
PATHOGENETIC ROLE OF LIPID PEROXIDATION IN KIDNEY DAMAGE ON THE BACKGROUND OF ACUTE
LUNG INJURY .............................................................................................................................................................. 162
. .

D. V. Semeniv
PHARMACOLOGICAL STUDY OF LIPID-LOWERING PROPERTIES OF ARONIAS SUBSTANCES ................................... 165
. . , . . , . .

. . , . . , . .
FEATURES OF RADIOGRAPHIC PICTURE OF BONE DEFECTS RESTORATION IN RATS JAW IN EXPERIMENT WITH
USING OF IMPLANTATION MATERIAL BASED ON HYDROXYAPATITE AND POLYLACTIDE ...................................... 169
. .

. Ye. Smashna
THERAPEUTICAL RESISTENCE OF NEUROTIC DEPRESSIVE DISORDERS OF NEUROTIC REGISTER AS A RESULT
OF VIOLATIONS OF COMPLIANCE .............................................................................................................................. 173
. . , . . , . .

Yu. V. Soroka, Yu. O. Kovalchyuk, O. M. Oleshchuk
FACTORS OF OXIDATIVE STRESS DEVELOPMENT IN INDUCED CANCEROGENESIS AND ITS ABSORPTION
CORRECTION .............................................................................................................................................................. 176
. .

N. R. Sokhor
APOPTOSIS OF THE WHITE BLOOD CELLS IN DIFFERENT SUBTYPES OF ISCHEMIC STROKE IN ACUTE PERIOD .... 181
. . , . . , . .

I. O. Sulkhdost, N. A. Shutova, M. O. ucheryavchenko
ACTIONS NONSELECTIVE BLOCKER OF NALOXONE OPIOID PEPTIDES ON THE STATE OF THYMUS ON THE
BACKGROUND OF INFLAMMATION ........................................................................................................................... 185
. .
SCORZONERA HISPANICA
M. F. Tkachenko
CHROMATOGRAPHIC-MASS-SPECTROMETRIC DETERMINATION OF VOLATILE COMPONENTS OF LEAVES
OF SCORZONERA HISPANICA .................................................................................................................................... 188
. . , . .
RORGT- -

. O. Topol, O. M. Kamyshny
INFLUENCE OF SOCIAL STRESS ON THE DISTRIBUTION OF RORT-EXPRESSED CELLS OF THE INTESTINEASSOCIATED LYMPHOID TISSUE OF THE RATS ....................................................................................................... 191
. .

O. I. Tuchak
METABOLIC CHANGES IN TISSUES OF CEREBRUM AND THYROID GLAND IN RATS WITH EXPERIMENTAL HYPOTHYROIDISM .. 196
. . , . . , . .

S. V. Ushtan, N. E. Lapovets, L. Ye. Lapovets
NONSPECIFIC IMMUNE PROTECTION IN THE MUCOUS AT THE UNCOMPLICATED FRACTURES OF THE MANDIBLE ..... 199
. .

O. Ye. Fedoriv
EFFECTS OF LEAD ACETATE ON THE BACKGROUND OF DRINKING WATER CONTAINING POTASSIUM AND SODIUM
STEARATES ON LIPID PEROXIDATION IN THE BODY OF EXPERIMENTAL ANIMALS ............................................... 2 0 2
. 2013. 2
. . , . . , . . , . . , . .
NO-/

I. S. Fomenko, V. Yu. Yemelyanenko, N. B. Panasyuk, L. P. Biletska, O. Ya. Sklyarov
INFLUENCE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS ON THE STATE OF NO-SYNTHASE/ARGINASE
IN THE COLON UNDER CONDITIONS OF STRESS ..................................................................................................... 207
. . , . .
-3

K. O. Shebaldova, K. M. Mishchenko
PHARMACOLOGICAL CORRECTION OF CARBOHYDRATE METABOLIC DISTURBANCES BY VITAGERM-3
IN ANIMALS WITH HYPOXIC SYNDROME ................................................................................................................... 210
. .

L. V. Shkrobot
LEVEL OF ENDOGENOUS INTOXICATION IN EXPERIMENTAL ACUTE ILEUS SIMULATION AND IN APPLYING
OF A NEW METHOD OF ITS CORRECTION ................................................................................................................. 215
. .

N. . Shutova
PATHOGENETIC ASSESSMENT OF THE CYTOCHEMICAL METHOD OF DETERMINATION OF EOSINIPHILS
FANCTIONAL ACTIVITY AT THE ACUTE INFLAMMATION ........................................................................................... 219
. . , . . , . .

O. Ya. Shuturma, N. Ye. Lisnychuk, . . Dovhalyuk

CIRCULATING IMMUNE COMPLEXES AND THEIR ROLE IN THE OCCURRENCE OF CONCOMITANT
PATHOLOGIES OF THE DIGESTIVE SYSTEM ............................................................................................................. 223
. . , . . , . .

L. V. Yakovlyeva, Yu. B. Laryanovska, I. V. Stefaniv
THE MORPHOLOGICAL STUDY OF THE INFLUENCE OF TINCTURE KASDENT ON THE STATE OF THE MUCOUS
MEMBRANE OF THE ORAL CAVITY IN RATS ON THE MODEL OF GINGIVITIS IN EXPERIMENT ............................... 2 2 6
. . , . . , . . , . .
-

Z. M. Yashchyshyn, L. M. Zayats, O. D. Svystak, V. H. Rohuzhynska
CHANGES IN MICROCIRCULATORY BED OF MUSCULAR-INTESTINAL NERVOUS INTERLACEMENT
OF GULLET AFTER THE RIGHT SIDE TRANSECTION OF TRUNCUS VAGOSYMPATICUS ......................................... 230
VI -

31 1 2013 .
. . , . . , . . , . . , . .

......................................................................................................... 234
. .

........................................................................................................................................... 235
. . , . . , . . , . .
................ 236
. . , . . , . .
- , ,
............................................................................. 236
. . , . . , . . , . .
NO-
...................................................................................................................................................... 237
. . , . .

.............................................................................................................................................................. 238
. 2013. 2
. . , . . , . .
-NO- ...................... 239
. . , . . , . . , . .

........................................... 239
. . , . . , . . , . .

......................................................................................................... 240
. . , . . , . .

........................................................................................................................ 240
. . , . . , . .
- ........ 241
. . , . .
- -
................................................................................................................................................ 242
. .
- ........................ 242
. . , . .

.................................................................................................... 243
. . , . .
................... 244
. .

- ........................................................................................... 244
. . , . . , . . , . .

.............................................................................................. 245
. . , . . , . . , . . , . .
-
................................................................................................................................. 246
. . , . .

2 ........................................................................................................ 246
. . -, . . , . . , . . , . .

........................................................................................................................................................ 247
. . , . . , . .

2 ............................................................................................................................. 248
. . , . .

......................................................................... 249
. . , . . , . . , . . , . .

.......................................................................................................................................... 2 5 0
. . , . . , . . , . .
............................................................................ 2 5 0
. . , . . , . . , . .
SHR
...................................................................................................................... 251
. . , . . , . .
,
............................................................................................. 2 5 2
. .
-
..................................................................................................................... 253
. . , . . , . . , . . , . .

........................................................ 254
. .

.................................................... 254
. . , . . , . . , . .

.......................................................................................................................................................... 2 5 5
. 2013. 2
. .

................................................................................................................................. 2 5 6
. . , . . , . .
-
........................................................................................................................ 257
. .

............................................................................................................................................. 257
. . , . . , . .

, - ....... 2 5 8
. .
-
........................................................................................................................................ 2 5 8
. .

, ................................................. 2 5 9
. . , . . , . .

............................................................................................................................ 2 6 0
. . , . .
-
........................................................................................................................................................... 261
. .
-
........................................................................................................................................ 2 6 2
. .
HELICOBACTER PYLORI
............................................................................................................... 2 6 2
. . , . .
- ...................... 263
. . , . .
M. GASTROCNEMIUS
................................................................................................ 263
. .

- ............................................................................ 264
. .
, -
..................................................................................................................................................... 2 6 5
. .
............. 2 6 6
. .
- ........................................................................................... 267
. .
, ....................... 2 6 8
. .

................................................................................................................................. 2 6 9
. . , . . , . . , . .

............................................................. 2 6 9
. . , . .

................................................................... 270
. . , . . , . .
..................................................... 271
. .

..................................................................................................................... 272
. .

.......................................................................................... 273
. .
4BL .................... 273
. 2013. 2
. . , . . , . .
- - .................. 274
. . , . . , . . , . .
....................................... 275
. .

....................................... 277
. .
................................ 278
. . , . . , . .

.......................................................................................................................................................... 279
. .

..................................................................................................................................................................... 279
. .
- ........................... 2 8 0
. .

.................................................................................................................... 281
. .

...... 2 8 2
. .

................................................................................................................................................................... 2 8 2
. .

.......................................................................................................... 283
. . , . .
-
....................................................... 284
. . , . .
: .. 2 8 5
. . , . .
NF-KB
................................... 2 8 6
. . , . .

.............................................................................................................................. 287
. . , . . , . . , . . , . . , . .

......................................................................................... 287
. . , . . , . .

.............................................................................................................................................................. 2 8 8
. . , . . , . . , . . , . .
NO-/
.......................................................................................................... 2 8 9
. . , . .
..................................................................................... 2 9 0
. . , . .

.................................................................................................................................... 2 9 0
. . , . . , ..

............................................................ 291
. . , . . , . . , . .
....... 2 9 2
. . -, . .
............................................... 2 9 2
. .
, ,
- 2007-2012 . ............................................................................ 293
10
. 2013. 2
. . , . . , . .

.......................................................................................................................................... 293
. . , . .

............................................................................................ 294
. . , . . , . . , . .
.................................................................................... 2 9 5
. . , . . , . .

............................................................ 2 9 5
. 2013. 2
11
, ,
616.125-008.313-07
. . , . . , . .

. () ,
11,5 % . 1884 . Engelmann T. ,
.
,
.
:
, . , ,
, , , . ,
.
,
.
. ,
. , ,
, , ,
.
( )
. , ,
. .
.
. ,
.
: , , ,
.
. () ,
11,5 %
[1, 2] .
,
,
, , [3].

5
2 , . 50 % ,
, 550 % [4]. 46 %
. , ,
, .
12

, -
. ,

[5].
XIX
, 1884 . Engelmann T.
,
[6].
Garrey W. 1914 . , , .
, ,
. 2013. 2
, ,
: 1)
, ; 2) re-entry [7]. 1925 Sir Thomas Lewis [8],
micro re-entry ,
[9, 10].
1959 . Moe G. Abildskov J.
micro re-entry
.
,
. , , [11].
Allessie .

[10, 12], .
Konings K. et al. .
micro re-entry
[13]. Ikeda T. et al.

re-entry, [14].

: , , , .
,
[15].

, , .
, , .
( 96 %) , ,
[16].
re-entry,
,
,
, ,

[17, 18]. Haissaguerre . et al.
, 35 %
,
[19].
,
. (re-entry). re-entry ,
[20].

,
,
.

[16],

.
, ,
.
, .

,

.

/ ,
, , ,
[21].
,
.

,
[22]. , , ,

. ,
[9].
re-entry,
, . ,
[22].
, -
. 2013. 2
13
, ,
[23].
:

[24].
, , ,
, , [9].
, [25]. , ,
[26]. , ,
L-
[27].
.

[28].

1995 . . MorilloC. et al. [29] ,
() 15 % . Wijffels . et al.
() ( 45 %),

[30]. , ,

, . ,
6 82 % 15 , 2 4 , 10 %
. 23
90 %
. ,
,
,
Atrial fibrillation begets atrial fibrillation [31].
14

,
,
, .
.
, -
, :
1) ( ); 2) , ; 3) ,
. ,
, ,
.
,
.
[32] [33].

, .
, , , ,
, , [34].
, ,
[35]. , , ,
,

,

[36].
,

[37].
contraction-excitation feedback (- ). ,
, / .
Zeng T. et al., , , [38].
Kamkin A. et al. ,
-
. 2013. 2
, ,

. ,
. , ,
, , ,
. ,
.
, .
,
,
[39].
. . . ,

,
,

, - ,
, , [40].
, ,
. ,
.

( ) .
, ,
-
. . . [41].
, .
[33].

, ( ), .

.
,

,
,

[42].
: -
.
.

, .

, , .
-
, ,

[3].
1. 2012 focused update of the ESC Guidelines for the

management of arterial fibrillation; An update of the 2012
ESC Guidelines for the management of atrial fibrillation;
Developed with the special contribution of the European Heart
Rhythm Association / A. J. Camm, Lip GYH, R. De Caterina
[et al.] // European Heart Journal. 2012. Vol. 33.
P. 27192747.
2. .. . , / . . , . . // .
2009. 18. . 2021.
3. ACC/AHA/ESC 2010 guidelines for the management
of patients with atrial fibrillation-executive summary /
A.J. Camm, P. Kirchhof, Y.H. Gregory [et al.] // Eur. Heart J.

2010. Vol. 31. P. 23692429.
4. Haft J.I. Echocardiographic and clinical risk factors for
atrial fibrillation in hypertensive patients with ischemic stroke /
J.I. Haft, L.E. Teichholz // Am. J. Cardiol. 2008.
Vol. 102(10) . P. 13481351.
5. .
/ . ., 2011.
159 c.
6.
/
. 2013. 2
15
, ,
C.., .. , .. [ .] // . 2009. 4. . 7886.
7. Garrey W. The nature of fibrillary contraction of the
heart: its relation to tissue mass and form / Walter E. Garrey //
Am. J. Physiol. 1914. Vol. 33. P. 397414.
8. Lewis T. The mechanism and graphic registration of
the heart beat / T. Lewis. London : Shaw & Sons, 1925.
529 .
9. Pathophysiological mechanisms of atrial fibrillation:
a translational appraisal / U. Schotten, S. Verheule, P. Kirchhof
[et al.] // Physiol. Rev. 2011. Vol. 91(1). P. 265
325.
10. Allessie M. A. Mechaninisms of initiation of atrial
fibrillation: implications for non farmocological treatment /
M. A. Allessie // Int. Cardiol. 2000. Spec. Issue. P. 3439.
11. Moe G. K. Atrial fibrillation as a self sustaining arrhythmia independent of focal discharge / G. K. Moe, J. A. Abildskov // Amer. Heart J. 1959. Vol. 58. P. 5970.
12. Allessie M. A. Electrical, contractile and structural
remodeling during atrial fibrillation / M. A. Allessie, J. Ausma,
U. Schotten // Cardiovas. Res. 2002. Vol. 54. P. 230246.
13. High density mapping of the right atrium during
acute and chronic atrial fibrillation in the goat / K. T. Konings,
M. Wijffels, R. Dorland [et al.] // PACE. 1999. Vol. 22.
P. 727.
14. Induction of mandering functional reentrant wave
front in isolated human atrial tissues / T. Ikeda, L. Czer, A. Trento
[et al.] // Circulation. 1997. Vol. 96. P. 30133020.
15. . .
/ . . ,
. . // . 2005. 26.
C. 3445.
16. Spontaneous initiation of atrial fibrillation by ectopic
beats originating in the pulmonary veins / M. Haissaguerre,
P. Jais, D. C. Shah [et al.] // N. Engl. J. Med. 1998.
Vol. 339, 10. P. 659666.
17. Prolonged fractionation of paced right atrial electrograms in patients with atrial flutter and fibrillation / Ching-Tai
Tai, Shih-Ann Chen, Jyh-Woei Tzeng [et al.] // J. Am. Coll.
Cardiol. 2001. Vol. 37(6). . 16511657.
18. / . . , . . , . . [ .] // . 2004. 1.
. 4349.
19. Haissaguerre M. Catheter ablation of atrial fibrillation:
targeting the triggers / M. Haissaguerre, D. C. Shah, P. Jais //
Catheter ablation of arrhythmias / Eds. Zipes D. P.,
Haissaguerre M. [2-nd ed.]. New York : Futura Pub. Co.,
2002. Ch. 5.
20. . . : ? / . . // . 2006. 44. . 5457.
21. Veenhuyzen G. D. Atrial fibrillation / George
D. Veenhuyzen, Christopher S. Simpson, A. Hoshiar // CMAJ.
2004. 171 (7). . 755.
22. Jousset F. Characterization of Atrial Repolarization
Alternans and Activation Time Kinetics based on Intracardiac
Electrograms / Florian Jousset // Ecole polytechnique de
lausanne, Suisse. 2011. 134p.
23. Prediction of conversion from paroxysmal to
permanent atrial fibrillation / M. Budeus, O. Felix, M. Hennersdorf [et al.] // Clin. Electrophysiol. 2007. Vol. 30 (2).
P. 243252.
16
24. Mauro Biffi. Atrial Remodeling: Evolving Concepts

Indian Pacing / Mauro Biffi, Giuseppe Boriani // Electrophysiol.
J. 2003. 3(2). . 81.
25. Atrial fibrillation and electrical remodeling: the
potential role on inflammation and oxidative stress /
P. Korantzopoulos, T. Kolletis, K. Siogas [et al.] // Int. J.
Cardiol. 2003. Vol. 91. P. 7579.
26. Electrical Remodeling of the Atria Following Loss of
Atrioventricular Synchrony : A Long-Term Study in Humans /
B. Sparks, G. Mond, K. Vohra [et al.] // Circulation. 1999.
Vol. 100. P. 18941900.
27. Van Wagoner D. R. Electrophysiological remodeling
in human atrial fibrillation / D. R. Van Wagoner // J. Cardiovasc.
Electrophysiol. 2003. Vol. 14. P. 803809.
28. . .

/ . . , . . ,
. . // .
2011. 4. . 1318.
29. Morillo C. A. Chronic rapid alrial pacing. Structural,
functional, and electrophysiological characteristics of a new
model of sustained atrial fibrillation / C. A. Morillo, G. J. Klein,
D. L. Jones [et al.] // Circulation. 1995. Vol. 91. P. 1588
1595.
30. Electrical remodeling due to alrial fibrillation in
chronically instrumented conscious goats: roles of neurohumoral changes, ischemia, alrial stretch, and high rate of
electrical activation / M. C. Wijffels, C. J. Kirchhof, R. Dorland
[et al.] // Ibid. 1997. Vol. 96. P. 37103720.
31. Atrial fibrillation begets atrial fibrillation: a study in
awake chronically instrumented goats / M. C. Wijffels,
C. J. Kirchhof, R. Dorland [et al.] // Circulation. 1995.
Vol. 92. P. 19541968.
32. ACC/AHA/ESC 2006 Guidelines for the Management
of Patients With Atrial Fibrillation. A Report of the American
College of Cardiology/American Heart Association Task Force
on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines / V. Fuster,
L. E. Ryden,D. S. Cannom [et al.] // Circulation. 2006.
Vol. 114. P. 257354.
33. Lip G. Management of atrial fi brillation / Gregory Y H
Lip, Hung-Fat Tse // Lancet. 2007. Vol. 370. P. 604618.
34. Is left atrial appendage occlusion useful for prevention
of stroke or embolism in atrial fibrillation? / C. Stollberger,
J. Finsterer, G. Ernst [et al.] // Kardiol. 2002. Vol. 91.
P. 376379.
35. Lopez-Candales A. Is the presence of interatrial septal
hypertrophy a marker for atrial fibrillation in the elderly? /
A. Lopez-Candales // Am. J. Geriatr. Cardiol. 2002.
Vol.11(6). P. 399403.
36. Correlates of left atrial size in hypertensive patients
with left ventricular hypertrophy: the Losartan Intervention
For Endpoint Reduction in Hypertension (LIFE) Study /
E. Gerdts, L. Oikarinen, V. Palmieri [et.al.] // Hypertension.
2002. Vol.39(3). P. 739743.
37. -

/ . . , . . , .. [ .] // . 2006. 44.
. 4448.
38. Zeng T. Stretch-activated whole cell currents in adult
rat cardiac myocytes / T.Zeng, G.C. Bett, F. Sachs //
. 2013. 2
, ,
Am. J. Physiol. Heart Circ. Physiol. 2000. Vol. 278(2).
P. 548557.
39. Machanelectric feedback in right atrium after
ventricular in arction in rats / A. Kamkin, I. Kiseleva,
K. D. Wagner [et al.] // J. Mol. Cell Cardiol. 2000.
Vol. 32(3). P. 465477.
40. . . / . . ,
. . , . . //
. 2001. .32. 2. . 5887.
41. . . - / . ., .. // . 2002. 1 (11). . 711.
42. Goette A. Electrical remodeling in atrial fibrillation.
time course and mechanisms / A. Goette, C. Honeycutt, J. Langberg // J. Circulation. 1996. Vol. 94 (11). P. 29682974.
STRUCTURAL HEART REMODELING IN ATRIAL FIBRILLATION PATIENTS

I. M. Fushtey, O. V. Soloviov, Ye. V. Sid
SI Zaporizhzhia Medical Academy of Postgraduate Education of MPH of Ukraine
SUMMARY. Atrial fibrillation (AF) - the most common form of cardiac arrhythmia, which occurs in the general population of 1-1.5 %,
and attracted the attention of many scientists to reveal the secrets of her origin. In 1884 Engelmann T. put forward the
hypothesis that AF is caused by the frequent formation of pulses in several ectopic atrial focuses.
AF can cause a variety of changes in the atrial myocardium, which contribute to the maintenance or recurrence of arrhythmia
this phenomenon has been called atrial remodeling in atrial fibrillation. Electrophysiological processes and restructuring
related: hypertrophy and dilatation of the left cardiac electrophysiological remodeling speed and vice versa. It is known that
the development leads to the AF and the cellular electrophysiological changes in the atrium, which in turn helps to preserve
AF, and subsequently causes electrophysiological remodeling. Found that electrophysiological remodeling affects the frequent
arrhythmias and recovery of AF. The main characteristics of this process is the shortening of the refractory period with
increased dispersion, reducing the level of adaptation, conduction disturbances on the atria. Echocardiographic studies have
shown that long-existing AF leads to atrial dysfunction. The atria and subsequently enlarge why restoring sinus rhythm atrial
contractility full recovery often takes time. Dilation of the left atrium can be both a consequence and a cause of AF. Structural
changes in the left ventricle, accompanied by his systolic and diastolic dysfunction, and as a result, increased pressure in the
left atrium with its subsequent dilatation are also factors that lead to the development of AF. In the process of remodeling of
cardiac myocytes in response to various factors first increase its size (more than typical concentric remodeling) and are
arranged in parallel in several layers. When eccentric remodeling increases not only their size, but also the length, there is an
increase of cardiomyocytes consistently and placing them in a small number of layers. The number of fibroblasts increases
significantly. The result is activation of the collagen matrix and its progression is beginning to prevail over its destruction.
Cardiac output is lowered.
Thus, the problem of the relationship of phase transitions and morphological functional state of the myocardium is still
relevant today.
KEY WORDS: atrial fibrillation, atrial electrical remodeling, dilatation of the left atrium, morpho-functional state of the myocardium.
. 2013. 2
17
, ,
615.212.7:[616.831.4:616.379-008.64]
-

. . , . . , . . , . .

.
() , -.
-. , -
, .
-, 23 , .
5 44 % 49 % .
: - 98 %, 80 %.
-
13- .
, -
.
: -, ,
. , - - -,
,

,
.

, ,
[14, 7, 9]. - ()

[3,4].
- ,
, .
-

.
. 22 - 250270 .
18
(SIGMA Chemical, ) 50/.

(6,00,2) / 2
(8,50,4) / 5
. 48

120 (SIGMA Chemical, ) 20
0,9 % NaCl. -
14 .
( = 7,4)
40 (T = 4-6 oC) - ( IgG 1:200, Amrsham, ).
45
( = 37 o) (1:64) IgG , FITC (SIGMA Chemical , ).

- (9:1).
VIDAS-386 (Zeiss-Kontron Elektronik, ).
VIDAS-2.5 (Kontron Elektronik, ),
-
. 2013. 2
, ,
, . (2), ( ), ,

- . - ,
. VIDAS -2.5
(Kontron Elektronik, ). -
t- .
.
,
()
-
() , (. 1).
,
(. 2).

-
(. 3).
1. , -, (Mm)

88
57348
##8
)#8
"692348
(737348
123452674829
7828
27887 8
278!87 8
$%8&8
'%8&8
##8&8
#'#8&8
: (*) p<0,05 .
2. - (), ()
(Mm)
9566
%338752
6

32552
6

6074
6
7035258956
123456789
35
33685752968 8166
3
32 6 756!6"#6 756$6"#6
&'()(*6
(,')!$6
&*-)!.46
!+*)!,6
(-&)$-6
('*)(+6
&.&)(.6
&'+)&&6
&**)(.6
!+')-(6
-+.)!+/6
(*!)((,/46
$'.-!6
-($*((/6
&!&+--+/46
8762
527
962366
3
32 6 756!6"#6 756$6"#6
(.,)'&!6
($*)'!$6
*,+)'$./46
!($)'!+6
!*$)'$.6
&!!)'$+/6
(&-)'(,/6
+.*)'++/46
&,()'(*6
!.-)'!-6
-!')'-!/6
&(&)'!*/46
($-6
-$'&/6
&&!-!/46
:
p<0,05 (*), 2- (#).
6
3. () - (Mm)
123456789
79
7 689
&7 8789
7 9
!9
%" !9
83999
" #9$9
'% ''9$9
83999
""% %!!9$19
'! 9$19
: p<0,05 (*), 2- (#).

,
, 2 2,5
3,5 .
, 35 %
58 % . ,
, ,
, 2,8 ,
.
5
- , ,
24 %, 2- ,
98 % 79 %.

-
, 43 % 49 % .
, 5- ,
44 %
. 2013. 2
19
, ,
. -
3,4
,
5,4 .
, , 8,3 , 12,6
.
,
-
. , - ,
- -
,

[18, 10].
. 1.
, -.
2. - .

-
.
1. . . -

/ . . , . . // -. . 2012. 3, .1. . 1114.
2. . . -
/ . . , . . //
. 2010. . 5, 3.
. 2730.
3. . . --
/ . . // . 2011. . 8, 2. . 2123.
4. . . -
/ . . , . . // .
2012. . 9, 3 (41), . 1. . 9193.
5 . .
/ . . ,
. . // . 2005. . 2, 3. C. 2023.
6. Dietary fat stimulates endogenous enkephalin and

dynorphin in the paraventricular nucleus: role of circulating
triglycerides / G.-Q. Chang, O. Karatayev, R. Ahsan [et al.] //
Am. J. Physiol. Endocrinol. Metab. 2007. Vol. 292:
P. E561E570.
7. STZ-induced diabetes decreases and insulin normalizes POMC mRNA in arcuate nucleus and pituitary in rats /
E. M. Kim, M. K. Grace, C. C. Welch [et al.] // Am. J. Physiol.
1999. Vol. 276, N5, Pt. 2. P. 13201326.
8. Participation of various divisions of the hypothalamus
in the pathogenesis of experimental diabetes in rats /
Yu. M. Kolesnik, A. V. Abramov, G. V. Vasilenko, V. A. Zhulinskii // Neurosci. Behav. Physiol. 1996. Vol. 26, No.4.
P. 365371.
9. Diabetes increases the expression of hypothalamic
neuropeptides in a spontaneous model of type I diabetes,
the nonobese diabetic (NOD) mouse / F. E.Saravia,
S. L. Gonzalez, P. Roig, V. Alves [et al.] // Cell. Mol. Neurobiol.
2001. Vol.21, N1. P.1527.
10. Swanson L. W. Hypothalamic integration: organization
of the paraventricular and supraoptic nuclei / L. W. Swanson,
P. E. Sawchenko // Ann. Rev. Neurosci. 1983. V. 6.
P. 269324.
FUNCTIONAL STATE OF LEU-ENKEPHALINERGIC SYSTEM OF HYPOTALAMIC

ARCUATE NUCLEI IN THE COURSE OF STREPTOZOTOCIN-INDUCED DIABETES IN RATS
. V. Abramov, . N. Karnaukh, . V. elnykova, H. I. Bessarab
Zaporizhzhia State Medical University
SUMMARY. The distribution of the neurons that synthesize leu-enkephalin in subnuclei of arcuate hypothalamic nuclei (ARH)
was studied in the course of experimental diabetes in the rats with the help of immune fluorescence method. The neurons
morphometric characteristics and qualitative indices of leu-enkephalin accumulation were studied. It was established that
normally leu-enkephalin is synthesized in solitary cells of ARH, mainly of dorsomedial subnucleus. In diabetes expression of
leu-enkephalin in ARH rises, the number of neurons that synthesize it increases in 2-3 times. In 5 weeks after diabetes onset
the content of leu-enkephalin in ventrolateral subnucleus of ARH is increased by 44 % in neurosecretory cells and by 49 %
in their axons. In dorsomedial subnucleus of ARH these indices are more impressive: leu-enkephalin content in neurosecretory
cells is increased by 98 % and in axons by 80 %. The intensification of leu-enkephalin synthesis and secretion in ARH
subnuclei is accompanied by almost 13-times increase of neuropeptide content in hypothalamus medial eminence. The
obtained data evidence about the active participation of leu-enkephalinergic hypothalamic system in neuroendocrine response
of the organism to diabetes mellitus development.
KEY WORDS: leu-enkephalin, diabetes mellitus, hypothalamus.
20
. 2013. 2
, ,
616.33-002.1/4-072.1/2

. .
. .
. .
Helicobacter pylori.
: , , Helicobacter pylori.
. 1874 W. Bottcher .
, ,
.
1982
Helicobacter pylori (Hp). 1983
, , , .
. (1987 .).

. () - , -
,
() , (), , , -, .
Hp [1].
() , , . Hp
,
,
[1].
. Hp

(. 1) .
70 % ,
[2, 3]. 1. Hp
1234567

5235377
26377
26377
77
!"537#2$%377
&3"537#2$%377
!(71353377
92377
87539

557
7
7
7
7
'7
'7
)7
7080 % [4], 6490 %,

7080 %.
[5] , , , MAL,T .
(. 1): ,
()
()
[6, 7, 8].
111,
[9].

Hp.
1. Hp
, .
2. Hp ,
, ,
(g A, Vac A) 1
(IARC, 1994).
3. () H :

;

;
;

.
4. / H
,
.
.
() :

-, ,
.
. 2013. 2
21
, ,
1
12345677
589
436 67
7
1
1
2345674321
1
1
382345674321
9
21
11
11
1
389
21
!"11
"1
1
#!"#$1
" 1
. 1. .
: - , .
- .
:
- .
-
Hp.
: (, LO-, -, -, URE-).
Hp .
Hp .
.
:
13 ( ) 14 , .
() : IgG, IgA; -
.
-
( : ,
, , ).
Stool test .
1 .
Hp
2
1 . p (CLO- .)
Hp.
22
H
Hp , , , , Hp. ,
.

[10, 11].
: (, ), , ,
, .
[11, 12].
-.
,
Ig A i G ,
.
:
1. .
2. -

.
:
( ): 13 , ;
Stool test (, );
.
111 1V

Hp -

[13,14]. 4-6 .
. 2013. 2
, ,
. 1. .
2.
Helicobacter pylori
: 13-
.
, .
1. . .

/ . . . // . , , . 2012. 3
(25). . 1215.
2. Helicobacter pylori un developing countries World
Gastroenterology Organisation Global Guideline / Hunt R. H.,
Xiao S. D., Megrand F. [et. al.] // J. Gastrointestion, Liver
Dis. 2011. Vol. 20, 3. . 299304.
3. Epidemiology and diagnosis of Helicobacter pylori
infection / Tonkic A., Tonkic M., Lehours P., Megrand F. //
Helicobacter. 2012. Vol. 17, Suppl 1. P. 18.
4. . . Helicobacter pylori - / . . ,
. . , . . // , . 2011. 4. . 8488.
5.
/ . . [ .] // .
2008. 1 (39). . 46.
6. . .
( TE ST H. Pylori
Ag) // . 2010. 4 (6), 2. . 5052.
7. . . , Helicobacter pylori / . 2011. . 92, 2. . 257261.
8. Rajindrajinth S. Helicobacter pylori infection in children /
S. Rajindrajinth, N. M. Devanarayana, V. H. Silva // Saudi J.
Gastroenterol. 2009. Vol. 15. 2. . 8694.

9. Current concepts in the management of Helicobacter
pylori infection: The Maastricht 111 concensus reports /
P. Mathertheiner, F. Mtgaranek, C. O. Morain [et al.] // Gut.
2007. Vol. 56, 6. . 772781.
10. . .
/
. . , . . // . 2008. 4 (42). . 4851.
11. . . elicobacter
pylori: / . . , . . // . 2008. 1 (39).
. 5561.
12. . . / . . // . 2008. 19 (1). . 14.
13. . . Helicobacter
pylori Helicobacter pylori
/ . . // .
2012. 2. C. 3236.
14. Helicobacter pylori ( 1V , 2010) / . . , . . , . . , . . // .
, , .
2012. 3 (25). C. 33.
ASPECTS OF DIAGNOSIS OF ACID DISEASES

H. V. Lykhatska
SHEI Ternopil State Medical University by I.Ya. Horbachevsky of MPH of Ukraine
SUMMARY. The article adduced the modern points of leading scientists concerning the diagnostics of acid disorders.
Special attention is focused on the invasive and non-invasive methods of detection of Helicobacter pylori.
KEY WORDS: diagnosis, acid disease, Helicobacter pylori.
. 2013. 2
23
, ,
371.27:001.891.5

. .
. .
.
. . .
.

.
: , , .
.

, [15].
, , ,

[6].
. .
. .

.

.
.
MS Excel
(Microsoft Office 2003).
.

. .
() 139
01.06.2006,
, 2006/2007

(). (),
[7]. 24

.
- 2008 -
() .

()

( 1 ),

. 600 . 1 2 (
3 ). 33,5 .
8 .

, ,

-3. . ( , ).
.
300,
( 0,05 %).
-
(
1 15 ).
,
.

. , - , 24
. 2013. 2
, ,
48 ,
( , ). i- i,
.
,
(
32268) [8].
FormReader.
.

,
.
() , .
.
. ,
( ),
, .
.

. ,
2011/2012
235 1 (5,090,37) .
341 - 2
(>0,05) (5,590,23) .
269 3 ((7,400,24) ) , 1 2 (<0,05). 4
(201 ) (7,790,16) ,
3 (>0,05). 5 (234 )
((8,450,24) ),
(4 ) (<0,05) 237
6 ((8,400,11) ) (>0,05). ((7,090,18) ),
,
((7,710,07) ) (<0,05), 1 12- .
-

(r=+0,7). ,
1 ((7,660,22) ) 2 ((7,370,14) ) ,
(<0,05), 3
(3 (7,820,20) , 4
(7,760,15) , 5 (8,040,10) , 6
(7,670,12) )
(>0,05). C , ((5,020,50) )
((4,500,48) )
(<0,05).

2011/2012 .. 1 (5,720,28) .
2
(>0,05) (6,260,17) .
3 ((7,300,30) ) ,
1 2 (<0,05). 4 (6,300,30) ,
3 (<0,05)
1 (<0,05). 5
((8,240,16) ),
(4 ) (<0,05). 6 ((6,100,30) )
, 5 (<0,05) 4 (>0,05).

(<0,05), (1
(6,680,27) , 2 (7,180,18) ,
3 (8,170,12) , 4 (7,850,11) , 5
(8,080,09) , 6 (7,700,10) ),
12 12
.

(r=+0,5) .
, ((6,850,13) ), , ((7,820,06) ) (<0,05), , (>0,05).
C ,
((5,730,25) ) ((5,010,33) ) (<0,05).
262 3 , ,
. (r=+0,6)
,
(>0,05).
. 2013. 2
25
, ,
2011/2012
, (<0,05),
3 (1 (5,390,24) ,
2 (5,930,15) , 3 (7,340,20) ,
4 (6,840,24) , 5 (8,320,14) ,
6 (6,900,29) ).
- -

(r=+0,6).
(r=+0,6).
,
, ,
(<0,05),
3
1-2 1 5 .
. 1. -,
, 2011/2012 .. * <0,05 .
2010/
2011 (<0,05 ) 2 (1
(4,810,35) , 2 (6,870,17) , 3
(7,270,20) , 4 (7,980,19) , 5
(8,320,17) , 6 (9,050,20) ).
1, 3
5 (>0,05),
1 5 . - (r = + 0,7).
, 2011/2012 , : 1 1,13 %, 2 1,41 %, 3
3,23 %, 4 4,59 %, 5 5,54 %, 6 4,69 %.
.
26
, , . ,
, ,
.

,
,
, ,
3 1 1 5 12 . , ,
- .

3-6
2011/2012 .. 1
,
. 2013. 2
, ,

.

(2010/2011 .. 2011/2012 ..).
(+0,6)

,

(+0,6) i. -
, ,
.
,
,
,
.
.

-.
1. . . / . . . . :
- , 1995. 168.
2. . . / . . , . . . . : - , 2003. 616.
3. EpsteinR. M. Assessment in Medical Education /
R. M.Epstein // The New England Journal of Medicine.
2007. 1 . P.356 387.
4. NorciniJ. J. The death of the long case? / J. J. Norcini //
British Medical Jornal. 2002. 324 (7334).
P.408409.
5. The quality of in-house medical school examination /

R. F. Jozefowicz, B. M. Koeppen, S. Case, R. Galbraith //
Acad. Med. 2002. Vol. 77, 2. P. 156161.
6.
. . :
, 2006. 35.
7.
. /
. . . . : , 2006. 290 .
8. C . .
: .. . : 01.05.03 /
. , 2011.
218 .
SUBSTANTIATION OF EFFICIENCI TEST EXAMINATION AS AN IMPORTANT STAGE

OF PREPARATION OF HIGHLY QUALIFIED DOCTOR
P. R. Selsky
SUMMARY. The experience of the innovative assessment methods implementation in Ternopil State Medical University by
I.Ya. Horbachevsky was revealed. The testing procedure using multiple-choice questions in the form of answer sheet tests
and subsequent automatic processing of the results was highlighted. According to the evaluation of the students results, the
quality and objectivity of complex semester test examination was substantiated.
KEY WORDS: innovative methods, test assessment, complex semester test exam.
. 2013. 2
27
, ,
612.015+616.155.194-053.2

. . , . .
. .
. ,
. ,
, .
. 64
6 3 . , ,
;
.
, .
: , , , , .
. ,
[1, 2].
( -). ,
( ) , ; ,
,
,
; ,
. , ,
, , , ,
, -
. , : , , ,
. ,
[3, 4].
(). , .
, , [5], :
-
, , 28
, -2.

[6, 7]; .

,
, [811], ( ) .
:

.
. 64 3 ,
.
20 ,
, .
: , (, ),
; [12].

9 10.01.2005 . [13].
[14].
. 64 6
3 . (37,5%) (34,4 %) -
. 2013. 2
, ,
. ,

( ).
, , , ,
,
. ,
, .
- ,
39,1% .
,
,
, .

21(32,8%), 14(21,9%),
17(26,6%), V 12(18,7%) . , ,
,
(. 1).
1. , , ,
(Mm)
1234567378
%72&4
32&'854528(3(2 )8
926
2 88
"#!8
%8(3(2 )8
+$"+8
,%8(3(2 )8
$"""8
-763872&4
34832&8(3(2 )8
"$!+8
-7638'.48(/)02128
94
4454838
##!#""!8
!#""8
8
8
8
8
8
8
*8
8
8
8
8
8
8
8
*8
8
8
8
8
8
8
8
*8
8
8
8
8
8
8
8
*8
8
8
8
8
8
8
8
*8
8
8
8
8
8
8
88
*8
8
:
1. * <0,001 ;
1
2. ** <0,01 ;
3. *** <0,05 .
,
, , - , . ,
(6,450,27)/,
(98,381,06)/; (V )
(3,270,42)/ -

785888
8
!"#$ 8
" 8
#! 8
!"""#+ 8
!$$"! 8
""! 8
"$" 8
!"+ 8
!+"+# 8
"!!# 8
$##+ 8
"#+! 8
""+++ 8
""## 8
""$ 8
#"$#8
#"++!" 8
$""+ 8
##+8
" 8
++ 8
+#"# 8
+! 8
(43,921,71)/.
,
35/, 2,5 .
, .
, -
. 2013. 2
29
, ,

,
[15, 16].
,
, ,
(. 1).

,
. ,
. , , .
. ,
(12,250,57)/
(. 1). , . , , (,
), ,
.
,

(r=-0,659; ?0,05);
(r=-0,382; <0,05);

(r=0,271; <0,05),

.
(r=-0,248; <0,05).
,
,
,
,

.
.

-
.
.
( )

,
, .
1. . ( - ) / . // : . .-.
. . 2010. 1. . 7577.
2.OConnor N. R. Infant formula / N. R. OConnor // Am.
Fam Physician. 2009. 79. . 565570.
3. . . / . . , . . , . . // .
2012. 1(41). . 4148.
4. . . / . . , . . //
. 2011. 3. . 1014.
5. . . / . . // : . 2008. 1.
. 4750.
6. . . / . . , . . //
. 2011. 4. . 51.
7. /
. . , . . , . . [ .] //
. 2012. 5. . 3739.
30
8. Serum and hair levels of zinc, selenium, iron, and

copper in children with iron-deficiency anemia / M. K. Gurgoze,
A. Olcucu, A. D. Aygun [et al.] // Biol. Trace. Elem. Res.
2006. 111. . 2329.
9. Risk of zinc, iodine and other micronutrient deficiencies
among school children in North East Thailand / R. A. Thurlow,
P. Winichagoon, T. Pongcharoen [et al.] // Eur. J. Clin. Nutr.
2006. 60. . 623632.
10. Hotz C. Assessment of the risk of zinc deficiency in
populations and options for its control / C. Hotz, K. Brown //
Food. Nutr. Bull. 2004. 25. . 99199.
11. Serum Zinc and Copper in Iron Deficient Adolescents /
L. Wajeunnesa, N. Begum, S. Ferdousi, S. Akhter,
S. B. Quarishi // J Bangladesh Soc Physiol. 2009, Dec.
Vol. 4(2). P. 7780.
12. . . / . . // , 2005. 616 .
13. 9 10.01.2005 . .
14. . . . STATISTICA / . . . . : -
. 2013. 2
, ,
, 2002. 312 .
15. . . ,
/ . . , . . // -
. 2012. 2 (42). . 1824.

16. : , / . . , . . //
. 2010. 2 (23). . 140145.
MICROLEMENTS BALANCE IN CASE OF IRON-DEFICIENCY ANAEMIA

IN CHILDHOOD
N. V. Banadyha, Ya. V. Rohalska
RESUME. It is generally known that iron and zinc take part in the processes of erythroid haematopoietic lineage, the formation
of immunological resistance. Yet, there are few studies dedicated to the interconnections between iron and zinc balances in
children which are of great interest for clinical physicians. The aim of the study was to investigate the state of zinc metabolism
in children with iron-deficiency anaemia and to establish their interconnections. The group of patients included 64 children
aged from 6 months to 3 years. It was found that sideropenia increases with progression of anaemia and significantly
correlates with serum zinc concentration. Besides, there is close return correlative dependence between them and total and
latent iron-binding capacity of blood serum. The received data condition the necessity of purposeful diagnostics of diselementosis
that grounds the individuality of approaches to the treatment and rehabilitation of patients.
KEY WORDS: children, anaemia, iron, zinc, catalase.
. 2013. 2
31
, ,
612.34:612.014.484/.015.111
, NO-

. . , . . , . . , . .

. - () -
() , L-/NO-/ (NO)
(). ,
, NO- (iNOS) . ,
,
L-/NO-/NO , .
: , , NO-, , L-.
. (
)
, .
( )
--
, ( ) .
,
, . : , , , ( ) .
, , ,

.
L-/NO-/NO,
iNOS , , NO.

(- ) [3].
, L-/NO-/NO
.
. 32 - 180 240
. . , .

4 : 1 (n = 8) ; 2 (n = 8)
32
,
(t
= 23 ) 3 ; 3 (n = 8) ,
5 [13]; 4 (n = 8) , ( 2 /
) [2]. (40 /) ,
, . (- ) [9].
L-/NO-/NO NO- [8] [14];
- [15], L-
[1]. ANOVA t- .
.
,
,
.

-
40911,4 /. : - 20 % ( < 0,05),
5 17 %,
3 15 %.
NO-
NOS (0,480,92 /),
NOS (0,120,19 /),
NOS [11, 16].
17,70,67 /, 0,310,03 /. L- 38,65,7 /
(. 1).
. 2013. 2
, ,
1. NO- ( m)
12345678925
6 72579

6
6 66
6
%
726
&&'(&6
/016-26
,,',6
/016.26
*',6
"016
))+'&&36
6
86
('6
(&',-6
*'.36
)-').36
:
* < 0,05; ** < 0,01.
6
6
86
)'*6
+,'&36
&('.-36
-.'..336
3 NOS 4 ( < 0,05),

NOS 2,5
( < 0,05), 23 %. - L- ( 18 %).
5
NOS
6 ( < 0,01), NOS
3 ( < 0,05) .
29 %, L-
20 %.
,

,

;
, , [7, 18].
, NOS
, .
[6].
NOS
11 ( < 0,01),
( 42 %, < 0,05).
NOS ,
. - 26 %
( < 0,05), 23 %
L- .

,
- , , NOS -
[4, 5, 17].
!6
86
+,'*)6
*'--36
.'&-36
(,'+6
"2
9#96
86
-'-6
)+'+6
))'-6
,'(36
$92

6
6
-,('.&6
-.'-,+6
-&')-.36
)*,'+&36
, , NOS .

, , ,
, . ,
NF-, TNF- IL-1, L-8 ,
NOS
NO [10, 12, 20]. ,
, , ,
---, -2, 2
[19]. ( ),
,
,
[21].
. 1. , L-/NO-/NO

. 2. 5
17 %, NOS 6 , NOS ( 3 ) ( 29 %), L- 20 %. 3.
, NO-
: NOS
11 , NOS 1,5
, ,
4 5 ; NO 20 %,
42 %, L- 23 %.
i.
. .
. 2013. 2
33
, ,
1. . .
/ . . , . . . . : . 1988. 239 .
2. . .
/
. . // . 1988. 1. . 2427.
3. . . . /
. . . . : , 2010.
352 .
4. NO-

-
/ . . , . . , . . [
.] // . 2013.
. 3, . 1 (102). . 245249.
5. NO-
- /
. . , . . , . . [ .] //
- . 2012. . 15,
3, . 1 (59). . 131134.
6. . .
NO- /
. . , . . , . . // - . 2013. .16,
1, . 3 (61). . 6972.
7. . . -
/ . . , . . , . . . : - , 2004. 254 .
8. . .
, /
. . , . . // . . . 2000. 3. . 37.
9. . . / . . , . // . 1981.
4. . 209 211.
10. Alderton W. K. Nitric oxide synthases: structure, function
and inhibition / W. K. Alderton, C. E. Cooper, R. G. Knowles //

Biochem. J. 2001. Vol. 357. P. 593615.
11. Al-Mufti R. A. Increased nitric oxide activity in rat
model of acute pancreatitis / R. A. Al-Mufti, R. C. N. Williamson,
R. T. Maathie // Gut. 1998. . 43. . 564570.
12. Chronic stress sensitizes rats to pancreatitis induced
by cerulean: role of TNF-a / M. G. Bincer, A. A. Bincer-Cosen,
D. Richards [et al.] // World Journal of Gastroenterology.
2010. Vol. 16, 44. P. 55655581.
13. Gastric mucosal damage in water immersion stress:
Mechanism and prevention with GHRP-6 / Shu Guo, Qian
Gao, Qing Jiao [et al.] // World J. Gastroenterol. 2012.
Vol. 18, 24. P. 31453155.
14. Geyer J. W. Rapid method for determination of arginase activity in tissue homogenates / J. W. Geyer, D. Dabish //
Anal. Biochem. 1971. 39, 2. . 412417.
15. Green L. C. Analysis of nitrate, nitrite and (1515)
nitrate in biological fluids / L. C. Green, A. W. David // Anal.
Biochem. 1982. Vol. 126. . 131138.
16. Matthew J. di Magno. Nitric oxide pathways and evidence-based perturbations in acute pancreatitis / J. di Magno
Matthew // Pancreatology. 2007. 7. P. 403408.
17. Nasadyuk C. Thymohexin exhibits cytoprotective effect
in experimental gastric lesions in rats both through the
inhibition of inducible nitric oxide synthase and reduction of
oxidative mucosal damage / C. Nasadyuk, A. Sklyarov //
Regul. Pept. 2013. Vol. 80. P. 5057.
18. Ovsiannikov V. I. Mechanisms of realization of the
pathogenic potential of stress / V. I. Ovsiannikov // Med. Acad.
Journ. 2010. Vol. 10. 4. P. 2129.
19. Pacher P. Nitric oxide and peroxynitrite in health
and disease / P. Pacher, J. S. Beckman, L. Liaudet // Physiol.
Rev. 2007. Vol. 87 (1). P. 315424.
20. Pancreatic stellate cells respond to inflammatory
cytokines: potential role in chronic pancreatitis / P. Mews,
P. Phillips, R. Fahmy [et al.] // Gut. 2002. Vol. 50.
4. . 535541.
21. Role of oxidativestressin the pathogenesis of
caerulein-induced acute pancreatitis / Dabrowski A.,Konturek
S.J.,Konturek J.W. [et al.]. // Eur. J. Pharmacol. 1999.
Vol. 377. 1. P. 111.
CHANGES OF LIPID PEROXIDATION PROCESSES, NO-SYNTHASE SYSTEM

AND ARGINASE ACTIVITY IN PANCREAS OF RATS
UNDER THE STRESS CONDITION
T. I. Bondarchuk, N. B. Panasyuk, L. P. Biletska, O. Ya. Sklyarov
Danylo Halytsky Lviv National Medical University
SUMMARY. The influence of water-restrained stress (WRS) and epinephrine-induced stress (EIS) on parameters of lipid
peroxidation, L-arginine/NO-synthase/nitrogen oxide (NO) and was studied in experiments on rats. It was shown, that both
types of stress lead to the enhancement of lipid peroxidation processes, the increase of inducible NO-synthase (iNOS) activity
and the decrease of arginase activity. It was noticed, that there is a direct influence of stress duration in WRS model, whereas
EIS affects studied parameters of L-arginine/NO-synthase/nitrogen oxide system more intense than WRS.
KEY WORDS: stress, lipid peroxidation, NO-synthase, arginase, L-arginine.
34
. 2013. 2
, ,
616.127-073.97-092.9

. . ,. . , . .
..
.
(30, 60, 90 ).
.
,
,
.
: , , , , , , , .
. ,
, ,

-
[1, 2].

, [3, 4].
-
, [5, 6].
, [4].

, ,

.

.
. 36 .

(30, 60, 90 ). 48 10 %
() 3
5 / . 6 () 0,2 /
. 7 [5, 6].
0,9 % .
30, 60 90
CardioLabCE
().
100 R-R
. :
(, .-1);
(, ) R-R,
; (,%)
R-R, , ; (, )
R-R ; (),

=/(2);
(),
, : =/; (),

, : =/;
(), , [5, 6].
.
, , . ( - 25 / -
. 2013. 2
35
, ,
).
,

.

(,1985), (, 2001) [9].

[10] () (m).
U- -.
..
StatsoftStatistica. p0,05 (95,5 %).
. , , : 1
13 %, 2 21 %,
3 32 % (. 1).
, , , , ,
. ,
, , .
1 15 %, 2 19 %, 3 42%,

- .
1.
967
7 8!"#7
*97
7
,*97-7
./7
7
0172
374
97
05672
374
97
7872
374
97
,872
374
97
96397
7
$%&'7
%&'7
)&7
$'&7
$)'&$7
$&$+7
&7
%&%7
123456789
58266 7
745
7
745
57
7
7
$&'7(((7
%'&7(((7
$'%&)7(((7
'+&'7(((7
)&7((7
&'%77
'&7
%%&'7(((7
%))&'7((7
&'7(((7
+%&+)7(7
'&'7(((7
$&7
%&)7(((7
))&7(((7
$%&7(((7
745
57
7
&)7(((7
&%7(((7
+&%7(((7
)&%7(((7
''&%'7(((7
+&7(((7
+&+7(((7
&+7(((7
: 1. * p<0,05; 2. ** p<0,01; 3. *** p<0,001, .
,

.
1 . , 25 %,
2 46 %, 3 58%,
.
,
,
.
, 1
.

,
36
. , 2
71 % , 3 2 ,

.

, ,
,
. 1 , , 40, 31 35 %
, .

-
. 2013. 2
, ,

, , .
2 . 3,2 , 2,5 ,
1,7 , 2,1 . , ,
.
3
6,3 , 3,9 ,
2,6 , 2,8 ,

. ,

.

,
, . (1 )

,
(2 3 )

-,
, .
.

.
1. - / . . ,
. . , . . [ .] // . .
. . .. . 1997. . 83, 56. . 94106.
2. . .

( )
/ . . , . . , . . // . 2002.
. 42, 9. . 1722.
3. Mitochondrial ROS generation following acetylcholineinduced EGF receptor transactivation requires metalloproteinase
cleavage of proHB-EGF / T. Krieg, L. Cui, Q. Qin [et al.] //
J. Mol. Cell. Cardiol. 2004. Vol. 36, 3. P. 435443.
4. Endogenous corticotropin-releasing hormone inhibits
conditioned-fear-induced vagal activation in the rat / M. J. Nijsen,
G. Croiset, M. Diamant [et al.] // Eur J Pharmacol. 2000.
389 (1). . 8998.
5. . .
/ . . , . . // .
1996. . 36, 10. . 8797.
6. . . / . . ,
. . , . . . . : , 1984. 221 .
7. . .
/ . . //
2005. 1. . 3233.
8. . . :
// . . , . . .
: - , 2005. 240 .
9. / . . , . . , . .
[ .] // . . . 2008.
3. . 162164.
10. . . . / . . . .: , 2006. 816 .
FEATURES OF CARDIOINTERVALOGRAPHY WITH CARDIOMYOPATHY

UNDER CONDITIONS OF ENDOTOXEMIA
P. O. Vavrukh, Ya.Ya. Bodnar, H. P. Vavrukh
SHEI Ternopil State Medical UniversitybyI.Ya.Horbachevsky of MPH of Ukraine
SUMMARY. Conducted mathematical analysis of heart rate variability under conditions of oncogenic endotoxemia on white
nonlinear rats males at three time intervals (30, 60, 90 days).Oncogenic endogenous intoxication modeled by introducing
carbon tetrachloride and bacterial lipopolysaccharide. Data analysis cardiointervalography in simulated endotoxemia testify to
disbalance of autonomic regulation of the heart, namely the reduction of adrenergic component in the formation of the heart
rate, the growing influence of the vagus nerve on the functional activity of the sinus node pacemaker.
KEY WORDS: cardiomyopathy, endotoxemia, rats, carbon tetrachloride, heart, autonomic regulation, cardiointervalography,
heart rate variability.
. 2013. 2
37
, ,
616.12-005.4-073.55

-

. .
,
.
, - .

- ,
.
: - , , ,
.
. -
() , . , ,
. [1-5]

:
-
;
, (,
, .) ;
,
1 [6-16].
{}
{2 } =
2 1
1 1 33
1
1 32
1
1 31
1 123
1 1 13
122
1 12
121 ,
1 11
(1)
12
1 22 = 234 2 8 + 467 2 8 234 5
1 243 42 = 234 8 467 8 (9 234 )5

1 = 467 2 8 + 234 2 8 234 5
1 = 44
1413 14 = 234 8 467 5
1
= 467 8 467 5
213 12
1 11 = 234 1
867
867
2 =
39 3 + 3 3
16
1
1
12
(2)
867
867
=
39 3 3 3
15
1
1
= 3 2 3
16
2 = 3 2 3 1 = 63534321
12
16
14
3 41
(3)
3 21

38
- .
.

1-4- , - 314342312 (2 1) .
.
:
(), .
[1].
(=104) H-N (=0,6328 ).
9 45 ( 1 ) ( 1 )
CCD . (mn) 1 [2]
14 : 1 0; 2 90; 3 +45; 4 ( ).
. 2013. 2
, ,
3 1
(2 52 2 1 431 )2 2
1 2 =1
3 1
((2 52 2 1 431 ))26 2
36 =
1 2 =1
3 3 1
5
3 5 = 5 ((2 52 2 1 431 ))2 2
2 6 1 2 =1
3 3 1
2
3 2 = 6 ((2 52 2 1 431 ))2 1
2 6 1 2 =1
"-"
- Z34 (mn) x1, ..., m 3 = 1 123 .
(2 =
1)
12 1
(N)
345
345
2 12 (1 ) = 1 , - ( 1 1( 1 ) )
2 12 (1 ) = 1 , - ( 11(1 ) ).

251
2 41
2 11
1 3 (2 ) 4 1 3 3 1 3 3 2223 1 3 1
1 (2 ) 4 1
3
42
231
32
3 1
31 =
1112
2 41
3 2223
11
(2)
"" Z34
(mn)[3-5].

Z34 (mn)
2 1 ( 1 ) 21 ( 1 ) 1 =5242321 , (4) [6, 7].
11 = 433 233
CCD-.
. Z34 (mn)
h(Z34 ) "-" Z34 1.
()
()
()
()
. 1. "-" :
, ; , ;
, ; ,
.

"-" Z34 .
Z34 (mn),
, 1 1 12 1 .
"" Z34,
( q=29 q=21) , ( (4)) 14
2 =5343132 (112 ) (. 1).
14
2 =5343132 (112 ) , 1
. 2013. 2
39
, ,

'
. -
M1(Z34), M2(Z34), M3(Z34) M4(Z34) .
1. 1-4 "-"

2 (1 12 ) 1
1
234567891
914 1
91 89 891849861
1
1
1
1
1
1
!1
1
2 3 (1 12 ) 1
2 4 (1 12 ) 1
2 1 (1 12 ) 1
2 2 (1 12 ) 1

N(Z34=0)0) N(Z34=1)1). ,
. (N(Z34=0)0)) ,
(N(Z34=1)1)) (. 2, 3).

N(Z34=1)1 N(Z34=0)0
-

N(Z34=1)1.
Mj=1;2;3;4(N0;1), N0 N1 (. 2).

"-"
Z34
'
()
()
()
()
. 2. N(Z34=1)1 "-" Z34 -

: ;
;
; .
40
. 2013. 2
, ,
()
()
()
()
. 3. N(Z34=0)0 "-" Z34-
: ;
;
; .
2. 14
"-" Z34

2 (1 1 ) 1
1
22 (1 1 ) 1
2 3 (1 1 ) 1
2 4 (1 1 ) 1
2 5 (1 1 ) 1
2 ( 11 ) 1
1
2 1 ( 11 ) 1
2 3 ( 12 ) 1
2 4 ( 12 ) 1
1
2 5 ( 12 ) 3
234567891
914 1
91 89 891849861
1
1
1
!1
1
1
1
!1
234567891
914 1
91 89 891849861
1
1
1
!1
1
1
1
! 1
.
3 4 N1(x) - Z34 (mn)=1 .

, Z34 (mn)=1,

, M3(N1) ( 2,4 )
M4(N1) ( 2,2 ).
.
"-" Z34 .
. 2013. 2
41
, ,

,
Z34 (mn)=1
: M3(N1)
2,4 M4(N1) 2,2 .

- -

,
.
. .
1.
/ . . , . . , . .
[ .] // : . 2000. 305 .
2.Correlation and singular-optical approaches in diagnostics of polarization inhomogeneity of coherent optical fields
from biological tissues / O. V. Angelsky, A. G. Ushenko, A. O. Angelskaya, Yu. A. Ushenko // Ukr.J.Phys.Opt. 2007. Vol. 8,
2. P. 106123.
3. Polarization-based visualization of multifractal structures for the diagnostics of pathological changes in biological
tissues / O. V. Angel'skiy, A. G. Ushenko [at all.] // Optics
and Spectroscopy. 2000. Vol. 89, 5. P. 799804.
4. Polarization speckle-reconstruction of biological tissues
architectonics; Part 1. Coherent introscopy of phase-inhomo-
geneous surface and layers / A. O. Agelskaya, Yu. A. Ushenko,

A. G. Ushenko [at al.] // Proc. SPIE. 2007. Vol. 6635. P. 15.
5. Topological and statistical describing inhomogeneously polarized light fields / P. V. Polyanskii, S. G. Hanson,
A. G. Ushenko [at al.] // Ukr. J. Phys. Opt. 2007. Vol. 8,
No.4 P. 217227.
6. Ushenko A. G. The Vector Structure of Laser Biospeckle
Fields and Polarization Diagnostics of Collagen Skin Structures / A. G. Ushenko // Laser Physics. 2000. Vol. 10,
5. P. 11431149.
7. Ushenko Yu. A. Statistical structure of polarization-inhomogeneous images of biotissues with different morphological
structures / Yu. A. Ushenko // Ukr. J. Phys. Opt. 2005.
Vol. 6, 2. P. 6370.
DIAGNOSTICS OF ACUTE CORONARY INSUFFICIENCY BY MEANS OF THE METHOD

OF THE STATISTICAL MULLER MATRIX ANALYSIS OF THE POLYCRYSTAL MYOSIN
NETWORKS OF THE MYOCARDIUM
O. Ya. Vanchuliak
Bukovynian State Medical University, Chernivtsi
SUMMARY. The paper ascertains the principal characteristics of laser polarimtetric images of the human myocardium under
the conditions of acute coronary insufficinecy obtained by means of the method of the statistical Muller matrix analysis. There
was demonstrated the diagnostic efficacy of using this particular method not only for ascertaining acute coronary insufficiency
of the human myocardium in the practice of a forensic medical examiner, but also for a differentiation with other ischemia
injuries of the myocardium.
KEY WORDS: Muller matrix analysis, acute coronary insufficiency, laser polarimetry, diagnostics.
42
. 2013. 2
, ,
616.895.87 085.214.2] 036.8

. . , . . , . .
. .
. 63 .
-, , -
(, ),

, .

. , ,
, ,
, - .
: , , , ,
.
. ,
, [1, 2, 5,
7].
,
[1, 2, 4].

[3, 5, 6],
. ,

,

.
.

.
:
.
: -, ,
.
. -, ( PANSS, PSP, AIMS,
ESRS), -, - ( , -
, 10 ,
), -
.
63 ,
20112013 .
,
(F20.0) -10.
, ,
,
.
,
(97,2 %), , ,
(55,4 %), (44,7 %), (96,1%),
(83,2 %).
(93,2 %).
(93,8 %).
, , , . ,
, , .
,
. -
. 2013. 2
43
, ,

( ,
,
, - , ).
(PS) , - , , 47,3 ,
85,6 ,
41,5 %. 26 30 , ,
47,2 ,
(
42,6%). 31
35 52,3
( 41,2 %).
13
- , , 53,2 ,
.
.
10 , ,
, 16 % , .
41 %,
. , 10 ,
.
. , 30
(<0,05) ,
36 , , ,
20 .
,
31 35 .
, 20 . , .
,
, 46 %, . ,
,
. , 44
1 3
(0,220,44) , 20 (0,540,98) . ,
, , , ,
( (74,449,10) (94,1111,18) ),

.

. ,
, .
(
36 ), .
, , , 36 ,
. ,
.
-
, , , (4,130,16)
( 11 ), (1,350,60)
( 5 ).
1015 ,
20 . 3 7
710 . , , 31 35 ,
(3,920,76)
(1,230,44) , .
- ( 10 )
31 35 .
, ( , r=0,3
(<0,01), ,
r=-0,47 (<0,01), ,
r=-0,43 (<0,01), r=0,3 (<0,01)
, r=0,3 (<0,01)).

.
. 2013. 2
, ,
- (35,3 %) , (92,4 %),

(93,1 %), (100 %),

(100 %), (96,7 %), (95,8 %).
- (36,2 %)

(97,8 %),

(87 %), (95,7 %),
(100 %),
, (89,1 %),

(93,5%), (97,8 %)
(95,7 %).
- (12 %)

(100 %),
(93,5 %), (93,4 %),
(84,5 %), (92,2 %), -
(82,4 %), ( (84,1 %), (75,5 %), (72,2 %)

(81,3 %)).
- (16 %) (100 %),
,
(96,3 %),
(88,4 %),
(93,6 %), (84,2 %), (90,2 %).

, ,
26 30 15 20 . 36 1
3 .

26 30
31 35 , 13 1520 (<0,05).
36 37 13 . , r=0,84 (<0,01).

.
1 .
1. ( %)
456789
6
2
5565
772 72 57222
%55
772 72 57222
46()9927
2872*2
.
97/792872*2
01627
2872*2
1967972 55/92872 952
29634275962727
2872 952
65)957 5982
992797542 52
65)957 5982
9927975426792
0537929963597992872:;:2
12

592
! 2
#!&2
'2
$"!&2
&!"2
,"!'2
,!$2
$#!,2
!"2
#"!&2
.
-

112
75
52
"! 2
#!'2
!+2
$&!"2
'2
&#!&2
'!&2
&'!'2
, ! 2
+!"2
1112
57987 92
#2
#'!'2
#!,2
,!2
,"!"2
'2
$!2
"'!'2
$+2
##!&2
132
7
2
#$!2
'"!'2
'-#2
&!+2
$'!2
#2
&!#2
$'!,2
!'2
'!'2
.
: 1. , , , -
. 2013. 2
45
, ,
.
2.
- ( 62,5 %,
73,0 %), (
41,0 % , 16,0 % ),
( 48,0 %), (23,2 %).
3. ,
( PSP),
42,6 %,
26 30 ( 43,7 %). 13
, 37,2 %. -
,

( , r=0,3 (<0,01), , r=-0,47 (<0,01),
, r=-0,43 (<0,01),
, r=0,3 (<0,01) ,
r=0,3 (<0,01)).
4.
, ,
, .
, , ,
; ,
, .
1. . .
/ . . . :
, 2007. 308 .
2.
, /
. . , . . , . . [ .] // . 2006. 7. . 5763.
3. / . . , . . ,
C. JL. [ .] // . 2006. 3. . 6879.
4.

/ . ., . ., . ., . . // -
. 2011. . 21, 1.
. 4349.
5.
/ . . , . . , . . ,
. . // .
2007. 2. . 6469.
6. . . / . . // . . . . . 2006. 1. . 4749.
7. . . /
. . // . . . 2012. . 112, 2, . 1.
. 8588.
INFLUENCE OF COGNITIVE DEFICIT ON SOCIAL FUNCTIONING OF PATIENTS

WITH PARANOID SCHIZOPHRENIA AND DIFFERENTIAL APPROACH
TO ITS PHARMACOLOGICAL CORRECTION
O. P. Venher, O. Ye. Smashna, Yu. I. Mysula
SUMMARY. This investigation presents the results of a complex inspection of 63 patients with paranoid schizophrenia. Using
clinical-psychopathological, psychometric, clinical-catamnestic and psychodiagnostic methods studied the interdependence
of dynamics in different groups of symptoms (productive, negative and cognitive) characteristics and expression of extrapyramidal
symptoms and patients quality of life during the treatment with some classical and typical neuroleptics, the role of cognitive
impairment in clinical picture structuring.
The results obtained in the study provide an opportunity for the differentiated approach to the treatment of patients with
paranoid type of schizophrenia, depending on the structure of cognitive impairment. For patients with memory disorders amisulpride has to be recommended, in order to improve the processes of switching the attention amisulpride and
risperidone, and to enhance concentration, intellectual ability and logical conceptual thinking olanzapine has to be
recommended.
KEY WORDS: paranoid schizophrenia, cognitive disorders, quality of social functioning, pharmacotherapy, treatment optimization.
46
. 2013. 2
, ,
. .
. .
.
,
.
: , , .
.
.
,
, .

, [1; 4; 6; 7; 9; 14].
()

() .
.
2050%,

. ,
.
.
.
. , ,
01
01D .
(2012 .),
(1 .),
, : D03 , ( D03 , D08 (
D0810 )1,3,4,6,11. , , , , .
. [6; 9; 13; 14]. . , , .

1970 .
, - [12;13].
1990
().
6 . , ,
.
36,1 50,3%,
35,9 30,5%. , , ,
.
0,0450,05%. 35%. ,
, [8; 14].
. ,
. ,
.
. , ,
.
1974 . 1989
A. Scheie
. A. Gaffarn (1995) ,
, , -1,
. 2013. 2
47
, ,
, ,
, -,
. , 1225%, 36%,
2225% [10; 11; 13; 14].

, 7090%.
, . ,
, [3; 5; 12].

, , Loe
Shiott 1970 . ,
6890% 6090% [4; 6; 9].

(, ,
.), (-, ,
.), [3; 5].
,

(). ,
,
. , 0,5 ,
20 /,
, () , , (Y. Goodson, 1989).
, , , ,

.

, . , (M. B. Hurzeler
et al., 1998, S Lindiskol et al., 1998) [1; 4; 9; 13; 14].
. . . (1997, 1998) -.
[2].
(1,64%) . ,
1,64%

4 .
( ) .
48
,
, , . [6; 7; 8].

- [8; 9].
, , :
,
;
.
, , , ,
. :
25%

(). .
1 ;
2%
, , (,
, );
25% , ().
.
,
( 10 ) ;
10% , , Poly-DI- N- -2- ().
, 68 , [1; 6; 9; 11].
, ,
().
, (. . ., 1997).
[9; 10; 11].

( , ),
(, ). ,

.
.
, ,
-
. 2013. 2
, ,
.

. -
:
.
. , ,

.
1.
/ . . , . -.
. : , 2004. 328 .
2. . . / . . . . : . . 2004. 144 .
3. . .
- / . . , . . , . . // (IX)
. ., 2004.
. 195196.
4. . . / . . . , 2011. 643 .
5. . . / . . , . . // (IX)
. ., 2004. . 214216.
6. [ ]. : http://www.moz.gov.ua/
7. / . . ,
. . , . . [ .]. : .
2011. 246 .
8. . .
/ . . // . 2002. 5. . 710.
9. 2012 /
. . . . . . : , 2012. 2240 .
10. . .
/ . . , . . // :
/ . . . . .
. : . -. 2003. 212 .
11. . / . . :
. 2004. 256 .
12. . . , / . . // . 2002. 6. . 58.
13. . .
/ . . . . : . . , 2004. 136 .
14. Fernandes C. L. Microbiological assessment of
subgingival plaques from argentinian pati ents with adult
periodontitis / C. L. Fernandes // Pap. Congr. Anaerob. Bac.
and Anaerob. Infec. 1999. 3 4. P. 263265.
15. Johnson T. C. Experimental gingivitis in periodontalsusceptible subjects / Johnson T. C., Reinharradt R.A. //
J. Clin. Periodontal 1997. Vol. 24. P. 618625.
16. Zappa U. Cell populations and episodic periodontal
attachment loss in humans / U. Zappa, H. Yrah // J. Clin.
Periodontal 2007. Vol. 18. P. 508515.
USE OF MODERN ANTIMICROBIAL AND ANTI-INFLAMMATORY TOPICAL

PREPARATIONS IN THE TREATMENT OF INFLAMMATORY PARODONTIUM
DISEASES
O. M. Vynohradova
Lviv National Medical University by Danylo Halytsky
SUMMARY. In the study of highlights retrospective and modern places of antimicrobial drugs and anti-inflammatory actions in
parodontium tissue damage, and provides information about the groups of medicines that improve the dental status of
patients.
KEY WORDS: drugs, parodontium diseases, antimicrobial and anti-inflammatory, action.
. 2013. 2
49
, ,
612.017:579.233:616.214]:504.5
. . , . .

.
. . ,
90 . , .
, TLR-2 TLR-4, LMP-2, Nf-KB sIgA .
,

. .
: , , , .
.
() .

. , , , , .
,
. - (TLR)
[1].

(NF-kB). ,

: , (sIgA) [2, 5, 9]. ,
, , .
[36].
.
. .
. , 90
. . 50
: ,
33 , , 57
. .

.

,
.

,
, , ,
.
(),

( /L),
.

TLR-2 TLR-4, LMP-2 Nf-B.

TLR-2 TLR-4 (HycultBiotech, ), (FITC), p50
p105 Nf-B LMP-2 (SantaCruzBiotechnology, ).

0,1 , 60 ( = 37 )
IgG , FITC. ImageJ (NIH, ). , PrimoStar (ZEISS, )
390
(FITC) AxioCam 5c (ZEISS,
. 2013. 2
, ,
) ,
AxioVision 4.7.2 (ZEISS, ). ,
, TLR-2, TLR-4, LMP-2
Nf-B. .

IgA (sIgA) (-, ).
Statistica-6,1.

mx,

- ,
0,05.
.

1. ,

.
10 %, 2
1,3 1 . ,
, 2
, /L 2
1,8 , 1 .
1. ( mx)
7228

752288
864654!8"#3#8
&'(8
89
8
8
$%$$8
)%8
1234567489
28
89
8
8
$$$8
*)$8
: * 1 <0,05; ** 1 <0,01.

. 2. sIgA
2 .

1
2 . TLR-2+ , Nf-B+ .
TLR-2, TLR-4,
LMP-2 Nf-B .
1,4 TLR-2+ 2 , 1,6
TLR-4+, 1 .
LMP-2+ Nf-B+ 2
1,3 .
2.
( mx)
7228
8998458
%&'(8)9
75*2+28
"8
,45-74.+-8/38
%&'(8)64+654*2+28
"8
,45-74.+-8/38
%&'(#8)9
75*2+28
"8
,45-74.+-8/38
%&'(#8)64+654*2+28
"8
,45-74.+-8/38
&12(8)89
75*2+28
"8
,45-74.+-8/38
&12(8)864+654*2+28
"8
,45-74.+-8/38
34(568)9
75*2+28
"8
,45-74.+-8/38
34(568)64+654*2+28
"8
,45-74.+-8/38
89
8
8
#8
#8
$!8
08
!8
!8
$$8
8
0!8
8
#$!8
!!8
0$8
8
00 !8
8
1234567489
28
89
8
!! 8
$#8
#8
#18
!$8
!008
#$8
#018
$08
0$8
$!8
0018
8
#8
#8
!18
$8
: * <0,05.
. 2013. 2
51
, ,
.
, NF-B
500 , ,
,
,
[10].
IL-1, IL-6, IL-18,
TNF ,
- Th17- Th1-.
Nf-B+-
, . ,
.
,
, IFN [8]. X(5, Y (1) Z(2) LMP7 (5i),
LMP2 (1i) LMP10 (2i), 8-11 [8]. -

MHC I .
LMP2
Nf-B . , ,
, IFN,

(IFN-LMP2-Nf-B-IFN) [79].
.
,

. .
.

,
.
1. . . Toll-
-

. 1. TLR / . . ,
. . , . . // .
2012. 5. . 116121.
2. . .

[ ]:
http://aspirans.com/sekretornyi-immunoglobulin-kak-faktormestnoi-zashchity-slizistoi-dykhatelnykh-putei-i-prichiny-ego.
3. . .

( . ) / . . // . , 2004. .43. .374379.
4. . .
/ . . , . . , . . // .
2009. 3 (39). . 7477.
52
5. . . ,
/ . . // Therapia.
2008. 2. . 3334.
6. . .
/ . . , . . // . 2008.
12. . 3336.
7. . . Toll_like_
/
. . , . . // . . . 2008.
. 80, 3. . 520.
8. . . :
// .-2010. 4. . 277300.
9.
/ . . , . . , . . , . . //
. 2012. 4. . 104107.
10. Hayden M. S. NF-B inimmunobiology / M. S. Hayden,
S. Ghosh // Cell Res. 2011. Vol. 21(2). P. 223244.
. 2013. 2
, ,
EFFECTS OF ANTHROPOGENIC POLLUTION ON MUCOSAL IMMUNITY

O. V. Voytovych, O. M. Kamyshnyi
SUMMARY. In this work investigates the possible impact of anthropogenic pollution on performance mucosal immunity of
nose residents of Zaporizhzhia. Investigated samples of biological material obtained from the mucosa of the distal inferior
turbinate 90 healthy young men residents of Zaporizhzhia. The study identified two groups: the first - material received from
33 residents conditionally clean areas, the second - the material received from 57 residents conditionally dirty areas Zaporizhzhia.
Analyzed performance rhinocytogram and functional mucosal immunity of nose based on antigen detection immune fluorescence
markers TLR-2 and TLR-4, LMP-2, Nf-KB and sIgA by ELISA.
Found that in terms of more intensive anthropogenic pollution is increased cytological signs of inflammation in the form of
increased granulocyte content of the nasal mucosa and increased destruction of epithelial cells. Revealed tensions mucosal
immunity of nose grounds imbalance immune regulatory mechanisms.
KEY WORDS: mucosal immunity, hereditary immunity, immunoglobulin A, anthropogenic pollution.
. 2013. 2
53
, ,
611. 018.42

. . , . .
. .
. , ,
, .
.
, , .
.
: , , , , .
. ,
, .
,
[3].

97 % , 67 % [5, 7].
, . , -
[2].
, ,
, .

.

.
. 4 ,
. 4 %
.
,
.
, .
Novoscan 30.
esla- S-613.

54
- . . . .
.
-
(. 1).
. 1.
.
. .: 1200:
1 ; 2 ; 3
.
, ,

.

,
, , ,
23 (. 2).
. , .

, -
. 2013. 2
, ,
. 2.
.
. .: 3300:
1 ; 2 ; 3
; 4 .
. 3. .
.: 2000.
1 ; 2 .

[1, 4, 6].
, ,
, .

,
: -
; ;
.
, -
.
,

.
.
.
3. , , ,
, ,
.

.

,
,
.
-
.
, ,
,
.
. III .

, .
, ,
IV .
.
,

.
.
.
1. B. . / B. . // . : . . , 1995. 247 .
2. . . /
. . , . . . . : -,
2005. 56 .
3. . .
. 2013. 2
55
, ,
/ . . , . . //
. 2013.
1 (37). . 5152.
4. . . / . ., . .,
. . . : , 2002. 87 .
5. . .
/ . . , . . , . . -
. . : 21 , 2002. 368 .
6. . / . , . . . : , 1983. 346 .
7. Bres E. F. Surface structure study of biological calcium
phosphate apatite crystals from human tooth enamel /
E. F. Bres, J. L. Hutchison // J. Biomed. Mater. Res. 2002.
Vol. 63 (4). P. 433440.
ULTRASTRUCTURAL ENAMEL AND DENTINE FEATURES OF HUMAN PREMOLARS

P. A. Hasyuk, N. Ya. Kovtun
SUMMARY. The paper presents the results of research that pelicle represented by homogeneous light strip that is formed by
filtration of proteins salivary fluid. This filtration barrier formed by ameloblasts atrophied and their processes. The process of
biomineralization of enamel prisms begins with tails, then moves to the head containing hydroxyapatite crystals. There is a
distinct ultrastructural organization in three different layers of cervical dentin areas.
KEY WORDS: cuticle, pelicle, ameloblasts, enamel prisms, dentine.
56
. 2013. 2
, ,
616.31-002-085.322:582.736]-053.2
-

. .
. .
. -

.
, .
:
,
. ,
, , ,
.
- ,
, ,
.
: , , , , .
. ,
,
- .
, . , , ,
, , .

, ,

.

-

, .
. 127 ( ) 6 .5 , ,
, .
12 . 30 34 .

-, .

.
.
.
30 . 32 (
, ), .

57 .
, ;
.

() ()
. . (2001) [592].
.
, , : , ,
, .
,
(Glycyrrhizae radices),
. 2013. 2
57
, ,

. [58].
, .
,
[51, 52].
,
3-4

, .
,
. , ,
, , , ,
.
, ,
55,1 %, 50,4 % .
, 1,070,01 ,
.
(1,69 )
, .

.

-
, . ,
2,04, 53 % (<0,03).
, -
,
, ,
,
, .
, ,
58
. , , ,
, , , .

,
56,52 %,

-
. , , ,
-
, , .
,
.
,
( ).

()
. ,
13 (8,81,5) %, (7,20,9) %;
(6,70,6) %. 45
(12,30,4) %,
(9,60,4) %,
(8,00,4) %.

.

. :
13 (8,40,2) % , 45 (11,70,8) %.
13
(7,90,3) %, 45
(10,40,7) %.

,
sIg
. , 13
sIg
0,320,01 / (0,2250,01 / , (t=7,84),
45
(0,250,01) /, (0,330,01) / (t=5,15),
< 0,05.
, ,
-
. 2013. 2
, ,
. () ,
,
() ,
(1,47 . . 1,73 . . ).

,
,
105102 CFU/2,

104106 CFU/ 2 (. . , . . , 1997).
. , .

. , ,
(6465 %), (35 %),
.

104 CFU/2. 3

105102 CFU/2.
, 9,9 %
,
. , 3 7 ,

,
.

. ( 3 )
, .
,

- , ,
ndida, - , . , -

1,07 . .

0,57 . . ,
- , -
Candida, , Candida V .
, , V
.

,
.

,
. ,

54,3 % . (71,8 %), . ,
. .
. .
, ,
.
.
,
, -

.
1. . . : . . - . . 2001.
208 .
2. / . . , . . ,
. . [ .] // .-.. 1999.
. 2013. 2
59
, ,
30. . 1416.
3. /
. . , . . , . . [ .]. . : , 2006. . 235245.
4. .
// . 2009.
6. . 2233.
5.

/ . ., . ., . . [
.] // . 2009. . 87. 3. . 8689.
6. . .
// . 2003.
1. . 3539.
7. , ,
/ . ., . .,
. . [ .] // . 2009. . 87.
1. . 95100.
8.
/
. . , . . , . ., [ .] //
. , .
2001. 2. . 5356.
9.
/ . ., . ., . . [ .] // . . . . : . : , 2009.
168 .
10. . . - / . . , . . , . . // . 2001. 6. . 6268.
11. . . / . . // . : VII . , 15
17 . 2010 . : ., . 2. , 2010. . 64.
12. . .

/ . ., . ., . . // . 2000. 3. . 8691.
13. . . : . . . . / . . .
, 2007. 23 .
14. / . ., . ., . . [ .] // . 2009. . 87, 2.
. 96100.
60
15. . . / . . //
Medicus Amicus. 2005. 5. . 2329.
16.
/ . ., . ., . .
- : - -. . . , 2004. 134 .
17. :
/ . . , . . ,
. . , . . // .
2007. 2. . 6266.
18. . /
. // . 2008. 1. . 4750.
19. . . . , / . . , B. C. , . . // .-. . 2003. 7. . 3639.
20. . . / . . , . . , . . //
. 2003. 4. . 169170.
21. . .
/ . . , . . , . . // . 2008. 4. . 1418.
22. . .
, / . . //
. 2009. . 87, 2. . 9296.
23. . .

-
: . . .. / . . . , 2002. 25 .
24. . .
:
/ . . // .
2009. . 87. 1. . 127132.
25. / . . , . . ,
. . [ .] // . 2002. 1. . 1113.
26. . . / . . , . . , . . //
. 2001. 4 (28). . 6064.
27. Baltina L. A. Chemical modification of glycyrrizic acid
as route to new bioactive compounds for medicine / L. A. Baltina // Cum. Med. Chem. 2003. Vol. 10. . 155171.
28. Herbal medicines for liver diseases in India /
S.Thyagarajan, S. Jayaram, V. Gopalakrishnan [et al.] //
J. Gastroenterol. Hepatol. 2002. 17. P. 370376.
. 2013. 2
, ,
CLINICAL AND LABORATORY STUDY OF EFFICIENCY LICORICE ROOT

IN THE TREATMENT OF INFLUENZA STOMATITIS IN CHILDREN
N. O. Hevkalyuk
SUMMARY. The data obtained clinical and laboratory studies were the rationale for the development of method of treatment
and prevention of influenza in children stomatitis with correction homeostasis mouth phytopreparation licorice. Inclusion in
the treatment of patients with influenza kids medication stomatitis licorice contributed to increasing the effectiveness of the
pathogenetic treatment, which provided more rapid recovery. Positive clinical results obtained in three main performance
criteria that include in reducing all-infective syndrome, the prevalence of its expression in the mucosa of the oropharynx and
oral cavity. Results of clinical studies indicate the need for a herbal anti-inflammatory, epiteliocytic, immunotropic, antiviral
effect in treatment of patients with influenza stomatitis, which was laboratory confirmed. As a result of the treatment following
the normalization of functional adaptive- compensatory reactions, as evidenced by normalization of the confidence interval
fluctuations oral pH, indicator of functional activity of buccal epithelium cells, normalization dysbiotic manifestations in the oral
cavity.
KEY WORDS: influenza stomatitis, licorice root, topical treatment, microbiocenosis, buccal epithelium.
. 2013. 2
61
, ,
611.81:612.13]-092.9

. . , . .
. .
. ,
, -
(,
, , , .). ,
,
.
( ).
.
: , , , , , .
.
,
, .

[1, 2].
,
,
:
- , , , ,
- [2].
,
,
, [3, 4].

,

, [5, 6, 7].
.
( , ,
, ) [8, 9, 10, 11].

,

.
, 62

, , .

, -,
[9, 10, 12]. ,
,
,
[8, 13, 14]. , , [8,
9, 14].
:

, .
. 16 -
190210 .
[15], () (0), (1) (2) ,
(0) : (1) ( 2)
. :
: H2 = 22 / (12 + 22), (1)
: = (12 + 22) / 02, (2)

[16]:
t = (l - ln) / ln 100 %,
(3)
t (tortuositas) ;
. 2013. 2
, ,
ln
;
l
.
, -
.

:
(51125 ) (3050 ).
30 ,
.

[17].

(d) (d1) , () [18]:
= (d d1)/2.
(4)
()

,
:
= (Sm/Sp) x 100.
(5)
- ():
= /.
(6)

20 .
Microsoft Excel. (), () (m).
.
, ,

.
,
(0,680,02) ,
(0,490,02) ,

(0,970,03) (. 1).
. , ,
, - . -
,
.

,
-
, , (
.. , , ,
, ).

,
(. 1, 2).
.

. ,
,
.

,
.
, ,
. ,

, .
.

,
(. . 1) ,
1,41,6, 1,3. ,
1,4 . ,
2,5 ,
,
1,4
. , , ,

, .
, 70 %
30 %
, ,
.
. 2013. 2
63
, ,
,
, (, )

[19].

, . - , ,
. (. 1 2, . 1).
(. 2) , 2,
. . . .
[15],
III (2 > 0,35).
,
,

2 . 1 2.
10 : 32, 10 : 21,

10 : 16. .
, ,
, ,

(2),
()
. .
,

.
, . , (. 3).
( ,
) , . ,

, ,
64
(, ,
),
, (. 4).
, , ,
. ,
.

,

. , (52,000,89) (16,670,17) ,
(15,670,75) (12,330,33) .
:
(169,461,96), (564,2519,37),
.
(26,170,60) (51,331,91)
, -
(0,510,01).

, ,
(,
), [19].

. ,
. -
,
.
. 1.

,

.
. 2013. 2
, ,
1. (Mm)
89
9
4
9
44
4
*225 5 4
+,4
12345632724
774
57794
76
74
577942794
76
74
57794
94
27
37
377794
799794
56794
9639794
56794
5
374
94
9639794
94
57794

94
!"# $4
%&# '4
(!# '4
$&# )4
$ # )4
) # )4
'$# )4
)(# )4
'"# '4
)!# )4
-4
-4
). #)&$4
'!)"#$ 4
%%"#) .4
$$$# .$4
) #)'!4
'!'# ('4
-4
-4
2. (M m)
97
8
7 78
9 638 28236538
7 78
8
9 638 28236538
4'(78
8
2'2) 288
*+ 28236538
,535
88
4'(28236538
- 288
236538
1232456378
123
448
423
448
523
448
53
8
123
32
8
3423
32
8
35233
32
8
8
!" 8
#$ 8
#$"!%8
#!##$8
&%# 8
%&##&8
!"$8
!"%8
#!%8
"%8
!%
$&8
#"#8
$"$%!8
&&%%&8
&!%$!8
#%8

%8
%8
!!#!"8
%$#%$8
$#% 8
$&$8
!"##&8
#%8
%$%8
%&%8
!!""$%8
%&%#8
$%$%%!8
"&$8
!$! 8
$ 8
%8
%8
!"% &&8
%"$ !%8
%$$"#8
$$$8
"####8
. 2013. 2
65
, ,
. 1. . . .
, 1, 2, 3,

4, 5, - 6, 7,
8, 9,
10.
. 2. . . .
1,
2, 3,
- 4, 5, 6.
. 3.
. . 140.
1, 2,
3.
. 4.
. . 180.
1, 2,
3.
2.
.
3.
.
:

,
.
1. . . () / . . . . : ,
1962. . 137140.
66
2. . . / . . , . . . ., 1960. 258 .
. 2013. 2
, ,
3. . .
/ . . , . . //
. 1960. 1. . 8290.
4. . . / . . //
. 1981. 2. . 3951.
5. .
/ . , . . :
, 1972. 286 .
6. / . . , . . , . . // . 1983.
2. . 16. . 36.
7. Schaper G. Ultrastructural morhometric analysis of
myocardium from dogs, rats, hamsters, mice and from human
hearts / Gytta Schaper, Eckhardt Meiser, Gerhard Stammler //
Circ. Res. 1985. Vol. 56, 3. P. 377391.
8. . . / . . , . . . ., 1955. . 174175.
9. . .
/
. . // . . -. , 1962.
. 4. . 147152.
10. Brown J. O. The morphology of circulus arteriosus
cerebri in rats / J. O. Brown // Anat. Rec. 1966. Vol. 156.
P. 99106.
11. Donald D. A. The distribution of blood to the

brain // D. A. Donald, J. Potter // J. Physiol. Vol. 114.
P. 356371.
12. . . / . . . . : ,
1973. 253 .
13. . . /
. . , . . . ., 1951. . 2. . 261.
14. . .
/ . . //
. ., 1937.
. 927.
15. / . . , . . , . . . : ,
1982. 123 .
16. . . / .. // . 1987. 8. . 488491.
17. . .

/ . . , . . // . 2007. . 144, 9. . 342345.
18. . . /
. . . . : . 1990. 382 .
19. . . /
. . . ., 1951. 356 .
FEATURES OF BRAIN CIRCULATION IN RATS IN NORM

I. Ye. Herasymyuk, Yu. M. Havryshchuk
SUMMARY. Using x-rays, histological and morphometric techniques is studied the anatomical, morphometric and structural
features blood supply to the brain of white laboratory rats and the main morphometric parameters of cerebral vessels in
normal (symmetry, the magnitude of the angles of branching, degree, smooth shell thickness, Vohenvort index and so on).
It is noted that as the size of vessels branching vascular resistance increases both by changing the geometry of the vascular
bed, and due to the structural and functional characteristics of the arteries of different caliber. It is established quantitative
relationships between the different pools vessels (internal carotid and vertebral arteries). It is indicated on their importance in
modeling vascular pathology in the experiment.
KEY WORDS: x-rays, tortuosity, media, smooth muscle cells, endothelium, elastic membrane.
. 2013. 2
67
, ,
617.7-001.17+616-085]-001.5

. . , . .
. .
. , 10 % NaOH
.
.
6 12 10 % NaOH.
24 -
, , .

,
.
: , , , , , .
. . , , ,
[13]. ,
[46]. .

,
,
[49]. , -

[10].
,
, . , . ,
, . ,
.
: .
. 54 2 2,5 3,0 . 6
. 24
10 % NaOH, 24
5
68

.
( 25 /)
1, 6, 12 24 ,
.
10 %
, ,
96 . 5
7 , - .
- 115. , , (, , , ), .
.
. , 10 % NaOH

. (. 1).
,
.
6
12 10 % NaOH.
24- - -
. 2013. 2
, ,
. 1. 6
. .
140.
1, 2,

3, 4.
, , .

1 .
,
,
. , , ,

, , ,
. , ,
, 100%,
52 % ,
,
, ,
30 %,
21 % , ;

:
, , 6 %, 11 % , (. 1).
.
, ,
,
1.
(Mm)
85349
7
65
355
7
(*7 7
!(7 7
$7 7
!7 7

63 77
57
35-97
7 35
-9/07
577
35-97
7 35
-9/07
57
35-97
7 35
-9/07
57
35-97
7 35
-9/07
9245637
535

27 7
2
797
526 37
447
447
!"#$%&7
!)#*'&7
'#("7
'#((7
(!#''&7
!,#)+&7
'#(!.7
'#+!.7
('#%'&7
!,#')&7
'#(+7
'#(,7
(!#!'&7
!,#,(&7
'#!(.7
'#+!.7
('#)'&7
!,#((&7
'#(%7
'#(*7
!%#$+&7
!+#),&7
'#('..7
'#("..7
('#!'&7
!)#"+&7
'#(+..7
'#(%..7
!(#%,&7
!'#,)&7
'#!)..7
'#++..7
!"#*'&7
!)#(%&7
'#()..7
'#((..7
6
27
9697
447
!''#++&7
*#+%7
!'"#$)&7
*#,"7
!'%#''&7
*#+(7
!!(#,+&7
%#'%7
!'*#%'&7
*#,%7
!!,#%'&7
%#!,7
!'!#$)&7
+#%"7
!')#++&7
%#(!7
")#$)&7
+#%)7
123245637
6
27
6
27

7
327

7
447
447
(,#++&7
(,+#++&7
'#,*7
!(#(!7
!')#!)&7
*$)#++&7
+#)%..7
!$#$"..7
%$#%'&7
+$"#++&7
+#(!....7 !*#+*..7
!($#%'&7
*""#++&7
(#,*..7
!$#+$..7
$%#,+&7
+)%#$)&7
(#,+....7 !+#**...7
!+(#''&7
*,*#++&7
(#%+..7
,#$)..7
*"#++&7
+!$#''&7
+#)!....7 ,#,,..7
!(,#,+&7
*))#,+&7
(#*'..7
,#*(..7
+)#!)&7
+'(#''&7
!#+7....7 !'#)(..7
6
27
537
447
9245637
3 97
447
6
27
3 97
447
%(+#++&7
!%#'!7
$(+#))&7
!)#"*.7
%%*#%'&7
!'#($.7
$)+#++&7
!$#!(..7
%%%#,+&7
"#%'..7
$%!#++&7
!%#++..7
%+(#++&7
!'#*(..7
$!*#%'&7
!*#)".7
%!+#$)&7
!'#!,..7
!*#"'&7
'#(*7
!%#!(&7
'#(,7
!*#"(&7
'#!"7
!*#,+&7
'#(*7
!*#)%&7
'#+!7
!+#*%&7
'#(,.7
!*#,)&7
'#+!.7
!!#*%&7
'#("..7
!*#,(&7
'#(,..7
+++#,+&7
"#)*7
+)+#,+&7
!'#$+7
+%,#$)&7
"#*+7
("+#%'&7
)#"".7
+$*#%'&7
!'#%)..7
7
+*(#$)&7
!!#*"1
7
+!)#++&7
,#+*1
: * < 0,05; ** < 0,01 ; (*) < 0,05; (**) < 0,01
.
. 2013. 2
69
, ,
(. 2).
, . ,

.
, 4070 . ,
.
. 2. 1
. . 140.
1,
2 3, 4,
5,
6.
6

, , .
, .

. ,
. ,
: , .
, , 48 %, 25 % 17 % , , .
24 % ( > 0,01)
70
. ,
,
.
12-

-
.
, .
.

, .
. , , ,
,
.
, , ,
(. 3).
. 3. 12
.
. 140.
1,
2,
,
4.
24-
. .
. 2013. 2
, ,
, ,
. .
(. 4).
,
.
, ,

.

.
. 1.
, .
2.
.

6
12 10 % NaOH.
. 4. 24
. . 280.
1, 2, 3.
3.

, .
.

.
1. . .
( ) / . . // .. 2010. 4. . 3741.
2. . . -
( ) /
. . , . . // ..
2010. 6. . 3136.
3. . . - / . . , . . //
. . 2004. 6. . 3336.
4. . . :
/ . . , . . . . :
, 2008. 135 .
5. /
. . , . . , . . , . . // . . ., 90- .
. . , 1819 . : . , 1998.
. 201203.
6. . . / . . // . . 2008. 6. . 7983.
7. . .

/ . . , . . // .
. 2007. 5. . 4043.
8. . . / . . ,
. . , . . . : , 2001.
272 .
9. Cytokine expression in the alkaliburned cornea. /
C. Sotozono, J. He, Y. Matsumoto [et al.] // Current Eye
Research. 1997. Vol. 16, 4. P. 670676.
10.
/ . . , . . ,
. . [ .] // : .. ., 2324 . : . ., 1997. . 29.
. 2013. 2
71
, ,
MORPHOLOGICAL AND FUNCTIONAL STUDY OF POLISORB PREPARATION

AS EFFECTIVE MEANS OF FIRST AID IN CASE OF CORNEAL ALKALI BURNS
I. Ye. erasmiuk, T. I. Romaniuk
SUMMARY. Due to the results of the study on rabbits it was found that corneal burns by 10 % NaOH are followed by
morphological changes on the part of all the eyeball structures. The cornea itself is primarily subject to destructive changes.
If there are no remedial measures, there occurs a total destruction of the cornea with violation of its integrity and eyeball
tightness within the period from 6 to 12 hours after the onset of lesions by 10 % NaOH. Further progression of the pathological
process to 24 hours leads to dystrophic and destructive disorders in all the eyeball tissues, including the optic nerve, which is
considered as the state of irreversible changes. Using sorbent solution Polisorb as first aid to irrigate conjunctiva can
significantly reduce the effect of alkali burn and thereby prevent deep structural changes on the part of the eye membranes
and especially the cornea, preventing its complete destruction.
KEY WORDS: burn, alkali, cornea, edema, hyperemia, sorbent.
72
. 2013. 2
, ,
616-056.52:618.3:612.129

. .
. .
. 1, 6, 10
. ,
, , .
: , , .
. , , , , , .
, .
,
,
[2, 4, 9].
635 % [2, 4].
- , , .
, [4, 10]. ()
[2, 4, 9]. , , , ,
[1, 3, 58]. , .

.
.
15 ,

2436 . 12 (2005).

.
10 ,
, 1 2.
,
1, 6 10
Stat Fax 303 (Awareness Technology Inc.,
) - ( , ;
-, ).

STATISTICA 8.0 (StatSoft Inc., ). . (25 %; 75 %), , 25 % 75 % ,
(n). U- -.
0,05.
. , , , .

. ,
4 , 7 , 2 , 1
. 1 ,
9,
2, .

1. . , -10
, - -6
, . -1
. ()
.
. 2013. 2
73
, ,
1.
123456738
1 8!"8
-./8!"8
-./,8!"8
-./8!"8
9
62648 488
#$$8%##&8#'()*8
)'''8%)#(($&8#''*8
)'8%$'$+&8',$*8
)$8%(,&8))'$*8

. ,
,
[2, 9].

Th1- [5,
6]. , .
. , , .
Th1-,
,
[8].
, [1, 4, 6]. ,
[5]. -
26 2648 488

)((+8%)+,&8#$(+*8
))'',8%+++&8)'')*8
$$$+8%#(((&8$()*8
)'$8%))+,&8),',*8
64668 8
$8
)8
#8
8
,

[5, 7]. Th2- ,

, [3, 5, 6]. ,

.
.
.
. ,
Th1- Th2- .
. , ,
, .
1. : / . . ,
. . . . : -, 2008. 272 .
2. / . . , . . , . . , . . . . :
, 2005. 440 .
3. . . : - / . . , . . ,
. . . . : -, 2010. 144 .
4. / . . , . . , . . , . . . . : , 2006. 480 .
5. . . :
. / . . , . . // . 2004.
. LIII, . 1. . 8997.
74
6. / . . . , . . . . : -, 2010. 576 .
7. . . / . ., . .. . : , 2010.
536 .
8. /
. . , . . , . . [ .] //
. 2007. . 6, 1. . 38.
9. Oxidative stress, inflammation and angiogenesis in
the metabolic syndrome. / Ed. by R.Soares, C. Costa. New
York : Springer, 2009. 214 p.
10. Ray J. G. Metabolic syndrome and higher risk of
maternal placental syndromes and cardiovascular disease //
Drug Development Research. 2006. Vol. 67, 7.
P. 607611.
. 2013. 2
, ,
CYTOKINE PROFILE IN PREGNANT WOMEN WITH METABOLIC SYNDROME

S. M. Heryak
SUMMARY. Levels of interleukins 1, 6, 10 and tumor necrotic factor in serum of pregnant women with metabolic syndrome
and healthy pregnant women were studied. It was proved that the cytokine profile in both groups has been different.
Proinflammatory cytokine level in pregnant women with metabolic syndrome was higher and antiinflammatory cytokine
level was lower than in healthy pregnant.
KEY WORDS: pregnancy, metabolic syndrome, cytokines.
. 2013. 2
75
, ,
616.36-002:599.322.4:615.272

. . , . .
. .
.
.
: , , , .
. ,
, [1].

[2].

, in vitro in vivo.

,
,
, .
,
, , ,
, ,

, , ,
[3].
.
- 80 -
1 . 5055 .

(, 2001),

, .
() 86 /
50 / ( -65 )
29 [4].
( ),
76
75 /, c
8 / ( , ).
30 , .
,
-, lympus 41.
. (),
, , . , - (.1).
[5].
-
.
. 1. ,
.
. - 200.
, ,
,

, ,
, , (. 2).
. 2013. 2
, ,
,
,
,
. , , .
, , , (. 4).
. 2. ,
. - .
- 200.
, ,
,
.
(. 3), .
. 4. ,
.
. - 200.
. 3. ,
.
. -
400.

(23 )

, .
, , , ,
,
.
.
, ,
,
. , ,
, (. 5).
,
,
, .
,
,
, (. 6).
- .
, , .
,
.
. 2013. 2
77
, ,
. 5. ,
.
.
- 200.
6. ,
.
. - 100.
. 1.
. 2.
,
, . 3.
, . 4. .
.
, ,
, , .
1. . . / . . // . 2010. 1. . 1318.
2. . . ( ): .
/ . . . ., 2010. . 57.
3. . .
/
. . , . . // . 2010.
16 (2). . 236241.
4. 77270 , (2013) G09 23/28.
/ . . , . . ;
. . . u2012 08154; . 03.07.2012; .11 .02. 2013, . 3.
5. . . /
. . , . . . 1985.
PROSPECTS OF QUERTIN USE UNDER CONDITIONS OF CHRONIC DRUG

HEPATITIS IN IMMATURE RATS
O. Yu. Huminska, N. A. Rykalo
Vinnytsia National Medical University by M. I. Pyrohov
SUMMARY. The article presents data of the Quertin using with hepatoprotective purpose in chronic drug-induced hepatitis
in immature rats.
KEY WORDS: Quertin, Antral, chronic drug hepatitis, immature rats.
78
. 2013. 2
, ,
577.115+616.441-008.64+546.15+546.56+616-08

. .
-
. , , ,
, , , -
, , .
. ,
.

. .
: , , .
.
,
, . [1]. ,
(), (, , ),

[2].
, (), (), (
) ( ).
, --,
[3].
, , .
.
, ,
[4].
,
, , , ,
- [1, 5].
.

() ,
( , ),
.
. 150 120180 .
:
(, 1 , n=30);
(+Cu,
2 , n=30); : (3 , n=30),
(4 , n=30), , , - - (5 , n=30).

(7,5 /100 ) [6].
14 .

[7]. d- (, Polfa Kutno Pharmaceutical Company,
) 100 /100
21 [8].
-100 (Nycomed Merck KGaA, )
50 30 [9].
-
. 2013. 2
79
, ,
(0,09 /100
) 90 [10]. (50 ) [9],
(0,09 /100 ) [10], - ( , )
(20 / ) 30 [11], - ( , ) (2,5 /) 3 .
, (f3)
(f4) .
, , , - .
J. Dunn . [12].

, , , .
30 , ,
( ).

(100 / ).
, (1986, 2007).

StatisticSoft 7,0. ,
, -.
,
. , , t- .
<0,05.
.
1 2 (. 1) . ,
f3 1 61,5 % (<0,02), 2
f4 63,6 % (<0,05),
.

,
2,3 (<0,05),
77,8 % (1-2<0,001) , 1 .
(35
) : 3 4
fT4 5,0 (2-3<0,001) 4,2
1.
, ,
, - - (Mm)
1234567589
8
$7%758"%
7 8
8&8'(88
-86234567%89
%8
1488&8'(8
*86234567%89
%8
1456788&8'(8
'86234567%89
%8
2
354814567826 628%4558
8&8'(8
)86234567%89
%8
2
354814567826 628%4558
%8349:%2856588&8'(8
086234567%89
%8
2
354814567826 628%45588
349:%285658;<22:
248
%3%285"2
57<
%3
%
%288&8'(8

26
27578
1288

23 78
3288
)*+,---8
('',(-(8

2
27 8
92
2788
8
(-),(--8
-+),(')/8
1
-12(++8
8
*..6()(8
8
(-0,((*8
(-.,((+8
-0(,((*/8
(-*(('/8
1
(+(6(-(/8
891(7((-8
('*((28
8
(-+6((.8
8
-0*1,(('/8
(0(6((*8
8937(((-8
8
()'6((08
897((-8
8
(()6((-8
8937(((-8
8
((*6((-8
897(((-8
8
'(-6(-.8
8
'++6(-28
89272((*8
3927((*8
!538268"83#58
948
-(('(,.-(8
+').,0-0/88
9127((02
889127((08
2(*(,1-'/88
9327((088
889327((08
2'*',-((*/88
8
9272(((-8
889272((-8
8
. * (<0,05) ;
.
80
. 2013. 2
, ,
(2-4<0,001) , 5 fT3 ( , 2-5<0,02)

fT4 ( 3,6 , 2-5<0,001) 2 .

.

( 87,5 %,
2-4<0,001)
( 93,8 %, 2-5<0,001) ,

4 5 [13].
(. 1).

3, 4 5 .
d-

( 34,1 %, 1-2<0,001), ( 20,0 %, 1-2<0,02) 2 , 1 (. 2). ,

,
, , ,
.
, .
2. , ,
,
, , - - (Mm)
232686

266
6!6"#6$6
(63 23686
.156 6!6"#$6
'63 23686
.123456 6!6"#$6
"63 23686

216.12346
3376
2256 6!6"#$6
+63 23686

216.12346
3376
2266
4376723256 6!6"#$6
,63 23686

216.12346
3376
2256
43767232566
45
36
756225
76 6!6"#$6
6
7 6
#5%#&#5"'6
86
7
6
(5)#&#5(*6
(5,"&#5,%6
6
'5%+&#5*"/6
6
#5)%&#5'(6
7690#5#'6
123456789
866
6
2
6
"5+"&#5+,6
(5%-&#5+*6
326
6
(5'"&#5#+6
'5'#&#5+#6
6
"5#*&#5"#/6
6
+5+(&#5*#/6
7690#5#,6
"5-#&#5'*6
6
'5++&#5(#/6
5670#5##(6
"5'#&"5#'6
6
'5-'&#5*#6
6
'5(%&#5'-6
6
'%#5*+&-)5+#/6
6
(5#,&#5#(/6
1
(5'*&#5#*6
56708#5##(6
(5)*&#5#,/6
6
(5#)&#5"-6
6
"5(*&#5%'6
6
,5-&#5",/6
76
0#5##(6
6
"5-*&#5"-/6
76
0#5##(6
6
'5##&#5#'/6
76
0#5##(6
6
(5#)&#5"-6
760#5#,6
6
"5'%&#5)(6
6
"5-)&#5-+6
560#5#,6
6
"5-*&#5"-/6
760#5##(6
6
"5",&#5"'/6
760#5##(6
6
, - , , . 4
, , [14, 15].
-
. ,

,

, , ,
,
[16].
, , , ,
. 2013. 2
81
, ,
, ,

[14].
3. ,
59,0 % (<0,02)
. ( 72,1 %, 1-2<0,001).
61,8 % (2-3<0,05) .

( 3,8 ,
2-4<0,05) ( 45,0 %,
2-4<0,05)
.
(, , , ) .
3. ,
, , -
- (Mm)
1234567589
8
82448
88948
7758
7 8
!"8#8$%8&8
+8623456789
8
!118"8#8$%&8
*8623456789
8
!112348"8#8$%&8
$8623456789
8
!2
235481123488526 628
4568"#$%&8
.8623456789
8
!2
235488112348526 628
456883472856588
"8#8$%&8
/8623456789
8
!2
235488112348526 628
456883472856588
892272
24832288
5 2
5793

28"8#8$%&8
%'()%*'8
%+,)%%*8
88
2448
+%*)%*+8
+**)%*.8
8
%$.)%%-8
5671%%%+8
%+$)%%'08
7681%%/8
%*()%%-8
8
%*/)%%$8
8
%*$)%%$8
8
+**)%*.8
8
+*%)%+*8
8
%(+)%*+8
8
*/-)%$$08
1
+'$)%/,8
8
+/')%*,8
8
+*,)%.(8
8691%%*8
%+')%%,8
8
%--)%+.8
7691%%%+8
8
++/)%*'8
8
%,+)%$%8
86
1%%/8
8
8
%$-)%%,08
8
%*,)%%-08
76
1%%%+8
86
1%%+8
896
1%%*8
++$)%$-8
8
.
( ).

. .
.
82448
+-+)%+%8
.
,

- .
1. . .
/ . . , . . , . . // . .
. 2005. 3. . 3743.
2. . .

:
. . . . . . . . /
. . . 1972.
82
3. . . , /
. . // . 2007. 1. . 913.
4. . .
/ . . , . . , . . // -
. 2013. 2
, ,
. 2010.
4. . 34.
5. Fields M. Level of dietary iron? Not type of dietary fat, is
hyperlipidemic in copper-deficient rats / Meira Fields // Journal
of American College of Nutrition. 1999. Vol. 18, 4.
P. 353357.
6. . .
/ . . // . 2007. 2.
C. 113115.
7. Martinez-Galan J. R. Early effect of iodine deficiency
on radial glial cells of the hippocampus of the rat fetuset /
J. R. Martinez-Galan, P. Pedraza, M. Santacana // J. Clin.
Invest. 1997. Vol. 99. P. 27012709.
8. D-penicillamine induced copper deficiency in
suckling mice: neurogical abnormalities and brain mitochondrial enzyme activities / Masahiko Yamamoto [et al.] //
Division of Ultrastructural Research, National Institute of
Neuroscience, N.C.N.P., Tokyo. 1990.
9. - . .

-100 / . . - //
. 2007. 6. . 7377.
10. . . -
/ . . : . . . . .
. . . . 1972.
11. . .
- / . . //
: . 2009. . 4 (28). . 143146.
12. Dunn J. Two simple methods for measuring iodine
in urine / J.Dunn, H. Grutchfield, R. Gutekunst // Thyroid.
1993. Vol. 3. P. 119123.
13. . . :
/ . . , . . //
. . . 2009. 1 (19).
. 124131.
14. . . -
/ . . , . . ,
. . // . 2011. 4.
. 3136.
15. . . :
// .
2011. 4. . 104109.
16. . . : - - / . . //
. 2013. 2 (100).
. 220223.
CHANGES OF INDEXES OF LIPID METABOLISM IN RATS WITH HYPOTHYROID

DYSFUNCTION ON THE BACKGROUND OF COMBINED DEFICIENCY OF IODINE AND
COPPER AND OPTIMIZATION OF THEIR CORRECTION
T. V. Huranych
SHEI Ivano-Frankivsk National Medical University
SUMMARY. The lipids of blood, thyroid status, contain of Copper in R.B.C. mass, in homogenates of thyroid gland, cerebrum,
heart and liver, concentration of Iodine in urine, in male rats with hypofunction of thyroid gland were studied in condition of
Iodine derivation, combined Iodine and Copper deficiencies and also their correction. The changes of indexes of lipid
balance were confirmed in animals with hypofunction of thyroid gland. It was revealed that combined microelements
deficiency is followed by more expressed changes of bloods lipids. Injection of Iodine and Copper contained drugs are
effected for correction for lipids profile in animals with microelement dysbalance. The rationale of antioxidants and nitric oxide
donators to the scheme of the treatment were proved.
KEY WORDS: hypothyroid dysfunction, deficiency of Iodine and Copper, lipids of blood.
. 2013. 2
83
, ,
616-002008.935.096

2
. . , . . , . .
. .
.
2 . 2
65 /
230 /.
50 60 .

2, ,
. ,
.
: , , .
. ,
, ,
- [2, 3, 29]. , 2
[20].
,
, ,
[2, 3, 19].
, , , .
,
[1, 6, 10].

: , ,
[7, 13, 16]. ,
.

, [7, 17, 28].
84
, (
0,84 6,23 100 ,
0,24 3,32 ), , ,
[10, 13].
,

[13, 19].
,

.
. .
,
.

2.
.

, ,

[15].
. 2

20020 65 /, -
. 2013. 2
, ,
( 4,5) ( 15 )
230 / [26, 27].

,
( 4,5).
[21, 27]
-
, ,
, 2.
- () Humalyser 2000,
ombilyzer plus, [6].
() Epics XL (Beckman
Coulter, ) (-) (Sigma
Aldrich, USA). (
).
(), - ()
()
[8, 22, 23].
()
[24] [14] () [11]
[4],
() [9], () [25].
,
[18]. (30 /)

ART (), 60
:
50 , 1,2 2
60 . 21 . 1 8 (50 /).
-
. .
, (), -
(m). Excel (Microsoft, ),

( p<0,05) [12].
. . (7,080,20) /, ,
3
2,1 (15,150,34) /, 7
(11,20,28) /, 14 (8,720,21) /
. .
(0,370,08) /, 3
2 (3,340,08) /,
14 (1,860,09) /,
21 (1,610,04) /
28 .

. , 3-
3,4 , 7
2,8 , 14 1,8 ,
. 7 ,
,
1 .
,
, , 2 . 14 ,
, 21
2.
[3, 21], ,
,
.
, , . , 2 ,
, 166 %
.
,
. 1
. 2013. 2
85
, ,
213 % ,
8 191 % ,
1,2
2. ,
,
,
. 1
231 % , 8
225 %.
, ,

. (Fe2+) - [8]. , ,
.

. ,
,
,
.
.

. ,
1 210 %
, 8 161 %, 2
255 % 241 %.
2,1 1 1,7
8 , 2 1
2,6 , 8
228 %.
, .

2,2 ,
1,5 . 8 176 %
,
152 %.
2 . 1

1,5 , 8 1,6 ,
. 86
1,4 1,2
2.

. 1 193 %
, 8 200 %,
326 % 321 % , 2.
, ,
, , , 2 , [7, 9].

, . ,
,
.
,
,

, , ,
.
,
,
. ,
, ,
83 %, 65 %.
81 75 % .
1
114 %, 121 % . 8
65 % 80 %
.
2
1
44 %, 39 % . 8 49 43 %
.

. 2013. 2
, ,
141 % , 8 75 % . , ,
1 61 %,
8 63 %.

. 80 % 1 69 % 8 .
1.
, (m)
2
68
59
84
568
"#$8%&28
1.83652
4
8
%&82/%08
1.82%23
48
%&82/8
5683652
4
8
%%207/08
123456789
5224648
82
8
!82
8
8
8
4
48
4
5668
8
8
8
'(8
)'(8
*+8
8982%23
48
%&82/8
,(8
51+8
,-(18
))(-8
')(8
*+)8
)(',8
*+8
))-(8
5 +8
1
)(4'8
5 +8
1
-)(18
5 +8
1
1-(8
5 +)
1
!-(-!8
')(,8
5+)
-()8
5 +8
1
'-8(8
5 +)
1
(-)8
52)8
!,(--8
5 +)8
1
'1(,8
5 +)8
1
1'('8
5+8
'1-(!8
5 +8
1
'-(!8
5 +)8
1
)(18
-! (-!8
1
3
5682%23
48
%%207/8
,!(8
51+8
23456789
5224648
82
8
!82
8
8
8
-(8
(8
51+
5 +
5 +8
5 +8
,')(,8
, '(8
5 +8
5 2)8
5 +8
5 +8
-)('18
))('8
5 +)
5 +8
5 +8
5 +)8
)1'(8
-1 (-8
5 +)
5 +
5 +8
5 +8
!) (')8
1,-(- 8
5 +8
5 +)
5 +)8
5 +)8
-1,(!8
-!!(-8
5 +
5 +
5 +)8
5 +)8
1
: 2
1. 2 ;
2. 1 2 2
;
3. 2 2 2 .
2.
, (m)
2
68
59
84
568
"#8528
$%28
"#82$2-
48
$%828
/
4
0

85288
$
408
4
48
4
5668
8
8
8
&8
'(&)8
5*8
1182$2-
48
$8
++&+8
51*8
'&,8
51*8
23456789
5224648
82
8
!82
8
8
8
,!&,8
,& 8
5 *
51*
5 *8
5 *8
)&'8
(&,8
5 *
5 *
5 *8
5 .,8
++&+8
'&,8
5 *
5 *,
5 *8
5 .,
,& 8
(!)&)8
5 *
5 *,
5 *8
5 *8
(!!&(,8
,'&(+8
5 *
5 *
5 *,8
5 *8
&(88
& 8
5 *
5 *
5 *8
5 *8
2
+!& 8
))&(8
5*8
+)'&)8
5 *8
1
'+&'8
5 *,8
1
()&(8
&+8
5
8
& 8
5 *8
1
+&'8
5 *,8
1
,!&'8
5*8
!+)&+8
5 *8
1
'+&8
5 .,8
1
,&'(8
5*8
+'(&8
5 *8
1
!,&,+8
5 *8
1
,(&)8
5*8
+(&'8
5 *8
1
(&(8
5 *8
1
1
3
. 2013. 2
+)&!8
( &+!(8
' +&!8
45657
/
4
0

8
2$2-
48
$
48
83652
4
8
$08
123456789
5224648
82
8
!82
8
8
8
87
, ,
2 57 % 54 %
. , , 2.
,
,
.
. 2

.
1. . .

: .
. ... . 1999. .19.
2. . . XXI /
. . // . 2000. 1. . 45.
3. . 2 :
/ . // . 2000. 1. . 1619.
4. . .
/ . . // . 2008. 2. . 9699.
5. . .
/ . . // .
1985. 12. . 737741.
6. . . /
. . , . ., . . // erra
medica. 2001. 4 (24). . 3032.
7. . . / . . , . . //
. 2006. 6. . 1114.
8. . .

/ . . , . . ,
. . // . . 1984. 9. . 540546.
9. . . /
. . , . . . , 1982. 311 .
10. . . / . . // . () ,
13 2004 . : . ., 2004. . 228229.
11. /
. . , . . , . . , . . // . 1988. 1. . 1618.
12. . . - Excel / . . , . . , . . . . : , 2000. 320 .
13. . .
2 .
. 2007. 6. . 913.
14. . . /
. . , . . // . . 1983.
6. C. 2427.
15. - / [ . .,
. ., . ., . .]. . :
, 2002. 156 .
88
16. // . . , . . , . . , . . // . 2006.
2 (47). . 3437.
17. . . / . . , . . , . . // . . . . . -
. . . . 2000. 2. . 137138.
18. 65771: . .,
. . / // 23. 2011 .
19. / . . , . . , . . [ .] //
(), 2830 2006 . : . , 2006. . 197.
20. . . 2 () // . 2005. 118. . 13.
21.
2 / . . , . . , . . ,
. . // . 2011. 3. . 1218.
22. . .
/
. . , . . // . :
; . . . . . :
, 1977. . 6668.
23. . . / . . , . . , . . //
. 1996. 3. . 1315.
24. .
/ . , . , . // . . 1985. 11. . 678681.
25. Ellman G. L. Tissue sulfhydril groups / G. L. Ellman //
Arch. of Biochem. and Biophys. 1959. Vol. 82, 1.
P. 7077.
26. Islam S. Nongenetic Model of Type 2 Diabetes:
A Comparative Study / S. Islam, H. Choi // Pharmacology.
2007. 79. . 243249.
27. Islam S. Experimental rodent models of type 2
diabetes: a rewiev / S. Islam, D. T. Loots // Methods Find Exp
Clin Pharmacol. 2009. 31(4). . 249261.
28. Pucher J. Periodontal disease and diabetes mellitus /
J. Pucher, J. Stewart // Current Diabetes Reports. 2004.
Vol. 4 (1). P. 4650.
29. Standards of Medical Care for Patients With Diabetes
Mellitus // Diabetes Care, American Diabetes Associations:
Clinical Practice Recommendations. 2001. Vol. 24.
P. 11151119.
. 2013. 2
, ,
FEATURES OF CURRENT FREE RADICAL PROCESSES AND ANTIOXIDANT SYSTEM

IN EXPERIMENTAL ACUTE PARODONTITIS ON THE BACKGROUND TYPE 2
DIABETES
K. M. Duda, B. V. Vons, I. M. Klishch
SUMMARY. In the experiment on rats the peculiarities of free radical processes and antioxidant system reproduced the model
of type 2 diabetes and acute parodontitis were studied. Diabetes mellitus type 2 modeled by intraperitoneal administration of
streptozotocin calculation of 65 mg/kg after previous administration maintenance dose of nicotinamide 230 mg/kg. Inflammation
in parodontium modeled by a single directional influence of ultrasonic vibrations at the frequency of 50 kHz exposure effects
in 60 seconds. The increase in the intensity of lipid peroxidation with a simultaneous reduction in antioxidant defense in
animals with acute parodontitis on the background of type 2 diabetes compared with animals that parodontitis modeled on
the background of normoglycemia. It is concluded that there are peculiarities of inflammation in parodontium against the
background of diabetes.
KEY WORDS: parodontitis, diabetes, streptozotocin.
. 2013. 2
89
, ,
616-056.5: [616.12-008.331.1 + 616-056.52 + 616.13.002.2-004.6 + 616.379-008.64]

,
,
. . , . .

. ,

-, - ,
.

,
.
: , , , , .
. , - , , , .

(C),

1025 % . 24 ()[15].
, ()
, (),
, , [6]. ,
[7]. ,
[8]. ,
, , ,
, , , in vitro [9], ,
,

.
35
, [10]. LIFE
(Losartan Intervention For Endpoint reduction in
hypertension) () 90

[11].

, , , ,
.
.
127
() , , 54
78 . 3 :
() 20 ; ,
57 ; , ,

50 .
. , 1 2
().

, , ,
, , , ,
, ,
,
- ,
. , .
. , - .
. 2013. 2
, ,

12 .

, , ()
()
.
,
. , , , ,
. . . . (1979).
, - . , 30 /2,
; 2530 /2
.

2,5 (-),
(-) . - , - .
- : , , ,
(),
(),
(); ().
(), (), (),

()
Teinchnolz LE et al. (1972).
.
() ()
, .
(159,691,88) . ., (163,231,78)
. .,
(149,401,52) . ., <0,05.

((98,851,18) . .
(99,441,21) . . )
((95,291,04) . ., <0,05).

,
((5,440,37), (6,190,41) (7,230,44) (3,23 0,24)
)
((1,140,12), (1,530,21)
(1,880,24) (0,270,11)).
,
((7,230,44)
(6,190,41))
((1,880,24) (1,530,21)).

.

: (1,140,01) , 1 (1,150,01) , 2 (1,16+0,01) >0,05 (. 1).
1. , ,

123456789
9
7
3 97!"#$%77
3 97$,%77
5"/%77
5/%77
3/%77
45%767
53
397
8977
%&'%'7
%*)'%'7
(%..)%-07
00%(()%7
-0%&-%7
(&%*'%*7

(<0,05): ,
2 (34,31,23) , 1 (36,51,05) ,
(51,991,83) .
(133,552,2)
(111,37+2,63) 1
(110,232,5) , <0,05.
6
89777
%()'%'7
%-)'%'7
0*%(%'(7
%02%*07
2(%'.%.7
(%'*'%(27
6
89777
%*)'%'7
%.)'%'7
0&%0%07
'%0%(7
2%%07
&.%'*'%(27
3 3
7
+'%'(7
+'%'(7
1'%'(7
1'%'(7
1'%'(7
1'%'(7
((83,482,2) )
1 2 ( (75,092,29) (72,112,13) ). ,

, ((49,060,54) %
(51,060,57) 1 (54,60,6) %
<0,05).
,
-
. 2013. 2
91
, ,
( = 0,36, <0,001) .

( = 0,32, <0,001) ( = 0,3, <0,001).
. III
((1,160,02)
(1,210,03) ), II
(1,140,02) (1,150,02) ),
.
, ,
2 III , II .

,
, .

((1,160,03) ) III
(1,190,03 ), II (1,130,02
1,160,02 ),
(>0,05).
,

,
.
2
(=50) ( = 22) ( = 28). 2.
2. ( )
(+m)
123456
7898
9
$%&'()

$1()

4&4)
5
4!4)
5
84)
5
9:);
8
73
3799

7
*)*+,-)-
*)*2,-)-
+.)*0,*)2.
***)76,+)+6
*)2.,)7+
0-)*7
( (1,160,01) (1,200,02) ,
( (1,130,02)
(1,140,02) ), (<0,05).

((70,883,18) ),
(81,462,93 , <0,05).
(47,13 % 50,19 %, <0,05).
.
8 73 893

7
*)*.,-)-
*)-,-)-
+.)62,*)2
*-6)..,+)67
6-),+)*
26)*+
!33"9#
9/-)-0
93-)-0
9/-)-0
9/-)-0
93-)-0
93-)-0
, ,
,
.
.

, , .
1. . . 2 / . . , . . , . . // Consilium medicum. 2006. . 8. 5.

. 5861.
2. . . / . . , . . // Consilium medicum. 2006. 8, 5. C. 5457.
3. Early activation of vascular endothelial cells and
platelets in obese children / G. Desideri, M. De Simone,
92
I. Lughetti [et al.] // J. Clinic. Endocrinol. Metabolic. 2005.

Vol. 90. P. 31453152.
4. Kahn B. B. Obesity and insulin resistance / B. B. Kahn,
J. S. Flier // J. Clin. Invest. 2000. Vol. 106. P. 473481.
5. Obesity-associated Hypertension. New insights into
mechanisms / K. Rabmouni, M. L. G. Correia, W. G. Haynes
[et al.] // Hypertension. 2005. Vol. 45. P. 914.
6. Metabolic syndrome and ischemic heart disease
in Gout / J. Vazguez-Mellado, C. G. Garsia, S. G. Vazguez
. 2013. 2
, ,
[et al.] // J. Clin. Rheumatol. 2004. Vol. 10.

P. 105109.
7. Mazzali M. Elevated uric acid increases blood pressure
in the rat by a novel crystal-independent mechanism /
M. Mazzali, J. Hughes, Y. G. Kim [et al.] // Hypertension.
2001. Vol. 38. P. 11011106.
8. Cardiovascular morbidity and mortality in the Losartan
Intervention For Endpoint reduction in hypertension study
(LIFE): a randomised trial against atenolol / B. Dahlof,
R. B. Devereux, S. E. Kjeldsen [et al.] // Lancet. 2002.
Vol. 359. P. 9951003.
9. EULAR evidence based recommendations for gout.
Part II: Management. Report of a task force of the EULAR
Standing Committee For International Clinical Studies

Including Therapeutics (ESCISIT) / W. Zhang, M. Doherty,
T. Bardin, [et al.] // Ann. Rheum. Dis. 2005. Vol. 65.
P. 13121324.
10. Sweet C. S. Pharmacodynamic activity of intravenous
E-3174, an angiotensin II antagonist, in patients with essential
hypertension / C. S. Sweet, D. C. Bradstreet, R. S. Berman
[et al.] // Am. J. Hypertens. 1994. Vol. 7. P. 1035
1040.
11. Burnier M. Renal effects of angiotensin II receptor
blocade in normotensive Subjects / M. Burnier, F. RochRamel, H. R. Brunner // Kidney Int. 1996. Vol. 49.
P. 17871790.
MORPHOLOGICAL AND FUNCTIONAL CHARACTERISTIC OF THE MYOCARDIUM

IN PATIENTS ON ARTERIAL HYPERTENSION COMBINED WITH UNSTABLE ANGINA,
OBESITY AND DISTURBANCIES OF PURINS METABOLISM
I. P. Katerenchuk, O. V. Mokhnachov
State Higher Educational Institution of Ukraine Ukrainian Medical Dental Academy
SUMMARY. It was established that the presence of obesity and purins metabolism disturbances in patients on arterial hypertension
and coronary heart disease leads to statistically relevant changes of morphological and functional indexes of myocardium
to statistically relevant decrease of end-systolic, end-diastolic and pump volumes and also to the decrease of ejection fraction
rate.
When comparison of morphological and functional characteristics were performed differentially on patients with gout and
hypeuricemia it was established that in patients on gout in statistically relevant character the thickness of interventricular
septum increases, the pump volume and ejection fraction of the left ventricle decreases.
KEY WORDS: rterial hypertension, coronary heart disease, obesity, hyperuricemia, gout.
. 2013. 2
93
, ,
612.017.1:616-092.9

. . , . . , . .

.
.
,
.
: , , , , , .
. . ,
.
,
[1, 2]. ,
.
[3, 4, 5].
,

: ,
.
,

, [6]. ,
. .

, ,
[7, 8].
, , - .
,

.
. 18 - .

(200 / , ), 94
(0,7 /, ). 7, 30 90
. . 10 %
. 56 -.

(1000 2) ,
.

- (r), :
( , , );

, ; ,
.
.

, 7 30
,
90
(0,71<r<0,96) (. 1).
,
(0,55<r<0,65).

, ,
7 30 ,
,
90 (0,74<r<0,98). -
. 2013. 2
, ,
. 1.
() (),

(),
()
.

, ,
, 7, 30 90
(0,83<r<0,99).
(r=0,29).
.
-
(0,29<r<0,99).
,

,
.
.

.
1. Wetzel M. A. Sediment pollution in the Elbe estuary

and its potential toxicity at different trophic levels / M. A. Wetzel,
D. S. Wahrendorf, P.C. von der Ohe// Sci. Total Environ.
2013. Vol. 449. P. 199207.
2.Bardana E. J. Indoor air pollution and health / E. J. Bardana, A. Montanaro // Occup. Environ. Med. 2000. 57.
P. 285288.
3. . .
, / . . , . . //
, , . 2010.
2. . 4046.
4. Rapid Induction of an Immune Response in Rat Peyers
Patch after Oral Administration of Enterococcus faecalis Strain
EC-12 / R. Inoue, T. Tsukahara, N. Matsukawa [et al.] // Biosci.
Biotechnol. Biochem. 2013. Vol. 46. P. 246251.
5. . . / . . , . . , . . // . 2004.
12. . 58.
6. . .
/ . . , . . // . 2005. . 8, 4. . 207212.
7. . . : . 10-
, / . . . :
, 2004. 479 .
8. Correlation of acanthosis nigricans with insulin resistance,
anthropometric, and other metabolic parameters in diabetic
Indians / P. P. Patidar, P. Ramachandra, R. Philip [et al.] //
Indian J. Endocrinol Metab. 2012. Suppl. 2. P. S436437.
RELATIONSHIP BETWEEN PARAMETERS OF SMALL INTESTINE PEYERS PATCHES

RATS AFTER CORRECTION BY IMUNOFAN OF IMMUNOSUPPRESSIVE STATE
S. A. Kashchenko, O. N. Morozova, O. M. Petizina
SI Lugansk State Medical University
SUMMARY. The relationship between parameters of the Peyers patches small intestine of immature rats after correction by
imunofan of immunosuppressive state were investigated by means of calculation coefficient of correlation. The results of the
correlation analysis showed that among the parameters of plaques in experimental animals has direct communication in
different periods of observation.
KEY WORDS: rat, small intestine, Peyers patches, imunofan, cyclophosphamide, correlation analysis.
. 2013. 2
95
, ,
089.844:599.731.1-035.51:615.468.21

. . , . .
. .
.
.

.
: , , , .
. .
, [1, 2, 8].

.
,
[3, 4, 5, 7].

35 [6, 9, 10].

, 79 .
[11,
13, 14]. .
[12, 15].

,
,
[13, 14, 16].
[13, 15].

,
, .
96

.
.
, ,
.
110
. 3 . ,
- . ,
.
.

(). 1.1, 2.1
3.1 <60, 1.2, 2.2
3.2 , >60.

: ,
,
, , ,
, -
. 2013. 2
, ,
. ,
- . . , . . . . [17].
.
1.1 1.2
(,
) - ().
, , ,
, . 37,538,7 , 90
115 .
8,710,9x109/.
.
,
. ,
,
.
,

, 34
- ,
.

, . 38,1
39,3 ,
12,314,7x109/, -
- . 1012 -
, 38,439,5 ,

13,415,1x109/, -
. 1517 ,
. . 1.1

2326 , 1.2
3037 .
2 3 .
-

0,1
0,2 . .
.
0,3
0,4 . - . . .
3.1 3.2 , .
23 .
,
, , , 37,337,9 ,
, ,
2.2 10,711,0109/, 3.2
10,511,1109/.

1014 .
, ,
, .

.
,
, 2
3 ,

.
79 , ( 2 3 )
, - .
.
. 2013. 2
97
, ,
,
7 , 2 3 -
, 14
-,
22 .

2.1 3.1
2024 , 2.2 2.3
2833 .
.
, , , , .

,

.
.

.
1. . . : . . . . . :
. 14.01.03. / ;
- . . .
. , 2008. 20 .
2. . . / . . ,
. . , .. // . 2006. 12. C. 915.
3. . . :
. . . . . :
. 14.01.03. / ;
. . . , 2002. 28 .
4. . . : / . . ,
. . , . . // .
2003. 3. C. 8889.
5. . . - / . . , .., . . // . 2003. 11. . 50.
6. . . / . . //
. . . . 2003. 2. . 724726.
7. . .
/ . . , . . , . . // .
2005. 1. C.136137.
8. /
. . , .., . . , . . // . 2006. 3.
. 215216.
9. / . . , .. , . . , . . //
. 2007. 2. . 614.
10. / . . ,
98
. . , . . , .. // . 2004. 4. C. 7980.
11. . . / . . ,
. . , . . // , , , - : .-. . : . , 2004. . 321324.
12. 7217
(UA), 01N1/00, G05D11/16. / . . , . . . 2004.1108922 ;
. 01.11.2004 ; . 15.06.2005, . 6.
13. . .
/
. . // . 2006.
3. C. 117119.
14.
/ . . , .., ..,
.. // . 2003. . 4, 1.
. 127130.
15. . .
: ,
, / .., ..,
.. // , 1720
2002 : . , 2002. . 2.
.536538.
16. . . /
.., .., . . //
: LV - , 150 . .. :
.-. . : , 2004. . 66.
17. . .
/ . . , . . . . : , 1942. 48 .
. 2013. 2
, ,
EFFECTIVENESS OF COMBINED USE OF ABSORBENT POLYURETHANE AND

PRIMARY WOUND COVERAGE DURING REALIZATION OF EARLY SURGICAL
TREATMENT OF PATIENTS WITH BURN INJURIES.
A. O. Kovalchyk, V. V. Demyanchuk
SUMMARY. The article presents data about the results of the application of lyophilized ksenodermoimplants in combination
with absorbent polyurethane at early stages of surgical treatment of patients with burn injuries. The high effectiveness of using
secondary polyurethane bandages and biological wound coverage is proven, in conducting early necrosectomy of affected
skin in patients with burn injuries.
KEY WORDS: burns, necrosectomy, ksenodermoimplants, polyurethane coverages.
. 2013. 2
99
, ,
616.127-091.8-071.3]-092.9

. .
. .
.
. ,
, .
.
: , , .
.
,

.
, .

,
- ,
[1], . ,
, 50 % . ,
[2].
,
.
, [3].
, - , , - [4].
[5].

, , [6, 7].
, , ,
, , ,

.

.
.
33 -
100
182190 , . 1
16 , , 217 ,

( U9401 15.09.2005).
- 72
.

. : (, , ,
); (, , ,
); , ,

(, , , ;
, , , ; ,
, , ; ,
, , ); - (, , ,
); -
(, , , ); - (,
, , ). . [8].
. 1.
,

. ,
(15,030,33) (16,140,23) . (<0,05)
7,4 %.
. -
. 2013. 2
, ,
1. (Mm)
856
66
#66
#%&6
&'(6
&'6(6
&'*+6(6
&6
*+&6
&'(6
6
#66
#%&6
&'(6
&'6(6
&'*+6(6
*+&6
&6
&'(6
66
#66
#%&6
&'6(6
&'6(6
&'*+6(6
&6
*+&6
&'6(6
66
#66
#%&6
&'6(6
&'6(6
&'*+6(6
&6
*+&6
&'6(6
56
6
! 6
6
)6
)6
$$6
6
,!!6
$6
)6
6
!6
)!!6
!,6
6
)!6
!6
))!6
$ 66,6
, 6
6
)!$ 6
)6
6
$$6
$!6
$6
))6
6
!6
)$$,6
!6
6
6
$!6
$! 6
12345674879
2

6
56
!"6
$"""6
!""6
) ! 6
!)"""6
"""6
"""6
$ ,"""6
! )!"""6
!""6
)"""6
"6
) 6
! """6
! """6
"""6
"""6
$)!"""6
$"6
! """6
!6
)6
$6
)"""6
6
!""6
,"""6
$!"6
)"""6
6
))6
)"6
!"""6
"6
""6
!!"""6
6
.
, : * p<0,05; **
p<0,01; *** p<0,001.
12,5 %,
. , ( 9,2 %)
(<0,01) .
. , (85,201,32) (83,601,46) %,
1,9 %. . 27,2 %.

(5,210,08) (4,200,08) %.

(<0,001) 19,4 %.

- - . (0,06110,0012)
(0,05100,0010). , (<0,001) 16,5 %. (0,17400,0024) (0,19600,0027),
12,6 %. -
. 2013. 2
101
, ,
- - [9].

.
(p<0,01). 6,8 %.
10,8 %. ,
. ,

(<0,05), . , 7,0 %.

. 1,7 %.
(<0,001), . , 14,8 %.
,
-
- (<0,001) , . ,
(0,06400,0015) (0,05530,0012). (<0,001)
. 13,6 %.
. 10,9 %
(<0,001).

(46,301,84) %, (39,801,45) %,
24,4 21,2 . (<0,001)
.
(. . 1).
. ,
,
, , , , -, -, - , .
.
, .
1. . .
/ . . //
. .-. . , , 2004. . 57.
2. . . (, , , , ) / :
, 1997. 200 .
3. Benjamin D. R. Mushrooms poisoning in infants and
children: the Amanita pantherina muscaria group /
D. R. Benjamin // J. Toxicol. Clin. Toxicol. 1992. Vol. 30,
1. P. 1322.
4. . .
/
. . , . . , . . // . 2000. 2. . 8385.
5. . . / . : , 1999. 416 .
6. Amann K. Cardiac structure and function in renal
disease / K. Amann, E. Ritz // Curr. Opin. Nephrol.
Hypertens. 1996. Vol. 5. P. 102106.
7. Canella G. Myocardial hypertrophy in chronic renal
failure: a multifactorial, reversible alteration / G. Canella,
E. Paoletti // Contrib. Nephrol. 1996. Vol. 119. P. 8692.
8. . . / . . : , 2002. 240 .
9. . .
/
. : , 1997. 448 .
HYSTOSTEREOMETRIC DESCRIPTION OF MYOCARDIUM IN CASE OF TOXIC LESION

M. F. Kovryha
SUMMARY. In the experiment on white rats the peculiarities of structural reconstruction of the heart muscle in Amanita
phalloides poisoning was studied. It was established that toxins led to the considerable structural reconstruction of myocardium
that characterized by changes of hystostereometric parameters. These changes were bigger in myocardium of left ventricle.
KEY WORDS: Amanita phalloides poisoning, heart chambers, hystostereometry.
102
. 2013. 2
, ,
612.24.015.11:616.248-092.9

. .

.
5 19 .
, 5 ,
19 ,
.
: , , ,
, , , .
. ()
,
. -
, , , [1]. , ()
() .
[2].
,

.

() , , , , ()
[3].
, .
. , ,
, , ,
,
, - ,
- [4].
(), -
(), (). , ,
40 %
. (), ()
()
[5]. - [5],
[6].

. , ,
.

.
. 60
() 180220 ,
5 12 . ()
,
(5 ),
(19 ), V
(26 ),
V 33- .
: .
5 19 .
26 33 .

. . (1979).
.
,

. 2013. 2
103
, ,
(, 1985). . . ,
. . (1989) [7],
. . (1989) [8].

R. Fried (1975) [9], B. Holmes,
C. Masters (1970) [10] . . (1988) [11]. .
.
.
(5, 19 )
20,1 % (<0,05) 38,8 % (<0,05),

.
, . , 5 19
29,5 %
(<0,05) 37,5 % (<0,05),
.

1.
1. (Mm, n=36)
1234567289
76
5
653 !623296
238
68 66
,8-,3 4,5926.6
3 59
86
5235667256
6
+6
"*6
, ,
35,7 % (<0,05) 5 , -

9
86
53 6
"#6
"#6
"#6
66429496
6
"#$%&'$(6
"%$*&'$+6
"/$#&'$*6
66
4294966
#'$)&'$*6
#($)&'$*6
#/$*&'$*6
. 19
(<0,05). 2.
2. ,
(Mm, n=36)
1234567289
76
#5
653 6
23296
/238
68 66
08103 405926236
3 59
86
523566
7256
6
+6
$46

9
86
53 6
5595566
424966
662496
6
!"66
424966
$%6
&%'()%'&6
$%('%)('*6
+',)-'.6
$%6
$%6
+$'.)$'&6
&('+)$'%6
$*,'$)$'*6
$%+'$)$'+6
*'&)-'&6
&'()-'&6

. 22,5 % (<0,05) 5
19 , (<0,05).
, , 11,8 % (<0,05)
5 . , 19
,
24,7 % (<0,05), .
.
.

104
. ,
5 ,
19 . ,
.

.

.
. 2013. 2
, ,
1. / . . , . . ,
. . , . . // . , .
. , 2012. . 147.
2. . .
/ . . // . 2000.
1(15). . 8693.
3. . . - - / . . // . 2006.
1. . 6668.
4. . .

/ . . ,
. . , . . // . 2004. 91. .7.
5. . . / . . , . . , . . // .
2006. 7. . 3741.
6. . . / . . ,
. . , . . // .
2009. 12. . 147.
7. . . / . . , . . // .
. : , 1989. . 170171.
8. . .
/
. . // . . 1989. 7. . 810.
9. Fried R. Enzymatic and non-enzymaticassay of
superoxide ifilii / R. Fried // Biochemie. 1975. Vol. 57,
5. P. 657660.
10. Holmes R. Epigenetic interconversions of the multiple
forms of mouse liver catalase / R. Holmes, C. Masters // FEBS
Lett. 1970. Vol. 11, 1. P. 4548.
11. .
; . .
. . . . : , 1988. .153.
CONDITION OF PROOXIDANT AND ANTIOXIDANT SYSTEM IN THE LUNGS

OF GUINEAS PIGS IN THE EARLY PERIOD OF FORMATION OF EXPERIMENTAL
BRONCHIAL ASTHMA
M. A. Kolishetska
SUMMARY. Gradual increasing of lipid peroxydations products malonic dialdehyde, diene conjugate had been determined
on the 5-th, 19-th days of experimental bronchial asthma development in this research. Primary increasing of the indices of
superoxidedismutase, glutationperoxidase and catalase were investigated in the pulmonary tissue on the 5-th day with the
following decreasing of these enzymes on the 19-th day of experiment. It testified about imbalance in antioxidant and
prooxydant systems.
KEY WORDS: bronchial asthma, antioxidant and prooxydant systems, malonic dialdehyde, diene conjugate, superoxidedismutase,
catalase, glutationperoxidase.
. 2013. 2
105
, ,
614.2:616.43(477.84)

. .

. , ,
14
,
-
, .
: , , , , .
. ,
.
,
- [2-4].
, ( ,
, ), , .

, , [3, 5].

20102012 ., 158999
159999
118999
119999
138999
139999
198999
199999
328999
329999
.
.

, , 14
( 1517 )
20102012 .
.
.
, , , 203 564 (. 1). .
(20102012 .)

0 17
,
,
112342
115653
132367
1996
199
1994
138318
1992
133139
1939
1933
194586
195867
1931
12345267489
7 863
. 1. .
106
. 2013. 2
, ,
., (
) (. 1).
(),
, (466,6 10 000 ), (190,3 10 000 ), (43,1
10 000 ). -
( 3,3 10 000
, 2,7, , , 0,8, 0,1) (. 1).
, (),

(191,9 10 000 ),
1. , ,
888
1389-
,247
#4
-
8567!
#4
-
85567!
289-
4786'
-
867!'!
4
,4'
-7
"#$%
8
+ )
)
.)
*
/
.*
/)
0*
*3*
)/.

)(0
30
(.
0)
(30
0*
303
(()
0
*
/
.
(.
/
3
)
3
*

3
)
*

**
3)
(
//
(*/
)/
0
..
(0
*+ .
268 8
+ .
+ )
*+ .
268 8
+ .
+ )
*+ .
268 8
+ .
+ )
*+ .
268 8
+ .
+ )
8348786
86,4
-
786'
-
*+ .
8989-
786'
-
268 8
87
+ .
87348
+ )
*+ .
93
12345673892
8968 8
12345673892
894349
9838
77
3! 3! 3! 3! 3! 3!
&6!'62
(
(
)

*
(
2 ,74-
.
..
/(
(
*
)
&6!'62
.0
.0
.
*
/

2 ,74-
/(
0
./

0
*
&6!'62

0

.
((
*
2 ,74-
0)
00

(
3

&6!'62
3/0
. 0/
3/.
.*
(/
0(.
2 ,74-
(0..
)(/
).0
*.)
/ )
.)(
&6!'62
//*
0 *
/*
/
(.
33
2 ,74-
333/
.).
. )3
*/)
.)/
33.
&6!'62
0. )
(
0.
(/(
) 0
(00/
2 ,74-
(
).//
)333
...
00.
0 0
&6!'62
*3
)3
) *
)
/
//
2 ,74-
0/
.
)3
.
3)
*
&6!'62
*.
)0.
)/
0*
.
(30
2 ,74-
/

0
0
.)
!*
&6!'62
((
0*.
/0.
0
/
*3
2 ,74-
)/
)*(
)(

/*
.*
&6!'62
0

/
0
3
(
2 ,74-
.

*
)

&6!'62
*
)(
(/

3
3
2 ,74-
3
)
0*
(
*
*
&6!'62
30
3(
*3
0

0
2 ,74-
(
(
.
0
3
)
&6!'62
/
/
/
(

2 ,74-
*
*
*

&6!'62
/
.
0

(
2 ,74-
/
.

*
*
.
&6!'62
3
*
.
*
)
*
2 ,74-
.
.
/

&6!'62
(*
)
).
)
0
)
2 ,74-

)
/

*
/
&6!'62
.

)
)

2 ,74-
(0
*
**
0

*
&6!'62
*
3
30
/
(
3
2 ,74-
)
0
((
)
3
/
&6!'62
/).
()
( 3.
.3/
/..
30.
2 ,74-
3*.
0/
//
)).
* 3
) )
&6!'62
33
.)
.00
3
.*
0
2 ,74-
*/
.
(/(
(.
)(
).3
&6!'62
(*/
(0))
(033
0/
*
//.
2 ,74-
3(
/3.
0(
)(
)0/
)3
32983298

38
268 8
+ .
+ )
*+ .
268 8
+ .
. 2013. 2
107
, ,
(42,6)
(7,5 1000 ),
(1,2 10 000 ).
, 510%
5%,
2% .

, , , [2, 5].
, 2011 . 7929 , ,
,
014 . ,
2012 . 211 017 ,
, 10,1
10 000 , 9,4
2010 .
(. 1).

, . ,

14
123 (7,2 10000 ) 2010 . 140 (8,3 10 000 )
2012 . (. 1).

. (2010 .
312,1; 2012 . 466,6 10 000 ), (2010 . 2,4; 2012 . 3,3
10 000 ), -
(. 1).
-,

[3, 6].

,
, (
).
25 %
, 15 %
[1, 2]. 1820
.
.
,
2 - .

. , 017
2010 . 163,1 10 000 , 2012 . 190,3, (141,1 10 000 ).
, .

, , ( , , , ).
,
, ,
(. 2).
2. , ,
32983298

38
12732
) (
"6!#62
3867
2 *74+
') $
"6!#62
2 *74+
.68 8
"6!#62
) $
2 *74+
127326727498 8 ) (
"6!#62
3897
2 *74+
') $
"6!#62
2 *74+
.68 8
"6!#62
) $
2 *74+
888
108
12345673892
8968 89838 12345673892
89434977
3! 3! 3! 3! 3! 3!
$%
&'
(
$

'
('
,%
'
(

,
'%
(%
((
'

(
,(
&

'

,&
,
%&

(
-
&,
'(
(
&

(
'
,%
-
'
,
,
,

$
,

(%
(
,(
,

-

%'
,
-
,

%
&,
%
'

(&
,%
,
%
$
&
. 2013. 2
, ,
, ,
(. 1).
,

, ,
- ,
(
), (
), .
.

, . , ,
14 , ,
. ,

, .

,

,
, , ,
.

,
, ,
, , .
,

,

, ,
.
1. . . / . . // . 2008.
. 5053.
2. . .
2010 [ ] / . . , . . , . . . http://www.mif-ua.com/archive/article/
17758.
3. . . [ ] /
. . . www.http://health-ua.com/articles/1342.html.
4. -

,
,
: 127 15.02.13.
5. . .
/ . . , . . , . . //
. 2011. 3 (13). . 6166.
6.
/ . . , . . , . . [ .] // . 2009.
. 88, 6. . 2731.
CURRENT STATE OF ENDOCRINOLOGICAL SERVICES IN TERNOPIL REGION

H. I. Korytskyi
ME of TRC Ternopil Regional Childrens Clinical Hospital
SUMMARY. A high prevalence of endocrine diseases in children and teenagers with simultaneous tendency to reduce the
incidence is revealed in Ternopil region by comprehensive analysis of the dynamics of basic health indicators prevalence,
incidence, its structure in children up to 14 years and teenagers. These indicators show the need for a qualitative examination
of children with active detection of diseases of the endocrine system of primary health service family physicians, pediatricians.
KEY WORDS: children, teenagers, endocrine pathology, prevalence, morbidity.
. 2013. 2
109
, ,
616.36-099:546.56-008.1-06:616-001.1

. .
. .
. ,
,
. ,
.
: , , , , .
.
.
, 23,5
85,0 % [14].
70 . , 40 [13].

, [4].
, , .

(, )
, 88 [12],
,

[8, 10].

,
[11],

. 20
3 , 2006
2010 . [7].

/
,
,
, , [9].
, , , [6].
110
. ,
,

, .

.
. 150 180200 .

5 -1
[5]. 14 (40 -1 )
(72 ) :
; (2022 % ),
; [1].
(72 ) . (6 ).
-
(60 -1 ) 1, 3
7 . ,
(
). ,
[2].
. STATISTICA 10.0 (StatSoft, Inc., ).
. 2013. 2
, ,
.
, (. 1) 1
%
(
16,4 % (<0,01), 8,2 % (<0,05).
( 7,6 %, <0,05).
32
125411

125

124
127
127819
12
126
1266
1234
1234526789
88
123
1236
1214
121
12

1
7
. 1.
( : #
(# <0,05; ## <0,01; ### <0,001);*
(* <0,05; ** <0,01; *** <0,001)).
3

.
%
12

(. 2) 1

,
126518
126
12941
129
12561
125
1233
1234
123
1237
124

121
12
!

1
9
. 2.
.
. 2013. 2
111
, ,
( 12,8 % ,
<0,05; 8,7 % ,
<0,05)
.
, ,
( 9,3 %, <0,05),
.

3 ,
, , 7,6 %
(<0,05),
%

.
(. 3)
, ( 35,4 %, <0,001; 42,4 %, <0,001;
17,5 %, <0,01).

, (
31,5 %, <0,001; 18,8 %, <0,001; 6,6 %,
<0,05).
62
3111222
62
629
626
625
6291111222

6285112
6278111
12
129
12331
1245
126
125
7
1
3
. 3.
.

37 ( 19,9 %, <0,001
10,2 %, <0,05).
,

, .
, , , , ,
,
[3], .

.
.
,

. ,
.
1. . .
/ . . , . . -
112
// - . 2012.
. 11, 3 (41), . 1. . 2426.
2. : -
. 2013. 2
, ,
; . .-. . . . . : , 2001. . 348.

3. . . / . . , . . , . . // . 2008. 1. . 5357.
4. . . -
/ .., . . : , 2008. 140 .
5. . .

/ . . , . . //
. . 1999. . 19. . 2124.
6. . .

/ . . // . . 2001.
. 42. . 90-95.
7.
i 2006 2010 . , 2005. 22 .
8. . . in vitro / . . // . : .
2000. 1 (8). . 5356.
9. . . -
() / . . , . . , . . [
.] // .
: . 2000. 3 (10). . 7278.
10. . .

/ . . //
. : .
2001. 2 (13). . 4449.
11. . . Anodonta
cygnea / . . , . . , . . //
. : . 2003. 2 (21).
. 9497.
12. . . : , ,
, / . . , . . , . . [ .] // .
2002. 3. . 1012.
13. . . /
.., .. , .. [ .] // . 2002. . 58.
14. Peden M. World report on road traffic injury prevention. / M. Peden, R. Scurfield, D. Sleet [et al.] // Geneva,
Switzerland: World Health Organization; 2004.
FEATURES GEMODYNAMIC LIVER DISORDERS IN THE DYNAMICS OF MECHANICAL

INJURIES OF VARYING SEVERITY WITH CHRONIC INTOXICATION OF COPPER
AND ZINC SALTS
O. Ye. Kopacz
SUMMARY. In experiments on rats showed that chronic toxicity of copper and zinc salts significantly affect the behavior of the
liver in skeletal injuries of varying severity, most notably in trauma medium and severe. In these circumstances, significantly
increased the swelling organ, manifesting a significant increase in liver weight index.
KEY WORDS: polytrauma, liver, chronic intoxication, copper, zinc.
. 2013. 2
113
, ,
612.335+591.434+615.9]-001.5

. . 2, . . 1
. . 1
2
.
. ,
,
.
: , , .
.

, [1].
,
,
.
.
,
,
, [2].

,

[3].

.
. , ,
32 - ,
. 1- ()
8 ,
, 2-
12 ,
7- , 3- 12 ,
14- .

6/
[4]. .
,
, -
114
[5].
10% 23
. ,
. -, -, , , . , , , ,
. .[6].
, , ,
.

<0,05. Excel
Statictica IBM.
. 1.
.

2- 7 (14,770,16) , 16,79 %
.
14
(15,310,18) ,
(2<0,05).
. 2013. 2
, ,
1.

2724789
89
879
9
!98!524"9 9
"#$%"9
!9 !8 54)5"9 9
%"%$%"#9
!98 54)5"9 9
&"%$%"%*9
!9 238 54)5"9 9
"(#$%"(9
!9!74"9 9
&"%$%"(9
2879
158
158
158
158
158
123456789
89879
96289
12
9
'9%"%%9
#"($%"99
'9%"%%9
"*$%"9
'9%"%%9
#"%$%"%&9
'9%"%%9
#"$%"9
'9%"%%9
(%"$%"((9
96289
9
"$%"&9
"%$%"(99
"*%$%"%9
#"#$%"#9
("#$%"(%9
19
39
'9%"%%9
'9%"%%9
'9%"%%9
'9%"%%9
'9%"%%9
'9%"%#9
'9%"%#9
'9%"%9
'9%"%9
'9%"%9
. 1 , 2
14 7 .
,
7 19,23 %, 14
15,48 % . .
7 (4,900,08) ,
14 (5,200,06).
(2<0,01) , .
, ,
7 22,08 % . 14 (15,120,18) , 3,76 %

7 , (1<0,001), .

7 (26,400,31)
(32,450,30) (1<0,001), 14 (30,780,33) (2<0,01),
,

(1<0,001)
.

,
. .
, ,
, 7
, .

7 (. 1).
. 1. 7
. (1), (2), (3). .: 17000.
. 2013. 2
115
, ,
. ,

. (, ) () ,
(, ) . ,
-
, ,
,
,
.
.
.
1. . . .
/ . . ,
. . , . . [ . ] // .
2010. . 4 , 2. . 127140.
2. . .

/ . . , . . , . . , . . // . 2011. 4. . 3844.
3. . . : (. .): . . . . : 03.03.04 / . . -
; [. . . . ]. ,
2010. 19 .
4. UA 65462 G09B 23/28, A61K 33/24
/ . ., . .,
. . u201105263. 26.04.2011.
.12.12.2011. . 23.
5. - / . . ,
. . [ .] . : , 2002. 155 .
6. . . / . . . . : , 2002. 240 .
MORPHOFUNCTIONAL FEATURES OF JEJUNUM HEMOMICROCIRCULATION

IN EXPERIMENTAL ANIMALS POISONED BY CADMIUM CHLORIDE
L. T. Kotlyarenko2 O. Yu. Ruzhytska1
National Academy of Internal Affairs1
SUMMARY. The article represents structural changes in small and medium-sized arteries jejunum of rats poisoning with
cadmium chloride. It was found a significant thickening of the walls of small blood vessels, narrowing of their lumen and
endothelial injury, with significant decrease in the blood flow capacity of these vessels and deterioration of blood supply to
studied organ.
KEY WORDS: white rat, jejunum, hemomicrocirculation.
116
. 2013. 2
, ,
616.216.1.76.08

. . , . . , . .
,
. -
, 55,17 %
, .
, .
: , , .
.
.
,
(. ., . ., 2005; . ., 2008;
Proffit, White, 2005).

, 42 %
. -
- (. ., . ., 2005).

. . .
, 12 %
,
17 % (. . ,
1989; . . , . , . .
2002; ., 2007).

, - .
.
- () 7 . 2006 2013 . 22
75
. 46
52 17 36 (
25,33,7).
, : - ,
, , , , , .
. :
, ,
, , , . , 48 .
42
.
23 .
: 12 -, 41 - 34 (. 1).

(. 1), ,
.
8,250,76 .
, - .

. 2013. 2
117
, ,
1. , Mm
89
77 54
4
'4
)*+*4
,-./*/4
,/-'4
026 942
4
82
4
172757243 54
4 2
757243 54
17 757243 54
94
4
!" "#$$
% "("#$$4
"$$4
#" "
&"&"
&&"( (" %
39 2
24
&" ("#%$$4
54
54
1
21
21
(9,20,63 )
(3,00,16 ) .
, , .
.
, ,

123452674
52 994
4
%"!"&$$
&("&"$$4
"%" $$4
%%"#"&(
!("%
(#" "
39 2
24
!"("%$$4
"(("%$$4
54
1
21
21
9 452494
4
%#""! $$4
&"&"$$4
(""&$$4
%("("
!(("
((" 4
39 2
24
"&(" $$4
"(("$$4
54
1
21
21

(13,80,52 )
(3,00,23 ).
, , .
2.
( ), Mm
89
77 54
4
4
' 4
) *4
*4
+,4
+,4
+-+-4
+*+*4
. )4
. /4
.) /4
.'04
123 445 2994
9 627#44412
8293 494 274
944
4
!"#"#44
$%#%#4
$!#(#44
""#"%#&4
"#%%#&&44
%%#"#$!44
$%##(4
"$#4"4#$44
%#%#44
!!#$%#(44
(#%#44
#((%#$&4
%#%#$(4
%##%44
123452674
52 9944
4
$"#$#!44
$%##4
!!#(4#4
""##$4
!#!#(44
&(#!#"4
$#$#4
"#&#4
#&#"4
!$#(%#4
(#"%#!4
(#!%#"&44
%##$4
&##%$44
9 452494
4
!%#"#&!44
$!##&4
(#4#(44
"#"#4
##44
&$#&"#&44
$##(4
"#"#444
#$#%44
!$#&%#&4
(#&%#4
!#$%#!4
!#!%#$4
!!##$44
"#&%#(444494695274
!#(%%#$444499695274
"#%#$44499695274
-

40,40,12 ,
201,332,5 2 .

118
(5,910,48. ). - 52,92,4 ,
322,5
. 2013. 2
, ,
191,43,06 2. 11 ,

. (7,800,36 . ).

53,54,2 , 33,62,4 177,42,6 2.
, , , -
. ,

, (26) (8) .

(15,30,46 .).
. ,

(55,17%),

.
1. . . -
- / . . //
Stomatologiya. 2005. 34. . 120124.
2. . . ,
: . . - . / . . .
, 1981. 32 .
3. . . , -
:
- . / . . . , 1987, 525 .
4.
- / . . , . . //

21 , 13 1999.
. . 37.
PECULARITIES OF RHINOMAXILLARY COMPLEX IN ADULT PATIENTS WITH UPPER

MICROGNATHIA
A. S. Kubayev, A. A. Abdukadyrov, Sh. Sh. Yusupov
Tashkent Institute of Advanced Medical
Tashkent Medical Academy
SUMMARY. Based on clinical and radiological examination of patients with upper micrognathia found that in 55,17 % cases,
there is difficulty in nasal breathing due to narrowing of the piriform aperture and reduce transversal, sagittal dimensions of the
upper jaw. Proposed to carry out a comprehensive treatment with an orthodontist, an otolaryngologist and other specialists,
as indicated.
KEY WORDS: face type, micrognathia, deformation of the jaws.
. 2013. 2
119
, ,
617.518/616.831+616.711]-001.3-06:616.34-009.7-092

. . , . .
. .
. , -
.

.
: , - , , , ,
.
.
[13].
,
23
. [46], -
.
,
63 % .
[7]. ,
,

, .
,
, - [8, 9].
, , ,

,
,
,
.
- .
. 104
180200 , . -
120
(40 -1 ).
,
. -
, [6]. .
, , 1, 3 7 . ,
, .
() - [10], [11] -
(): / - [12].
. 1,

- .

23,7 %
(<0,01), 26,3 % (<0,01),
42,9 % (<0,001); -
30,8 % (<0,01), 32,7 % (<0,001),
40,5 % (<0,001);
42,4, 45,7 62,1 % (<0,001).

.
12,5 %
(<0,10), 24,5 % (<0,001),
29,6% (<0,001); -
. 2013. 2
, ,
1. -
(Mm)
123456738
97
84 78
3648
#$ 437 6%8
2
&3781'(8
323)538
62
2532 48
444548
3343)538
8
248
8
118
8
248
112
3>8
8
118
!"1112
3>8
346%2
3648
8
1118
!!!1112
3>8
3648
8
68
!1112
3<8
8
!18
!1112
3<8
"8
!118
""1112
3<8
8
118
!"1112
3<8
8
118
!1112
3<8
!"8
!118
!!1112
3>8
62
2532 48
26288
"8
8
8
!8
346%2
3648
3648
*+,-8
.1/8
&02
08
62
2532 48
*+,-8
346%2
3648
*+,-8
!8
""8
8
248
1112
3<8
4<8
1112
3>8
4>8
!!!1112
3<8
4>8
"!1112
3<8
4>8
"!"1112
3<8
4>8
"!"1112
3<8
4>8
!"1112
3<8
4<8
!1112
3<8
4>8
!1112
3<8
4<8
:
1. * (* <0,05; ** <0,01; *** 0,001);
2. 1 1 ;
3. 3 3 .
- 12,7 %
(<0,05), 26,9 % (<0,001) 29,3 % (<0,001);

28,6, 37,2 39,9 % (<0,001).
.
30,7 % (<0,01),
43,3 % (<0,001),
52,0 % (<0,001); -
33,6 % (<0,01), 46,3 % (<0,001),
50,8 % (<0,001);
49,9 % (<0,001), 57,7 %
(<0,001), 63,6 % (<0,001).
, ,
-
, ( 15,4 %,
1<0,05)
( 13,1 %,
2<0,10).
- -
. , ,

( 13,8 %, 1<0,10).

,
( 17,2 %, 1<0,05 19,6 %, 10,01).
-
:
16,2 %
(1<0,05) 19,0 % (1<0,01) , . -
. 2013. 2
121
, ,
(
12,1 %, 1<0,10 15,9 %, 1<0,01).

3 ,
( 18,1 %, 1<0,01). 15,4 %

(3<0,01) 30,7 % (1<0,001)
. -
( 19,1 %, 1<0,01 26,0 %, 1<0,001).

, 27,0 % (1<0,01) ,
( 14,2%, 3<0,10).

,
,
.
- ,
,
- .
,
,
, .
-
-
,
.
.
, -
.
.
.
.
1. . . / . . , . . , . . //
. . 1988. 11. . 4143.
2. /
. . , . . , . . , . . //
, : . .-. . . :
. . ., 2002. . 1314.
3. . . :
/ . . , . . // . 2004. 4. . 46.
4. . .
-
/ . . , . . ,
. . // . . 2005.
3. C.128129.
5. - / . . , . . , . . [ .] // . 2002. . 1522.
122
6. . . -
/ . . , . . . : , 2008. 140 .
7. . . , - /
. . , . . , . . ; .
. . . : , 2004. 200 .
8. / . . , . . , . . , . . //
. 1988. 1. . 1619.
9. . .
/ . . //
. 2008. 1 (28). . 7375.
10. - / . . , . . , . . , . . // . .
2006. 1. . 2225.
11. (. .) / . . , . . ,
. . [ .] ., 2003 33 .
12. Keel M. Pathophysiology of polytrauma / . Keel,
. Trentz // Injury. 2005. Vol. 36, 6. P. 691709.
. 2013. 2
, ,
ROLE LIPID PEROXIDATION AND ANTIOXIDANT DEFENSE IN THE PATHOGENESIS

OF SMALL INTESTINE WALL DEMAGE IN THE DYNAMICS
OF CRANIO-SKELETAL INJURY
R. D. Levchuk, I. M. Deykalo
SUMMARY. In the pathogenesis of small intestine wall damage after skeletal, cranial and combined cranio-skeletal trauma the
activation of lipid peroxidation antioxidant depletion is taken place. The deviations of these indexes increase from the first to
the seventh day after the injury and are higher under the conditions of combined cranio-skeletal trauma in all periods of
observation.
KEY WORDS: skeletal trauma, cranial trauma, combined trauma, small intestine, lipid peroxidation, antioxidant defense.
. 2013. 2
123
, ,
616.34-006.04-085-06:[616.831.31+616.61+616.36]-091.8-092.9

-

. . , . . , . .
. .
.
,
-
.
, ,
.
: 1,2-, , , .
.

. ,

,
- [1, 2]. ,

()
.
,
, [3, 4].
i i i i i,
ii i : ,
i i i, ,
, .
Ii , ,
i iiii
i i, i
(). - (-).
-

[5].
. , , [6, 7].
-
124
.
.
55 (1905), .
,
, - [8, 9].
: 10 ; ()
15 ; ,
15 ;
, 15 .

1,2- (),
.
7,2 /
( ) 1 30 0,1 10 [10].
,
0,1
10 .
. 2 15 /
, 10 /
5 / 8 ,
[11].

. 2013. 2
, ,
2
1 ( 0,2 ) 100 [12].
- () [13];

()
() () [13]. (-), [13].
. -
: ,

, , , .

.
, 47,6 %, .
( 66,9 %
) - 13,2 %.
1,

, :
35,8 %. 39,0 %.
1.
(Mm)
123456738
832 38
94
834
38
()8*+2,8
-.)(8
926
2 8
8
&#8
$#&8
$$ %8
8
!"""8
&##!8"""8
&&"8
!%& 8"""8
7
2
4
7378
#"""8
&%#8"""8
%&!""8
&#&8"""8
7
2
4
737942468
$%&'''8
#'''8
&&8
!$&#'''8
. 1. * , (*
<0,05; ** <0,01; *** <0,001); 2. # ,
(# <0,05; ## <0,01;
### <0,001).

( 12,4 %)
-, ,
( 16,8 %), .
-

- :

=
.

, , -
(278,21,4)
49,8 %
(554,32,8).
- 69,6 %.
,
,
.

( 25,1 %),
, .

8,1 %
30,1 % ,
, .
- ,

2,8 ,
.
-

.
. 2013. 2
125
, ,
.
1.

, ,
, ,
.
2.

.
1. 1,2- / . . ,
. . , . . [ .] // . 2012. 1. . 2934.
2. . . / . . //
. 2000. . 6, 8. . 3338.
3. . . / . . // .
2010. 2. . 521.
4. . . / . . // .
. , 2009. www.russianscientist.org
5. . . /
. . , . . // . 2005. . 3, 3. . 1932.
6.
-2
/ . . ,
. . , . . , . . , . . // . 2010. . 82,
4. . 6977.
7. . .
-
/ . . , . . // . 2011. 4.
. 1417.
8. - / . .,
. ., . ., .. . :
, 2002. 156.
9. European convention for the protection of vertebrate
animals used for experimental and other scientific purposes.
Council of Europe, Strasbourg, 1986. 56 p.
10. . .
() /
. . , . . , . . //
. 2009. 1. . 3338.
11. . . , (
) / . . : . . .
. . , 2008. 22 .
12. / . ., . .,
. . [ .]. . : , 2010. 56 .
13. . / . , . , . // . 1991. 3. . 913.
ANTIOXIDANT PROTECTION FACTOR AS EFFECTIVE INDICATOR OF PRO AND

ANTIOXIDANT PROCESSES IN EXPERIMENTAL CARCINOGENESIS AND ITS
SORPTION CORRECTION
N. Ye. Lisnychuk, I. Ya. Demkiv, O. V. Chykhyra
SUMMARY. The significant reduction of antioxidant protection factor in simulated neoplactic intoxication under cytostatic
therapy as mathematical reflection of intensive formation and accumulation of TBA-active products and functional inefficiency
of antioxidant system enzymes is identified. Application of enterosorbent Karbolayn in simulated pathological conditions
conduces the reduction of the severity of free radical oxidation processes, optimization of antioxidant protection enzymes,
indicated by the normalization of antioxidant protection factor.
KEY WORDS: 1,2-dimethylhydrazine, cytostatics, antioxidant protection factor, cerebral cortex.
126
. 2013. 2
, ,
618-006.526-085.275.4
. . , . .
. .
: 50
, 5 -1,2,3,4-1,4- .
,
.
: , , .
.
.
.
, ,
38,8 % ,
50 % [15].
.
, , , , , [69].
.
, ,
[1012]. ,

. , , [1316].
, , , . , [1719].
,
-
, 5 -1,2,3,4--1,4- . [20,
21].
,
.
- [22, 23].
5 -1,2,3,4-1,4-
.
. 50 -.
, .

: 25 , 5 1,2,3,4--1,4-
2 / 1 15 ;
25 -
.
15 .
.
4 .
15- .
:
.
,
2 ,
.
( 24.4-13725905-002:2007).
. 2013. 2
127
, ,

, .
, (II-) .
.
.

, 4,4 ,
( ) 2,4 , 13 , 1,2 , 7 .
3
.
3,5 ,
10 23 .,
5,2 .
,

.
15- 5 -1,2,3,4--1,4-

4,6 3,1
( ). ,
(13 ) 26,4 , ,
.
,
, , 15- 0,9 %
- NaCl.
,

, , 15-

.
128
3
, , ,
, . .
3-
.
8
2,6 . 10
2,9 12
3,2 .
.

. 8

(2,0 ). 10
12 ,
2,2 2,4 . .
, ,

30 %, 46 %
30 % 25 %,
,
.

15- .

5 -1,2,3,4--1,4- .

.
19 % 13 %,
.
. ,
8

,
. 2013. 2
, ,
30 %.
8 12 32 % 34 % , .
.
1. 5 - 1,2,3,4 - -1,4- - -
,
.
2.
,

.
:

.
1. JI. B. :
/ JI. B. , . . . . : ,
1998. 320 .
2.-
/ . . ,
A. C. [ .] // .
2005. 2. . 7580.
3. . : . . / . ,
. , . . . : , 2000. 592 .
4. Arici A. Local cytokines in endometrial tissue: the role
of interleukin-8 in the pathogenesis of endometriosis /
A. Arici // Ann. N. Y. Acad. Sci. 2002. Vol. 955. P. 101109.
5. Khan K. N. Differential macrophage infiltration in early
and advanced endometriosis and adjacent peritoneum /
K. N. Khan, H. Masuzaki, A. Fujishita [et al.] // Fertil. Steril.
2004. Vol. 81, 3. P. 652661.
6. . . // / . . , . . , . . 2006. 5. .1115.
7. .. // / . . , . . . 2007. 2. . 4551.
8. . .,
: . / . .. : . , 2001. 274.
9. . . : / . . , T. B. //
. 1999. 2.1. . 912.
10. , . . / . . . . : , 1998. . 4350.
11. . . / . . // . 1999. 2. . 5658.
12. : /
B. C. , . . , . . [ .]. . :
H-JL, 2002. 21 .
13. . . /
. . , A. B. // -. 2004. 2. . 2730.
14. . . / . . ,
A. A. . : , 2002. 539 .
15.
/ . . ,
. . , . . , . . // . 2002. . LI,
3. . 5762.
16. in vitro

() / . . , . . , . . ,
. . // . 2004.
. 6, 35. . 390.
17. . . -
: . ...
. . . . : .., 2002. 24 .
18. / . . ,
. . , . . , . . // III .
. : . 1996. . 249.
19. . .
: . . . .
. . : .., 1997. 24 .
20.

/ . . , . . , . . [ .]. //
- 2008. 4.
. 2930.
21. / .., .., .. [ .] // . 2. 2004. . 7884.
22. . .
/ . . , . . , . . // , . 2005. . 4, 2 . 38 .
23. / . . , . . , A. B. [ .] // .
: .. ., . 70- 9-
. ., 2008. 126128 .
. 2013. 2
129
, ,
ARGUMENTATION OF USE OF METABOLIC IMMUNOMODULATOR

IN EXPERIMENTAL-INDUCED ENDOMETRIOSIS IN RATS
L. M. Malanchuk, L. O. Krasnjanska
SUMMARY. The results of studies of 50 outbred female rats with experimentally-induced endometriosis which underwent
immunotherapy by metabolic immunomodulator are described. As a result, it was determined a positive effect of modern
metabolic immunomodulator on the course of endometriosis, resulting normalization of time parameters, sexual cycle and
decreasing the severity of signs of organic disease manifestations.
KEY WORDS: endometriosis, immunotherapy, oestrous cycle.
130
. 2013. 2
, ,
519.876.2

. . , . .
. .
. .
. , ,
0,91, .
10 100 ,
.
: , , , , .
. - . 100 000
( ). ,
(, ),
,
, ,
- .
- , ,
[1] .
: , , ()" (. 1, ), (. 1, ); ,
(, ) (. 1, ); () (. 1, ); ( ) [2]. -

[3]
,
.
,
, .
. ,

, [4].

.
. ,
.
.
1878 Roux W.
[5], '
. 1. .
. 2013. 2
131
, ,

.
[6, 7].

, , -

, ,
,
.

, .
Murray C. D. 1926
[8]
.
[6].
[9],

100 , ,

. , -
100 .
100 , , , ( 100
). [1]
.
[17]
10 100
, , .
[1013]
[14, 15]. ,
.

.
.
. ,
11 ADCE (. 2)
.
1
51
1
1
41
. 2. .
: 1 = 12 ,
1 = 12 , 1 = 11 , 1 = 1 , 1 = 1 . ADCE - ,
13 3 1 12 2 1 11 1 ,
:
14 = 13 3 + 12 2 + 11 1 ;
, ,
,
D,
. ,
: ,
. 11 :
132
21
781
61
7
7
34 = 333 8245 2452 245 1 5 +
6
6
+ 323 234 122 + 31 2 234 12 1 1
(1)
,
,
11 , 11 , 11
31 = 1221 1 31 = 1221 1 31 = 1221 ;

, 12 ,
(2)
11 ,
12 12 11 , 11 , 1
,
' .
. 2013. 2
, ,
(1)
11 :
7
7
34 = 33 83245 32452 2245 1 5 +
6
6
+ 32 3 234 122 + 31 2 234 12 1 1

(3)
12 1 11 , 11 (3)
, 5123 1 4 123 :
21 45 1 4 3
=2
15123 1 14 123
.
21 45 1 4 3 = 2
(4)
(2)
(3) (4) :
8
673 5
8 7
7
9 216 6 345 4 + 215 6 345 4 = 2
5
5
15123 1 14 123
;(5)
8
673 4
7
8 21 7
+
=
2
21
4 6
4
9 6 6 345 4 4
345 4
(5) :
7 6 6
6 17 + 15 345 5 = 2
15123 1 14 123
;
7 1 6 + 1 6 345 = 2
7
5
4
6

(6)
12 1 11 :
17
15 = 6 5 234
5
15123 1 14 123
17
;
1 =
4 6 5 234 4
(7)
. . (7) ,
,
[16]. (, ', ,
) . 10 100 11 11 0,91,
.
. 3. Microsoft Excel .
. 2013. 2
133
, ,
(7) Microsoft Excel .
.

.
. 4. , 1 = 121 .

1 = 1 1 = 12 .
1 = 11 (. 5)
,
21 = 3211 21 = 43121
1 = 12 1 22 = 9845167 3 12 1 1 ,
, ' .
:
1. . .
2. 11 11 , , 0,95
. 5. ,
134
1 = 11 1 = 12 1 .
. 2013. 2
, ,
. 6. [16]
.
. 7. , Comsol Multiphysics.
. 2013. 2
135
, ,
0,91
, .
3. ; 1 = 11
,
21 = 3211
21 = 43121 1 = 12 1 22 = 9845167 3 12 1 1 ,
, '
.
.
.
1. . :
. . // . , . . . . : , 1969.
215 .
2. / . . , . . , . . [ .]. : , 1982. 183 .
3. . . ( ) : . . . . . : . 14.00.02. /
. . ; . . . . -, 1998. 23 .
4. . . / . . , . . //
. 1971. 11. . 5667.
5. Roux W. Uber die Verzweichungen der Blutgefasse /
W. Roux // Z. Naturwissenschaft. 1878. Bd. 12. . 205266.
6. Rosen R. Optimality Principles in Biology / R. Rosen,
London : Butterworth & Co. Ltd., 1967. 198 p.
7. Thompson D'Arcy W. On growth and form / D'Arcy
W. Thompson. New York, Macmillan: Cambridge University
Press, 1942. 1116 p.
8. Murray C. D. The physiological principle of minimum
work / C.D. Murray // The vascular system and the cost of
blood volume I. Proc. Natl. Acad. Sci. 1926. 12.
. 207214.
9. . . / . . , . . , . . // . . 1975. . 61. 10.
. 15011506.
10. Barfred M. Bifurcation analysis of nephron pressure

and flow regulation / M. Barfred, E. Mosekilde, N.-H. HolsteinRathlou // Chaos.1996. Vol.6. P. 280287.
11. Nonlinear interactions in renal blood flow regulation /
D. J. Marsh, O. V. Sosnovtseva, K. H. Chon, N.-H. HolsteinRathlou // Amer. J. Physiol. 2005. Vol. 288. P. 1143
1159.
12. Jensen K. S. Selfsustained oscillations and chaotic
behavior in kidney pressure regulation / K. S. Jensen,
E. Mosekilde, N.-H. Holstein-Rathlou // Mondes Develop.
1986. Vol. 55. P. 91109.
13. Holstein-Rathlou N.-H. A dynamic modelof the
tubuloglomerular feedback echanism / N.-H. Holstein-Rathlou,
D. J. Marsh // Amer. J. Physiol. 1990. Vol. 258.
P. 14481459.
14. Magnitude of TGF-initiated nephron-nephron
interactions is increased in SHR / Chen Yu-Ming, Kay-Pong
Yip, D.J. Marsh, N.-H. Holstein-Rathlou // Amer. J. Physiol.
1995. Vol. 269. P. 198204.
15. Cooperative phase dynamics in coupled nephrons /
D. E. Postnov, O. V. Sosnovtseva, E. Mosekilde, N.-H. HolsteinRathlou // Intern. J. Mod. Phys. B. 2001. Vol.15.
P. 30793098.
16. . . : . . : 03.00.13 /
. ., 1986. 189 .
17. . . / . . , . . //
. 2011. 3.
. 4952.
OPTIMIZATION APPROACH FOR THE STUDY OF MICROVASCULAR

OF BRANCHING NODES
V. P. Martsenyuk, D. V. Vakulenko
SUMMARY. We conducted a review in optimal vascular architectonics. A model of vascular bifurcations and tested it on the
survey results available to us. Our findings correlated with the values and the values obtained experimentally, the correlation
coefficient was greater 0.93, indicating the adequacy of the proposed model. Proposed to calculate the radius of vessels after
branching with a diameter of 10 microns to 100 microns model is correct and more universal and normally complements the
Roux used in the model of Murray.
KEY WORDS: microvascular nodes, optimality, radius of vessels, model of vascular bifurcations, internet.
136
. 2013. 2
, ,
616.314.17-018.4-02:616.33/.342-002.44022.7:579.835.2

. . , . .
. .
. -
-
, (94,4 %).
, ,
H.pylori .

.
: Helicobacter pylori, , ,
.
.
, , , ,
H. pylori [3, 5, 9]. ,
Vac A
IL-1 IL-8, ,
[4, 9]. IL-1 IL-8 ,
. , ( ),
,

.
, , , , 9095 %.
50 %
[14]. 70 % H. pylori , 30 % , .
,
, H. pylori,
,
, ,
. ,
, .

, , ,
[10].
,
, ,
, , [1, 2, 3, 6, 7]. [5].

H. pylori [11, 13, 15, 16]. ,
,
,
,
.
, ,
. ,
( 35 )
H. pylori.
, ,
[12].
,

H. pylori .
H. pylori
. H. pylori

.
. 2013. 2
137
, ,
,
.

H. pylori
.
. 36 (25 , 11
) ,
, 20 .
1868 . . .
: Green-Vermillion, -- () ().
.
H. pylori.

.
H. pylori [8].
.

,
, . ,
. - , . -
, .
, .
. ,
55 %, -
138
94,4 %.

(2,840,15; p<0,001),
(30,491,88;p<0,001) ,

(1,480,15), (15,351,40),
.
-S
(2,320,12; p<0,001),
(1,080,09).

: , . , 52,4 % .

H. pylori
19,4 % , ,
, 5 %.
, . ,

H.pylori 23,8 %,
4,8 %.
H. pylori .
.
1. , H. pylori , - (94,6 %).
2. ,
, H. pylori
.
3. H. pylori
.
.
, .
. 2013. 2
, ,
1.
/ . . , . . , . . ,
. . // . 2004. 3. . 2830.
2. . . elicobacter pylori- (- ) / . . // .
2006. 5. . 6468.
3. . . elicobacter
/ . . , . . // . 2007. . 88, 1.
. 5561.
4. . .
Helicobacter pylori / . . , . . , . . // . 1998. 8. . 1520.
5. / . . ,
. . , . . , . . //
. 2010. . , 4 (34).
. 137139.
6. . .

/ . . , . . //
. 2010. 4 (25). . 145148.
7. . .
/ . . , . . // . 2002.
1. . 2124.
8. / . . , . . , . . -
, . . // -
. 2007.
69 .
9. . . Helicobacter pylori / . . , . . // . 2011. . 15, 3. . 118123.
10. . . / . . , . . . . : -, 2004. 200 .
11. . .
Helicobacter
pylori / . . , . . // . 2008. 7. . 7273.
12. Agarwal S. Presence of Helicobacter pylori in
subgingival plaque of periodontitis patients with and without
dyspepsia, detected by polymerase chain reaction and culture /
S. Agarwal, K. D. Jithenda // Journal of Indian Society of
Periodontology. 2012. Vol. 16 (3). P. 398403.
13. Is Helicobacter pylori resident or transient in the human
oral cavity? / A. Al-Ahmad, A. Kurschner, S. Weckesser [et al.] //
J. Med. Microbiol. 2012. Vol. 61 (8). P. 11461152.
14. Helicobacter pylori in developing countries / WGO
Global Guidelines. 2010. P. 115.
15. Navabi N. Does the presence of the Helicobacter
pylori in the dental plaque associate with its gastric infection?
A meta-analysis and systematic review / N. Navabi, M. Aramon,
A. Mirzazadeh // Dental Research J. 2011. Vol. 8 (4).
P. 178182.
16. Helicobacter pylori and oral cavity inflammation /
O. Panahi, S. Rezaei, M. Marzi, F. Asghari sana // JPCS.
2011. Vol. 2. P. 1315.
H. PYLORI INFECTION IN THE DEVELOPMENT AND COURSE OF DISEASE

PARODONTIUM TISSUES IN THE GASTRODUODENAL ULCERS
N. V. Matsko, Yu. I. Bondarenko
SUMMARY. As a result of the above literature and conducted clinical and laboratory studies were revealed a high prevalence
and severity of inflammatory, destructive changes in parodontium tissues of patients with gastroduodenal H.pylori infection
(94,4 %). Severity of periodontal inflammation in these patients depends on presence of H.pylori in parodontal pockets and
duration, phase of concomitant disease. The features of H.pylori infection influence in the development of syntropy
generalized parodontitis and gastroduodenal ulcers require further study of their mechanisms were found.
KEY WORDS: Helicobacter pylori, peptic and duodenum ulcer, parodontium disease, hygienic indices.
. 2013. 2
139
, ,
616.711001.306:616.61091.8]092.8
-
, -
. . , . .
. .
. -
, , -
,
.
: , - , , ,
.
.
()
[5].

[2].

[3, 6]. ,
-

.
- , - .
. 104 - 160180 ,
. 4 :
(8 ), , .
, [9],
- [4], .
-
(40 -1 ).

1, 3 7 .
, - [1], [7] 140
-
(): / - [8].
. 1, ,
, : 1 19,0 %
(<0,01), 3 38,1 % (<0,001), 7 61,9 % (<0,001). - : 24,8, 30,5 57,1% (<0,010,001).
,
. -

: 1 48,6 %,
3 71,4 %, 7 2,0
(<0,001). , ,
-
(<0,050,01).
2,
: 1
21,8 % (<0,01), 3 41,9 % (<0,001),
7 44,7 % (<0,001).
( 29,5, 33,3 42,8 %,
<0,001). , 1 7
(>0,05),
3 ( 14,8 %,
<0,05). -
. 2013. 2
, ,
( 40,3,
51,4 60,6 %, <0,001).
, , (<0,05-0,001).
1. - (-1)
(Mm)
392543
92 6

695
(2 ) * 45

"#$+%
, -55
123456789
899254593 27
5
3
7
& 111
'111
!11
"#$ %
"#$ %
"#$'%
+11
! '111
!11
"#$ %
"#$+%
"#$%
! +111
+
+
"#$ %
"#$%
"#$%
.
.
.
/
/
/
/
/
/
2
2
2
2
345
346
546
111
111
2. (-1)
(Mm)
392543
92 6

695
'2 ( ) 45
,!!
"#$&%
* +55
2345
2346
2546
123456789
899254593 27
5
3
7
111
!& 111
!11
"#$%
"#$%
"#$ %
!111
! !111
111
"#$%
"#$&%
"#$%
!-!111
!,111
!1112
"#$%
"#$%
"#$%
.,
/,
.,
/
/,
/
/
/
/
(. 3)
1 7 :
34,2 % (<0,01), 58,5 % (<0,001)
66,1 % (<0,001); - 43,8 %
(<0,001), 48,7 % (<0,01) 63,8 % (<0,001);
60,0 % (<0,001), 71,8 % (<0,001)
80,8 % (<0,001). , 3
-
,
( 23,6 %, <0,05),

, (<0,010,001).
,
,
- . ,
. - , ,
3. - (. .)
- (Mm)
392543
92 6

695
&2 ' ( 45
* !
"#$)%
+ ,55
123456789
899254593 27
5
3
7
!111
111
!11
"#$%
"#$%
"#$!%
11
)*111
)111
"#$%
"#$)%
"#$%
!)
**111
--
"#$%
"#$%
"#$%
.*
/*
.*
/
/
/
/
/
/
2
2
2
2
345
346
546
. 2013. 2
111
111
141
, ,
, .

,
.
3 ,
-. ,
- .
- .

, ,
, [5].
, , ,
, , -
. - .
, ,
-
,
.
. , ,
, - ,

.
.

.
1. . . / . . , . . , . . //
. . 1988. 11. . 4143.
2. . .

/ . . , . . // . 2004. 4. . 1720.
3. . . / . . // . 2013. 2 (32).
. 149153.
4. . . -
/ . . , . . . : , 2008. 140 .
5. / . . , . . ,
. . [ .]/ : ,
2002. 360 .
6. . . / . . // . 2012. 3. . 103106.
7. / . . , . . , . . , . . //
. 1988. 1. . 1619.
8. -
/ . . , . . , . . , . . // . .
2006. 1. . 2225.
9. . .
/ . . , . . //
. 2013. . 17,
1 (65). . 96101.
FEATURES PROOXIDANT ANTIOXIDANT STATE OF CORTICAL LAYER OF KIDNEY

UNDER SKELETAL, CRANIAL TRAUMATIC INJURIES AND THEIR COMBINATION
D. I. Merlyev, A. A. Hudyma
SUMMARY. Modeling of skeletal and cranial injury and their combination leads to the accumulation of secondary products of
lipid peroxidation, the depletion of catalase activity, the significant shift of prooxidant-antioxidant ratio towards the predominance
of prooxidant mechanisms, which increase from the first to the seventh day of post-traumatic period and are significantly
higher on the background of combined cranio-skeletal injury.
KEY WORDS: skeletal injury, cranial injury, combined ingury, lipid peroxidation, antioxidant protection.
142
. 2013. 2
, ,
616.441-002+616-092.8+616.441-008.64+546.15+546.23+616-08
,

. .
-
. , (
, , , ,
) - ,
, . ,
,
. .
.
: , , .
.
, [1]. ,
,
[2].
-5- (
4
3), ( ,
) [3].
SePP, [4].

() () .
:
(),
,

.
. - 100150 ,
:
(1 , n=30);
(2 , n=30); -
: (3
, n=30), (4 , n=30), ( ),
( ), (-), ()
(5 , n=30). 30 , , .
(
),
7,5 /100 [5]. 14 .
[6].
, [7].
( -100, Nycomed Merck KGaA,
, 50 /) 30 [8]. ( , -, , 5 /) 20 [9].
(50 /
, 30 ) [8], - ( -, ,
, 20 / , 30 ) [10],
( -, , , 5 /, 20 ) [9],
- ( ,
, , 2,5 /, 20 ).

. 2013. 2
143
, ,
( 3
fT3 4 f4, ) [11].
, , , .
,
(), (), (), ,
().
, ( ,
100 / ) (1986, 2007).

(StatisticSoft 7,0). , , -.
, . , ,
t- .
<0,05.
.
1 (. 1): f3 64,8 %
(<0,001), f4 63,2 % (<0,001) .
,
,

[5].

(. 1).

(. 2): ( 27,2 %, <0,01),
( 55,5 %, <0,001) ( 27,9 %, <0,01) ( 47,1 %, <0,01)
( 18,2 %, <0,05)
. -- [12].
(. 3).
, (
21,91 %, <0,05), ( 64,7 %, <0,01),
( 41,02 %, <0,01) .
23,7 % (<0,02)
.

, ( 2,4 (<0,01), f3 (
74,3 %, <0,001) f4 ( 73,7 %, <0,001)
, f3
( 27,1 % 1-2<0,02), 1 (. 1). -
1.
, ,
, - - (Mm)
1234567589
8
$7%758"%
7 8&'(88
.86234567%89
%8148&'(8
-86234567%89
%8
145678&'(8
'86234567%89
%8
2
5568145267826 628%4578
&'(8
)86234567%89
%8
2
5568145267826 628%4578%8
34728&'(8
386234567%89
%8
2
5568145267826 628%4578
347289:22;
248%5%28
5"2
57:%3
%
%28&'(8

26
27578
1288
)*'+(',8
.0(+((,18
.-)+(.-18
89
24((-8
-3,+(.218
91242(((.8

23 78
3288
('*+((-8
(.)+((-18
(.(+((.18
8
()2+(()8
91248(((.8
-,2+(.)18
8
93248(((.8
8
'*(+(..18
8
9242(((.8
81924(((.8
83924((.8
(),+((-18
8
9324(((.8
8
()'+(()18
8
9242(((.8
8

2
27 8
!538268"8
92
2788 8 3#58948
(.)+((-8
.(('(/*.(8
(.*+((28
.3(/((-18
(''+((318
.(*(/((-18
1
((,+((.18
3-2(/0'(18
8
9124((.2
89124((32
8
8
9124((38
30'(/-(.18
((3+((.18
89324((388
932
8
9324(((.8
4((38
819324((38
((-+((.18
3,0(/*-(18
8
9242(((.8
889242(((.8
819242((.8
8
9242((.8
839242((38
8
. * (<0,05) ;
.
144
. 2013. 2
, ,

[13, 14].
,
-
89,070,9 % (<0,05)
34,591,0 % (1-2<0,05) 1 (. 2).
,
.
2. , ,
, ,
, , - - (Mm)
34696
484646
!"6#6
$-.6 34696
/156 !"#6
+-96 34696
/123456 !"#6
!-36 34696
82836/12834676
83456 !"#6
)-6 34696
82836/12834676
83466 2324756 !"#6
%-6 34696
82836/12834676
83456 23247566
5-862362756
4- 76 !"#6
1232456789
896
246
9346
7 6
786
$$%5&'('5%6
)!5*(+5+*6
$$)5$$(*5%,6
',5*+()5%6
46
36
$$'5'$(%5))6
')5)()5"&01
,)5!"(%5"*06
%"5*)(!5$$01
$"+5%$()5,+01
'%5,()5)01
+*5!(!5,$06
1567826"5""$6
$+)5%$(%5&&6
1769826"5""$6
$"5"%($5$%06
1567826"5""$6
!!5$'(!5+$6
1968626"5"%6
6
!'5$+()5!6
176
82"5""$6
6
,,5',(!5*"06
17628"5""$6
19682"5""$6
1
628"5""$6
!!5++(%5$,06
156782"5"+6
$!!5'()5"'06
176982"5""$6
6
$,"5"(,5+!06
176
82"5""$6
196
82"5"$6
'+5%%(%5)"06
17682"5""$6
19682"5""$6
1
682"5""$6
&5++(+5!06
156782"5""$6
*%5)*(%5%!6
176928"5"%6
$"5))($5$%06
156782"5""$6
$!$5+,(%5"!6
1769826"5""$6
&&5&(!5',6
176
82"5""$6
196
82"5"$6
$!"5+%(!5*"06
17682"5""$6
19682"5"%6
1
628"5""$6
$!%5*!(%5$&6
176
82"5""$6
6
$"&5"+(,5&)"06
17682"5""$6
19682"5"%6
1
682"5"+6
6
$)!5*,(%5+'6
176
82"5""$6
196
828"5"%6
$)&5')(!5"+06
17682"5""$6
19682"5"$6

2
( 33,863,2 % (<0,01) )
(. 3). , ,
( 33,8 %) ( 46,2 %)
.
,
,
fT3 f4 ,
3 (. 1).
, ,

, .
3,4 (2-3<0,001), 4,8
(2-3<0,001), 0,78 % (2-3<0,001), -
226
2486
5,9 (2-3<0,001)
2
.
53,4 % (2-3<0,001)
27,0 % (2-3<0,001) (. 3).

( 45,5 %
, ) (. 1).
(. 2).
( , 3-4<0,01),

3 (. 3). .
.
(5 )
f3 ( 28,4 %) ( 60,0 %)
. 2013. 2
145
, ,
3.
, , ,
- - (Mm)
1234567589
8
'7758
7 8
()*+,8-8
8623456789
8
(138)*+,-8
48623456789
8
(134568)*+,-8
+8623456789
8
(2
9:5;81342568
<26 62845=8)*+,-8
08623456789
8
(2
9:5;81342568
<26 62845=88
3949728)*+,-8
38623456789
8
(2
9:5;81342568
<26 62845=8
39497288
>?22@9
248
:92852
57?
3

28)*+,-8
8
48
2498
9811248
88
,../,018
,2/,,08
8
8
+01/,5068 ,+/,,8
8
1
301/568
,,5/,,68
778188,,8
54/,0568
,40/,,+8
7189288,,,8
718988,,,8
+33/4558
+33/8
+,05/08
8
4,1/0268
77818,,8
+1/+8
718928,,,8
50/,.468
718
288,,8
8
,4/,,+8
718
82,,8
8
0.5/038
718
28,,,8
8
3,0/,0468
718288,,,8
79828,,,8
7
8288,,38
,5/,,8
718288,,,8
798288,,38
8
03++/4568
71828,,,8
79828,,38
8
18
!8
4 (. 1).
f4

.

(. 2) ( 75,4 %,
4-5 <0,001) ( 30,4 %, 4-5<0,02), ( 48,4 %, 4-5 <0,001)
( 19,7 %, 4-5 <0,02).
(- -) ( 35,4 %, 4-5 <0,02)
4 .
, .
"
8
#826#8
$8
#826#8
%8
72489&8
,+2/,,48
,+2/8
,4+/,,068
8
,4/,,+68
8
40/,,368
7189288,,,8
8
,+/,,38
798
28,,,8
313,/+1,8
313,/8
004/+1068
8
014/3448
8
++12/+2268
718928,,,8
,5/,,48
,5/8
,,1/,,68
8
,,3/,,68
8
,40/,,38
718928,,,8
0451/+5568
8
,02/,,068
718
288,,,8
798
28,,8
,+1/,,38
71882,,38
798288,,,8
8
352/+,08
798288,,8
7
8288,,48
8
,+/,,+68
71828,,,8
7
828,,8
. , ,

. - .

.
.
,

.
1. . . : - - (
) // .
2013. 2 (100). . 220223.
2. . // . 2004. 10. . 4548.
3. - / . . ,
. . , . . , . . // . 2011. . 9. 3.
. 114116.
146
4.
/ . . , . . , . . , . . // . 2006. 3. . 4549.
5. . .
/ . . // . 2007. 2.
. 113115.
6. Early effect of iodine deficiency on radial glial cells of
the hippocampus of the rat fetuset / J. R. Martinez-Galan,
P. Pedraza, M. Santacana // J.Clin.I nvest. 1997. Vol. 99.
P. 27012709.
. 2013. 2
, ,
7. . . / . . // . 2008. . 140.
8. - . .

-100 / . . - //
. 2007. 6. . 7377.
9. . . .
, 1, 6,
// . 2003. 3.
. 612.
10. . .
- //
: . 2009.
. 4 (28). . 143146.
11. Dunn J. Methods for measuring iodine in urine /
J. Dunn // The Netherlands, ICCIDD, 1993. P. 1827.
12. . . .
/ . . //. . 2007. 17, 2. . 210.
13. . . () / . . , . . , . . . . : ,
2007. C. 816.
14. . .
/ . . //
100 / .
. . . , 2009. . 948.
INTERRELATION BETWEEN THE INDEXES OF THYROID SYSTEM, MICROELEMENT

BALANCE AND ANTIOXIDANT DEFENSE IN RATS WITH HYPOTHYROID
DYSFUNCTION ON THE BACKGROUND OF COMBINED DEFICIENCY OF IODINE
AND SELENIUM AND IN CONDITIONS OF CORRECTION
L. V. Nykolyshyn
SUMMARY. Interrelation between the indexes of thyroid status, microelement balance (content of Selenium in R.B.C. mass,
in homogenates of thyroid gland, cerebrum, heart and liver, concentration of Iodine in urine) and system of antioxidant
defense in male rats with hypofunction of thyroid gland was studied in conditions of Iodine deprivation, combined Iodine and
Selenium deficiencies and also their correction. It was revealed that the development of hypothyroid dysfunction is followed
by the decrease of anti-radical defense of bloods serum that has more profound character in animals with combined
deficiency of microelements. The Iodine and Selenium containing drugs are effective for the correction of the indexes of
pituitary-thyroid axis and antioxidant defense of the organism. The rationale of adding of antioxidants and nitric oxide donators
to the scheme of treatment was proved.
KEY WORDS: hypothyroidism, deficiency of Iodine and Selenium, antioxidant defense.
. 2013. 2
147
, ,
616.697-02:616.69-007.5

-
. . , . . , . .

. , -
, ,
, , .

, . ,
,
.
.
: , , .
. ,

,
.
, ,
, ,
,

[2, 4, 6].
, : -, ,
, ,
[8].
, [8]. ,
() [9,10]. ,

[9].
- .

,
[12]. ()
22
[12]. .
() NADPH- , 148
, , GSH.
(), ,
.

() - .
. 65 2144 ,
. . , .
:
(n=30) , , . (n=35)
- , .

, . [13].
: ; ,
.
[10].
[13].
~ 5 : + -
. 2013. 2
, ,
(NaCl 140 , KCl 4 , TRIS

50 , 7,6). 15 3000 /.
, 2 15
3000 /. . t = -20 C
.
,

0,2 % . Lowry . [11].
5,5---2--
,
SH-, [12]. =340 0,2
- ( 7,0), 2
. =
340 0,1 - ( 6,5),
1 , 1 1--2,4-, 5 GSH.
() [12].
, , -.
. , 21
30 (73,5 %). , -,
,
, , ; -, , ,
.

, , . , , : 23,5 %, +
17,65 %, +
17,65 %, 11,8 %, 8,8 %,
11, 8 %, +
8,8 %.
1 , .
1.
1
544 971397 556141
!787471""3 1397 556161"
141
&453471""3 19
'(6('1397 5561)1
"3 17 558*4('1+591)1
544 971,"5( 6161"
1'1#11
2345647189
71
1
#1
%1
$ 1
#%#$1
. * , <0,05.

[13]
< 20 / < 40 /, (

,
, >50 % [19]
70% [18] ,
>50 %
) [7],
3 : 40 59 /,
2039 /, 120 /.
54 9547189
71
1
$ %1
$1
#1
#$$1

-
. ,
. .
, , [8, 9], (. 2). , ,

, ( - ) . -
. 2013. 2
149
, ,
2.
() (, - )
1
3 11
458171
"
7 54#953$%7&711
51'()8171&711*61
"
7 54 9743-#97&711
51'()8171&711*61
"
7 549#%
7&71
451./01)8171&711*61
23456471
89
71
1
54 95471
89
71
! 1
+!1
,+ 1
+++1
+ ++!1
+++1
+!!++ 1
. * , <0,05.
1,46
(<0,05).

- ( ) ( ). ,

2,52 ,
(<0,05). 2,0 ,
(<0,05).
. 1,72 (<0,05).

( , , )
.

[6, 8].
, ,
-
[8, 9]. ,
, ,
[6,9].
.
[9, 14]. , 150
,
, . , [14,15].
,
- ,

, ,

. ,
, ,
.
.
1.
, ,
.
2. ,

.
3.
- .
4.

.
.
NO- - .
. 2013. 2
, ,
1. . . , / . . // . ., 2002. . 84126.
2. . . : / . . , . . // : ,
2008. 204 .
3. . .
/ . . , . . . ., 2000. . 1829.
4. , /
. . , . . , . . [ .] //
. 2000. 3. . 6267.
5. . . / . . . .,
2002. 106 c.
6.
/ . . , . . , . . [ .] //
. 2001. 1. . 4450.
7. . . /
.. . ., 1981. . 5361.
8. Agarwal A. Role of oxidants in male infertility: rationale,
significance, a treatment / A. Agarwal, R. A. Saleh // Urol.
Clin. North. Am. 2002. Vol. 29, 4. P. 81727.
9. Aitken R. J. Reactive oxygen species and human

spermatozoa, analysis of the cellular mechanisms involved
in luminol- and lucigenin dependent chemiluminiscence /
R. J. Aitken, D. W. Buckingham, K. M. West // J. Cell. Physiol.
1992. Vol. 151. P. 466477.
10. Haidl G. Management strategies for male factor
infertility / G. Haidl // Drugs. 2002. Vol. 62, 12.
P. 17411753.
11. Protein measurement with the Folin phenolreagent /
O. H. Lowry, N. J. Rosebrough, A. L. Farr [et al.] // J. Biol.
Chem. 1951. Vol. 193. P. 265275.
12. Mannervik B. Glutathione peroxidase / B. Mannervik // Meth. in Enzym. 1971. Vol. 77. . 1333.
13. WHO laboratory manual for the examination of human
semen and sperm-cervical mucus interaction // Cambridge,
England: Cambridge University Press. 3rd and 4th ed, 1992
and 1999.
14. Verma A. Effect of vitamin E on human sperm motility
and lipid peroxidation in vitro / A. Verma, K. C. Kanwar //
Asian J. Androl. 1999. Vol. 1, 3. P. 151154.
15. Yousef M. I. Effect of ascorbic acid and Vitamin E
supplimentation on semen quality and biochemical parameters of male rabbits / M. I. Yousef, G. A. Abdallah, K. I. Kamel // Anim. Reprod. Sci. 2003. Vol. 76, 12.
P. 99111.
STATE OF THE GLUTATHIONE ANTIOXIDANT SYSTEM OF SPERMATOZOA

AT EXCRETORY TOXIC FORM OF MEN INFERTILITY
. K. Onufrovych, R. V. Fafula, D. Z. Vorobets
SUMMARY. It has been shown that in infertile male with chronic genital tract inflammation the morphological and functional
semen changes (oligoasthenoteratozoospermia) correlate with increasing of spermatozoa lipid peroxidation in vitro and
decreasing of glutathione antioxidant enzymes activities - glutathione peroxidase, glutathione reductase and glutathione Stransferase. It is assumed that chronic urogenital infection initially leads to activation of lipid peroxidation and inhibition of
antioxidant enzymes of spermatozoa and then leads to the development of pathological changes in semen and male
infertility. Determination of lipid peroxidation and activity of antioxidant enzymes may serve as an additional test in the
diagnosis of infertility.
KEY WORDS: male infertility, spermatozoa, glutathione antioxidant system.
. 2013. 2
151
, ,
616.12-008.46+616.61]-036.12-085:616.155.194.8-07

,
,

. . , . . , . .

.
, ,
. ()

,
, , .
: , , , , ,
.
.
(),
[1, 2].
, ()
.
(Fe) ,

() [3, 4].

(Hb)
.
, , . Fe () ,
Fe ()
.
- ()

( 0111U001395).

Fe , (),
,
()
152
Fe ()
,
.
. 30 IIIV
() ()
III , 27 (
71,428,66 ). . Hb 86
92 /. , , - , , .
(NYHA), 6- .
,
(NKF) K/DOQ.
(ICST, 1989).

Living with Heart Failure Questionnaire
(MLHFQ). (),
Cockroft-Gault.
( - , -, ),
(Ferritin ELISA, DAI, USA). Fe
(Liquick Cor-FERRUM, Cormay, ). ,
Fe
, 20 %
.
. 2013. 2
, ,
[2, 5].
Fe (III)
100 12
(, Vifor, ) [2, 5]. Hb 3
4
(, Roche, ) / 2000 1 3 (3-5 ),
2000 1 7 .
Hb 110120 / [2, 5]. 4 .
STATISTICA 6.1.
.
F-.
.
.
Hb, 6- ,
.

. , , ,
.
Fe , Fe , (<0,05).
,
,
Fe,
.
,
(0,05).
1.
1.
(m)
12 689868349842669
"#$469#%9
8279 24 9.%9
01434567962!82669726!186939
5878696#%9
6059%7%,'919
8 28668993 79726!1869#%9
26899509
9
:!79/;78866<97.$899
=4!7.9>8779 29?@ABC9$289
54 82629!129 29?@ABC9$289
D349629!129 29?@ABC9$289
123456789629
9729
9 9264599
942669
4!942669
&'()*++9
,,)(,-*9
',(-*++9
,&*/('-9
,))*('/++9
-,*)(,49
,&'-(,,,+9
,/,)&(4)9
*/*(-49
*-(--/9
4/(,++9
,&)(,-9
4(,,+9
-/)()&9
,'/-'(4/++9
-'-'(*-49
/)'(,*'++9
'()49
-/'(*)++9
,')*()9
,/4('9
,*''(--9
. * <0,05 ; ** <0,0001

, ,
,
[1, 6]. -6, -1 Fe,
Fe

[6, 7]. Fe . ,
. ,
Fe, -

, Hb,
.
,
, .
: (beta=-0,763,
=0,00001), Fe (beta=-0,609, =0,0001),
(beta=-0,604, =0,0001),
(beta=-0,49, =0,0012). Hb (beta=-0,352, =0,018).
:
y=149,1695-0,9719*1-1,2940*2+0,0078*3-0,5610*4-0,1081*5,
y , , 1 , /, 2 , %, 3 ,
. 2013. 2
153
, ,
/, 4 , /, 5 ,
//1,73 2.
, ,

.
( Hb, Fe , , , )
.
,
,
, ,

[8]. , Fe
[1, 3, 6].
Fe
Fe () - , , -
, .
: 1. Fe ()

Fe, ,
, 6- , .
2. ,
.
,
Fe,

Hb
.
3. , ,
, ,
Fe , .

.
1. van der Meer P. Anaemia and renal dysfunction in

chronic heart failure / P. van der Meer, D. J. van Veldhuisen //
Heart. 2009. 95. P. 18081812.
2. ESC Guidelines for the diagnosis and treatment of
acute and chronic heart failure 2012. The Task Force for the
Diagnosis and Treatment of Acute and Chronic Heart Failure
2012 of the European Society of Cardiology. Developed in
collaboration with the Heart Failure Association (HFA) of the
ESC / J. McMurray, S. Adamopoulos, S. D. Anker [et al.] //
European Journal of Heart Failure. 2012. 14.
P. 803869.
3 nemia and iron deficiency in heart failure: mechanisms
and therapeutic approaches / D. J. van Veldhuisen, S. D. Anker,
P. Ponikowski [et al.] // Cardiology. 2011. Vol. 8, 9.
P. 485493.
4.
/
. . , . . , . . [ .] // .
. . 2012. .7,
4. . 6568.
5. Kidney Disease: Improving Global Outcomes (KDIGO)
Anemia Work Group. KDIGO Clinical Practice Guideline for
Anemia in Chronic Kidney Disease // Kidney inter. 2012.
2. . 279335.
6. Iron Repletion in Heart Failure Patients / D. Silverberg,
A. Iaina, D. Wexler [et al.] // Hypertension. 2011. 57.
P. 381382.
7. -6
/ . . , . . , . . [
.] // . 2012. 2 (17). . 118120.
8.
, / . . , . . ,
. . [ .] // . 2013. 2 (77). . 57.
INDICATORS OF FERROKINESIS AS PROGNOSTIC MARKERS OF QUALITY

OF LIFE IN ANEMIC PATIENTS WITH CHRONIC HEART FAILURE COMBINED
WITH CHRONIC KIDNEY DISEASE AND THEIR DYNAMICS UNDER THE INFLUENCE
OF THERAPEUTIC CORRECTION
N. H. Ryndina, P. H. Kravchun, M. M. Mishyna
Kharkiv National Medical University
SUMMARY. The most valid prognostic markers of quality of life in anemic patients with chronic heart failure and chronic
kidney disease is glomerular filtration rate, serum iron, ferritin and transferrin saturation ratio. Appointment of drug combination
of iron (III) and epoietin on a background of standard therapy of chronic heart failure and chronic kidney disease leads to
normalization of transferrin saturation ratio and soluble transferrin receptor level, indicating that the increased activity of
erythropoiesis in presents of adequate functioning iron, results in increase hemoglobin level and quality of life in patients with
cardiorenal pathology, mainly due to the parameters of physical activity.
KEY WORDS: anemia, chronic heart failure, chronic kidney disease, quality of life, iron metabolism, therapeutic correction.
154
. 2013. 2
, ,
616.311/32-008.87-02.616.2-022.6]- 53.2

. . , . . , . . , . . , . .
. .
. . ,
, , , , ,
, Candida ., .
.
6,90 lg /. ,
,
.
: , , , .
. ,
, ,
- [1, 2]. ,
,
, , , [3, 4].
, ,
[4, 5]. -
,
,
, ,

.
( , ,

[612].

.
.
.
146 ,
(, )
[13].
,
1 ,
, 24
48 .
, ,
. 1 (lg /),
.
[14].
Vitek-2[13].
.
, 2,7 % , 70,0 % , 8,9 % , 13,7 %
- ( ,
, ), 3,4 %
.
, 425 ,
, Candida, .
(. 1).
Streptococcus
(97,0 %), 76,0 %.
Micrococcus spp. Corynebacterium spp.
(17,8 % ), ( 8,2 %),
7,5 % . andida 8,2 % .
. 2013. 2
155
, ,
923 923
824
7128
1234
56789
2 3
421
123
56789
3
421
56789
4
526
523
3 3
4328
56789
123
23
56789
123
2312
56789
14223
3 2
14
. 1. .
1.
8552786
236
6
"6
"$6
""6
"6
$6
6
$6
$6
"$6
428556
4 !4556426 74 556
8556
%57 24 8&6
' 93 8&66
523 6
) 58*78624 8&6
,74 524 8&6426!3
-5572-6
./010/6
27386

(. 2).
, 76,1 %
, 7,8 % ,
,
, Candida
3,0 % , 8,0 %
Granilicatella spp., Leuconostoc spp.,
Gardnerell spp. .

6,9 lg /
123454267538934
26
6
6
6
##6
$ #6
$$6
(#6
(6
+6
($6
($6
$ #6
(. 2). Staphylococcus spp., Neisseria spp., Moraxella spp., Micrococcus spp.,

Haemophilus spp., .
Candid 4,8 -4,0 lg /.

- - - (. 2).
-
(76,9 % ). 4
- ,
- 4,2 %.
2.

726
"42#955$6
"4
455$6
,-3
966
/
253$66
/95
55$6
18#996254
96

$254
96
24
254
9642633823$66
23$3$6
5696
286
156
123452676895
9 96
236
6
%%%6
&'%6
%)*6
**'6
%&6
&.6
&'6
'%6
*&6
0(6
%%6
&'6
**6
0.6
%&6
&.6
%&6
&.6
**6
0+6
)&(6
%4446
96592 96

6 !86
(%6
'+6
).6
(*6
)+6
((6
)*6
(46
)46
(&6
(%6
. 2013. 2
, ,
73856
9
3456

123456
. 2. - - - .
, -
- 7,0 lg /,
-
250 (4,6lg /).
Staphylococcus
10 . S. aureus i
S. intermedius , , S. epidermidis (36,1 %). , ,
, , , 5,96,4 lg /.
2 (1,4 %)
Gemella
, 5,0 lg /. ,

[15, 16].

: Micrococcus, Dermacoccus, Kokuria Rothia.
, 4,7 lg /.
, 8,2 %
(. 1). (50,0 %)
, Enterobacteriaceae Enterobacter,
Escherichia Proteus.
, . , S. aureus (44,4 % ),
(27,8 %),
(33,3 % ).

S. mitis 37, 7 % , S. pyogenes

17,4 %, S. epidermidis S. haemolyticus
30,4 % 7, 4 % S. aureus 15,9 %
9 (13,0 %) Candida.
.
, , [1, 3, 17, 18].

.
: 1.
, , , ,
, ., . Candida
8,2 % .
2. .

6,90 lg /.
3. ,

.
.

,
, , ,
.
,

.
. 2013. 2
157
, ,
1. . .
: / . . , . . , . . . . : -, 2009. 312 .
2. . . / . . , . . // . 2008. 8. . 2024.
3. . . // . . , . . //
-
. 2012. 2. C. 5156.
4. . .
,
// . . , . . / / . 2008. 5.
. 6163.
5. . . / . . , . . // , . 2010.
6. . 7.
6.
/ . . ,
. . , . . , . . //
: - , . , 2012. . 396.
7. . . / . . // . 2000. . 8,
1314. . 559564.
8.
( 2009 .)
/ . . , . . , . . [
.] // . 2010. 1 . 1518.
9. . .
// . . , . . //
. 2006. 14. . 9094.
10. Rothberg M. B. Complications of viral influenza /
M. B. Rothberg, S. D. Hessler, R. B. Brown // Am. J. Med.
2008. 121. P. 258264.
11. Olivera E. C. Influenza pneumoiniae: discriptive
studies / . . Olivera, . . Maric, G. Colice // hest.
2001. . 17171723.
13. : . 3.
. . . . . / . . . . . : ,
2009. . 3339.
14. . 2 . /
. . , . , . , . , . [. . ; . . . . ]. . : , 1997. 800 c.
15. Purcel L. K. Gemella species endocarditis in a child /
L. K. Purcel, J. P. Finley, Rchenet [et al.] // Can J. Infect.
Dis. 2001. Vol. 12(5). P. 317320.
16. , Aerococcus,
Globicatella, Helcococcus Facklamia / . . ,
. . , . . [ .] // Annals of
Mechnikov Institute. 2009. 3. C. 1725.
17. / . . , . . ,
. . , . . [ .] // .
2009. 10. . 7173.
18. . .

/ . . , . . // . .
. 2008. . 7, 2. . 5560.
SOME FEATURES OF STOMATOPHARYNX MICROBIOCENOSIS IN PATIENTS

WITH INFLUENZA AND SARS
. . Savchuk, S. I. Klymnyuk, .V. Pkryshko, Yu. M. Andreychyn, N. . Krasiy
SHEI Ternopil State Medical University by I. Ya. Horbachevsky of MPH of Ukraine
SUMMARY. The results of examination of stomatopharynx microbiocenosis in patients with influenza and SARS are presented
in this article. It was shown, that microbiocenosis is formed by associations of Streptococci, Staphylococci, Neisseria, Moraxella,
Haemophilae, Enterobacteriaceae, Pseudomonas spp., yeastlike fungi Candida etc. Streptococcal and Staphylococcal bacterial
communities are dominated among them.
Bacterial populations are differed by their colonization levels. Streptococci had the highest ones 6,90 lg CFU/ml. It was
suggested, that there are some peculiarities in stomatopharynx micribiocenoses composition in patients with different
concomitant diseases and different degree of severity of main process.
KEY WORDS: influenza, acute respiratory viral infections diseases, stomatopharynx, microbiocenosis.
158
. 2013. 2
, ,
616056.3092:612.017]036.12092.2
IN
VITRO
. .

:
.
GSNO -,

.
,
.
: , , , , .
. , , , NOS- NO- [8]. NO

(GSNO), [4, 5].

()
.
. 20 - 200250 .
Cohrane C. Kofler D. [10]. (
. ,
15 12.12.2005 .).
40 / 10
[9, 11, 12].
, [7]. [1].

[3],
199 20 % , 37
5 % 2 1 .
, [6,
14]. NOS [2],
[13]. Microsoft Excel.
.
NO
(. 1)
: 2 NOS
(<0,001), GSNO (>0,05).
-. , NOS (<0,05), .
,
(<0,001), GSNO
. 90 %,
(129,7310,14) / (<0,001), 63,8 %,
(134,5611,02) / (<0,001).

(. 1) . , ,
GSNO.

GSNO . ,
90 % (129,7310,14) (<0,05).
GSNO 63,8 %
(134,5611,02) (<0,05).
GSNO, 66 % , (<0,05).
. 1. GSNO,

.
. 2013. 2
159
, ,
1. NOS GSNO ,
(/ ; m; n=10)
123456789
76
789
766723 5746
789
76465
8376723 5746
6
6
6
6
2326796
2326796
2326796
2326796
!"#$%&'#$'6
!'(#)*&!$#!"6
'(#)%&'#')6
!*"#+%&!!#$'6
-6
-6
.6$#$$!6
/6$#$+6
!$#)'&!#+'6
!'#)'&!#$'6
'*#''&'#!*6
"3#)%&"#'36
-6
-6
.6$#$$!6
.6$#$$!6
/6$#$+6
.6$#$$!6
/6$#$+6
.6$#$$!6
12345637
6
3836
,16
03612 6
,26
,1326
: 1 ; 2
; 1-2
.
641
631
621
611
1234516748959
72
4 274
14
51
1234516748959
6748959
41
1234516748959
6748959
4 7592
31
21
1
789
8
8
. 1. GSNO
.
2. in vitro,
, .
.
GSNO, . , -

.
,
,

,

.
1. . . / . . , . . , . . // X :
. --, 2004. . 386.
2. . . /
. . // . . . 2000. 4. . 510.
3. ( ) / . . -
160
, . . . . . , . . // .
. 1999. .45, 4. . 120124.
4. . . .
-
// Therapia 3 (56). 2011. . 2631.
5. . . / . . , . . , . . // . 2012. 3. . 7480.
. 2013. 2
, ,
6. . . () ST /
. . , . . , . . // . 2003. .9, 2. . 361370.
7. /
. . , . . , . . // . .
1983. 11. . 37.
8. . . / . . //
2003. .4, 2. . 514.
9. :
/ . . , . . ,
. . , . // . 2005. 34.
. 1927.
10. Cochrane C. G. Immune complex in experimental
animal and man / C. G. Cochrane, D. Koffer // Advanc.
Immunol. 1973. Vol. 16. P. 185204.
11. Cytoprotective effect of green tea extract and

quercetin against hydrogen peroxide-induced oxidative
stress / Jeong Y. M., Choi Y. G., Kim D. S. [et al.] // Arch.
Pharm. Res. 2005. Vol. 28(ll). P. 12511256.
12. Effekt of three flavonoids isolated from Japanose
Polygonum species on superoxide generation in human
neutrophils / G. Lur, W. Wang, N. Masuoka, T. Asobe,
K. Yanashita [et al.] // Planta Med. 2005. Vol. 71(10).
P. 933937.
13. Gerdel D. Ingibition of the catalytic activity of alcogoldegydrogenase by NO is associated with S nitrosyltion
and the release of zinc / D. Gerdel A. J. Gederbaum //
Biochemistry. 1996. Vol. 35, 50. P. 1618616194.
14. Lipocomal quercetin efficiently suppresses growth
of solid tumors in murine models / Yuan Z., Chen L., Fan L.
[et al.] // Clin. Cancer Res. 2006. Vol. 12. P. 3193
3199.
SPECIFIC OF THE SYNTHESIS OF ENDOTHELICYTES OF NITROZOGLUTATION

IN VITRO UNDER CONDITIONS OF THE MODELING CHRONIC IMMUNOCOMPLEXEMI
O. V. Sadlyak
Lviv National Medical University by Danylo Halytskyi
SUMMARY. The aim of our work was to study the characteristics of the synthesis of nitrozoglutation in endotheliocytes of white
rats with experimental chronic immunokomplexemi and determine correction influence of corvitini on these processes.
Analysis of incubation interaction of endothelial cells of animals with CIU showed a sharp decrease in GSNO in all test sites,
which can be regarded as a development nitrosoaktivity stress in the studied cells and is a testament to decrease antioxidant
system of cells under these conditions. Adding to the incubation medium corvitini bioflavonoid with pronounced antioxidant
and anti-inflammatory properties, led to normalization of all studied parameters.
KEY WORDS: nitrix oxide, nitrozoglutation, chronic immunocomplexemia, endotheliocyte, Corvitin.
. 2013. 2
161
, ,
612.26.014.49-02:616.24

. .
. .
. , 224 . .
, 2
.
: , , , .
. ()
, , - .
, ,
,
[4].
, - ,
,
, , , [3, 6].
(), ,
.
:
.
. 30
- 160180 . 5 .
- (40 -1 )

(pH 1,2) 1,0 -1 [5]. . 2, 6, 12
24
. , -
[1].

STATISTICA 10.0
(StatSoft, Inc., ).
162
. 1 1, -
: 2
23,6 % (<0,05), 6 58,2 % (<0,001),
12 90,8 % (<0,001), 24
, 2,5 (<0,001).
, ,
(0,05).
- , 612 . 98,6 % ,
(<0,001). 24 (
9,7 %, 0,05). 2,3 (<0,001).
-
2 66,1 %
(<0,001).
12 , 79,1 %
(<0,001) (0,05).
-
,

( 11,7 %, <0,10). 2
-

( 40,4 %, <0,001).
12 (>0,05). 12 24 , ,
-
, ( 20,6
17,1 %, <0,05).
. 2013. 2
, ,
1. - (Mm)
367967
!5294"97"527
#"#2 127
+"997 66%7
#"#2 "127
+"99752"%7
#"#2 "127
57
2452 7
7
727
7
$%( &%)37
$%& &%&'7
1234567859
67 667
727
727
7
7
333
%(&%&* 7
)%(&&%)3337
727
7
*%&%3337
%&%7
)%
&%&3337
*%(&% )3337
(%(&%3337
'%)&%
%&&%(7
*% &%3337
(% &%3337
*%&&%)(3337
(%$&% &3337
,&%&7
,&%&&7
-&%&)7
,&%&)7
,&%&)7
333
: 1. * (* <0,05; *** <0,001);

2. , .
26843123241
412
218471
19341
422
13341
1
849123
17
411
17347
169421
312
25148123241
16346
15248
12345
322
1234
567689
188
12
567896

4 6
6
34 6
4 6
. 1. - ( )
. (: 2,6,12 2, 6 12
, 0,05).
, ,
, .
24 , , ,
, .
612
.
, , , , ,
[2].
, 2 .

.
, 12 24
, ,

.

, .
. 1. , -
. 2013. 2
163
, ,
-
224 .

, ,
2 .
2. -
2 -

, 12 24
.
. ,
,
.
1. . . / . . // . . 1988. 11.
. 4143.
2. . . / . . // . 2012.
. 14, 1. . 104108.
3. Looney M. R. Neutrophil sandwiches injure the
microcirculation / M.R.Looney, M. A. Matthay // Nat. Med.
2009. Vol. 15. P. 364366.
4. Matthay M. A. The acute respiratory distress syndrome:

pathogenesis and treatment / M. A. Matthay, R. L. Zemans //
Annu. Rev. Pathol. 2011. Vol. 6. P. 147163.
5. Matute-Bello G. Animals model of acute lung injury /
G. Matute-Bello, C. Frevent, T. Martin // Am. J. Physiol. Lung
Cell Mol. Physiol. 2008. Vol. 295. P. 379391.
6. Komarova Y. Regulation of endothelial permeability
via paracellular and transcellular transport pathways /
Y. Komarova, A. B. Malik // Annu. Rev. Physiol. 2010.
Vol.72. P.463493.
PATHOGENETIC ROLE OF LIPID PEROXIDATION IN KIDNEY DAMAGE

ON THE BACKGROUND OF ACUTE LUNG INJURY
P. A. Sas
SUMMARY. On the background of acute lung injury it is observed the significant increasing of TBA-active products of lipid
peroxidation level in serum, lung and kidney tissue within 224 experimental hours. It gradually increased during the
observation period in serum and lung tissue while in kidney tissue it reaches a maximum value after 2 hours and remains at
the same level until the end of the experiment.
KEY WORDS: acute lung injury, lipid peroxidation, lung, kidney.
164
. 2013. 2
, ,
577.156.6:577.157.2:612.115

. .
-
. ,
, ,

. ,
,

.
.
: , , ,
.
.
[58]. ,

,
[12, 13, 15, 16, 18]. , , ,
, , ,
, [2].

()
, ( ),
[11].

, :
()
( ()), .
. [1].
20 -.

: 1- ; 2-
; 3- ,
2 /; 4- ,
0,1 /. 0,3 .
,
1,5 (
3 ).
.

: 1
: 2 /
0,1 /. -

. : ,
1,5 , 3 .
.
() () . , . (),
(), () (), -901 Labsystem.

() () [6, 8, 9, 10, 13, 16],

,
( -
( ) ) ( () ). - -
. 2013. 2
165
, ,
2- . . . . [14],

. ,
[3].

(t) [2].
. 13.
1 , 1,5

: 2,6 ,
1,6 , 2,7 ,
1,4 ( ) 1,5 (0,05).
1,5
1,4 ,
1,6 ,
1,4 (0,05)
.
. , 1,5

1,4 . ,
.
1.

2
6
472
6
5
96
6
'9()
966
28
6
16
*+!6
,-.6
,/-.6
,'.6
16
*+!6
,-.6
,/-.6
,'.6
16
*+!6
,-.6
,/-.6
,'.6
&676
1676

757
96

726
%012%%&6
&3&2%%&6
%4#2%%&6
%&2%%&6
%3%2%%#6
&%&2%%#6
&442%&%6
%482%&&6
%2%%66
%302%%86
&%82%%46
&62%&%6
%662%%06
%82%%16
%612%%#6
12345678529
6 6

72
56
!"16
457 6
#6 6
%012%%16
%0#2%%#6
&012%%&56
&4%2%%&556
%0#2%%#56
%0&2%%&6
%%2%%#6
%%2%%&6
%6&2%%#56
%612%%16
&%12%%&6
&#%2%%856
#&%2%%6556
#082%&&56
&882%&&556
##62%&%56
%62%%&556
%302%%656
%382%%#556
%82%%56
&862%&&56
&%42%&&556
8362%&%56
1&62%&%556
1#%2%%456
#8&2%&#556
%4&2%&%56
%3&2%%1556
%862%%156
%42%%&556
$"6
%&6 6
%0%2%%#6
&412%%46
%0%2%%&6
%&2%%&6
%6&2%%#6
&&62%%46
#8#2%&1556
&682%&&556
%42%&&6
%6#2%%&6
&882%&&6
18#2%&%556
1&62%&%6
%3&2%%6
%&2%%86
.
: 1. * (0,05). 2. **
6
(0,05). 3. n .
2.
( , /)
2
6472
6
%9&'
9628
6
$6+66
.6+66
12345678529
6 6

72
56
16
4576
6!6
#((*##$6
#(*##$6
$ $*##,-6
$$ *## 6
$/ *#$#-6
$#$*##$--6

757
96

726
#()*## 6
#()*##)6
#((*##/6
"6
#$6!6
#(*##$6
$$,*##(6
$.$*##6
3. (
-, /)
2
6472
6
%9&'
9628
6
$6/6
(6/6
166

757
96
726
#()*# $6
#($*##$6
#(.*##(6
12345678529
6 6

72
56
16
4576
6!6
#(+*#$$6
#(,*#$-6
#-*## 06
#(+*##-006
#-*##$06
#.)*## 006
"6
#$6!6
#(+*#$.6
#.)*##+6
#-#*##.6
. 2013. 2
, ,

( 3 ) 3
2,5
,
1,6 .
, ,
4,8 3,5 ,
1,5 , . 1,4
.
3 1,5 ,
1,4 , 1,3 1,3
(0,05).

1,4 .
, ,
.
, ,

, ,

(. 1).

1,2 ( 1,5 1,4 (
3 ), (. 2), 1,4 3 , .

1,5 ,
3 .
, :
1,5 - , ,
1,8 1,5
. 3 ,
,
2 (. 3).

. ,
- 1,5 1,5 1,4
3 (0,05). 1,5 3

- ( 1,2 ).
.
, ,

.
,
, - .
.
.
1. : . / . . . . . : , 2001. 528 .
2. . . . / . . , . . , . . // .
2007. 6. . 3539.
3. . . - / . . , . . . . : , 1990. 224 .
4. . . - : 2 . . :
, 2000. . 1. 495 .
5. . . , / . . , . . . . : ,
1995. 297 .
6. . . /
. . , . . , . . // . . . 2000. 1. . 5861.
7. . . -
/ . . ,
. . , . . . ., 2001. 78 .
8. . . -
- /
. . , . . , . . // . 2000. 7. . 4959.
9. . .
/ . . // .
2001. 66, . 5. . 592609.
10. . .
/ . . , . . // . . . 1999. 1. . 3234.
. 2013. 2
167
, ,
11. . . / . . // . .
2001. 2. . 98102.
12. . . : . .
. . / . . . , 2011. . 36.
13. . .
/ . . , . . // . . 2002. 56.
. 1216.
14. . .
: -
/ . . , . . . : , 1977. . 6668.
15. . . / . . // . 1998.
2. . 5052.
16. . .
: . . . . . /
. . . -, 2001. 20 .
17. CH-346086: an MTP inhibitor that lowers plasma
cholesterol and triglyceride in experimental animals and in
humans / C. E. Chandler, D. E. Wilder, J. L. Pettini [et al.] //
J. Lipid Res. 2003. Vol. 44, 10. P. 18871901.
18. Oxidants and antioxidants in atherogenesis. An
appraisal / S. Parthasarathy, N. Santanam, S. Ramachandran,
O. Meilhac // J. Lipid Res. 1999. Vol. 40, 12.
. 21432157.
PHARMACOLOGICAL STUDY OF LIPID-LOWERING PROPERTIES

OF ARONIAS SUBSTANCES
D. V. Semeniv
Ivano-Frankivsk National Medical University
SUMMARY. Studies showed that hydrophilic aronias substance has more expressed lipid-lowering activity compared with the
aronias oil, which was confirmed by a significant decrease of the level of atherogenic lipoproteins of very low density and
low-density lipoproteins and increased level of antiatherogenic high-density lipoproteins in the blood serum on the third
month of the experiment. It was found that hydrophilic aronias substance also shows the expressed anticytolytic and antioxidant
effect, as evidenced by the significant decrease in aspartate aminotransferase activity and the level of thiobarbituric acid in the
blood serum. The results confirm the expedience of new drugs establishing for the treatment of hyperlipidemia and
atherosclerosis from hydrophilic aronias substance.
KEY WORDS: hydrophilic aronias substance, lipophilic aronias substance, free-radical oxidation, low density lipoprotein.
168
. 2013. 2
, ,
616.716.1/4-007-089.844-073.75]-092.9

. . , . . , . .
. .
: ,
7, 14, 21, 30 .
,
. , 14
30 , .
: , , , .
. , ( ,
) , , ,
[1]. . ., 1
, ,
1/31/2 4
6 . 2/3
, 1216 . , , 45 %

1 10 , 25 % [ 2].
[3], ( )
(
)
(
) [4].
, ,
, [ . ., . ., 2006].
,
() () 30 .
. 24 - 180200 ,
.
2 : .
( 3 ).

(1990). .
0,04 5 %
, ( . .).
( . ., 1989 .), .
(
) 3 % ,
11,5 .
.
,
SURGEC XT (NSK, ) 800 .
0,9 % ,
. 2 .
.
1% . ( 80 %+
20 %). (Poly (L-Lactide) Purasorb PL 32
(Holland)jmk () 10-( 4) 6()2
0,1 ( =1050 ),
.
() 348
4,5 . -
. 2013. 2
169
, ,
1,52 .
134 RION
55 .
7,14, 21, 30 , . , Intra
(PLANMECA, ()), .UA1.007.0232012-12 (63,
8 , 0,050 c). , ,
,
10 % .
. 7

, ,

, . ,
, (. 1)
7
, (. 2, a).
.
14

, .
, (. 3, a)
14
,
. ,
, (. 4, ).
21 , 14 ,
, ,
(. 5, )
21
,
. ,
. 1.
. , 7 .
. 2.
. ,7 .
. 3.
. , 14 .
. 4.
. , 14 .
170
. 2013. 2
, ,
, 14 (21 ) (. 6).
30
, .
(. 7, ).
,
, .
30

.
, . , , (. 8, ). .
. 5.
. , 21 .
. 6.
. , 21 .
. 7.
. , 30 .
. 8.
. , 30 .
. , 7 : ,
.
14 ,
,
,
. 21
,
, ,
30 .
,

30 , .
.
, , , 90 180 .
, ,
.
1. . . - : /
. . , . . , . . . . :
, 2010. 928 .
2. .. / . . , . . // . 1999. 4.
. 1418.
. 2013. 2
171
, ,
3. . .
- . : [ ] / . . ,
. . , . . . . :
, 2011. 272 .
4. . .
: , , / . . , . . , . . // . 2008. 4. .103108.
5. . . / . . , . . . . : .
. , 1999. 452 .
FEATURES OF RADIOGRAPHIC PICTURE OF BONE DEFECTS RESTORATION

IN RATS JAW IN EXPERIMENT WITH USING OF IMPLANTATION MATERIAL BASED
ON HYDROXYAPATITE AND POLYLACTIDE
. . , . . , . .
SUMMARY. In this article analysis of X-ray images of rats mandible, which were taken on 7, 14, 21 and 30 day after bone
defect creation operation, was held. In the test group the defect was filled with implantation material, in the control group
wound healing was under bloot clot . There was found that regeneration processes are more pronounced in test group at 14
day and go in progress to 30 day comparatively with control group.
KEY WORDS: osteoplastic material, X-ray diagnosis, hydroxyapatite, polylactide.
172
. 2013. 2
, ,
616.895.4 08 039.11/78

. .
. .
. -, - .
, ,
, (
, ), ,
.
: , , , -.
.
, ,
. (. compliance
, )
[1, 2, 6].
, . ,
,
,
,
, [1, 6, 7]. ,
,
, ,
.
: ,
.
. 2013
. 40 , .
.
-
. -10, : 8
(F 48.0), 12
, 11 (F 43.21), 9
(F 43.22).
16 ,
, , 24
.
. . 19 ,
,
,
, .
21 ,
,

, ,
.

,

, ,
, .
- ,
: ,
[3]. - -
. 2013. 2
173
, ,
, ,
,

. - . .
( ,
, ). . ,
,
, , , , .
.
-
-.
, :
1. , :
( , , , , (, , ), , ).
2. (
, , ,
).
3. , - (
, , ( ,
),
).
4. , ( , , ).
5. , (
).
,
.

, ,
, .
: 1. -

,

.

, .
2.
,
, ( ,
), ,
.
3.
- , .
.
,
,
,
.
1. . . :
// . . . . :
, 2006. 363 .
2. . . - -
/ . . , . . ,
. . . . : -
174
/ . . . , . . , . . . ., 1994. . 193196.
3. . / . , . , . . ., 1991. 34 .
4. . . / . .,
. 2013. 2
, ,
. ., . // . 2007. 1 . 123129.
5. Horne R. Compliance, adherence, and concordance /
R. Horne. // Chest. 2006. 130. . 6572.
6. Osterberg L. Adherence to medication / L. Osterberg,

T. Blaschke // NEMJ. 2005. 353. . 487497.
7. World Health Organisation: Adherence to long-term
therapies, evidence for action / Geneva:WHO, 2003. 230 p.
THERAPEUTICAL RESISTENCE OF NEUROTIC DEPRESSIVE DISORDERS

OF NEUROTIC REGISTER AS A RESULT OF VIOLATIONS OF COMPLIANCE
. Ye. Smashna
SUMMARY. Results of clinical-psychopathological, social-psychological and experimental-psychological descriptions of factors
of liking for therapy at the depressed disorders of neurotic register are presented in work. It is educed that violation of
compliance carries an integral structure, is consonant with the bio-psycho-social approach of disease and includes various
factors, that is related both to biological conformities (pathogenesis of symptomatology, psychopharmacological and somatotropic
effects of therapy) and intrapsychical mechanisms, and also social descriptions.
KEY WORDS: depressive disorders, quality of social functioning, pharmacotherapy, treatment optimization.
. 2013. 2
175
, ,
616.61+616.36]-091.8-092.9

. . , . . , . .
. .
. 1,2
, ,
.

.
: 1,2-, , , , , .
.
[1].
,
.
.
,

[26].
, [7].
,
,
, , .
,
,
[8, 9]. ,
, ,
[10, 11].
() ,
, , ,
[12, 13].
176
,
, ,
.
:
60 (1905),
. ,
, - [14, 15].
:
10 ; ,
20 ;

, 20 . 1,2- ()
( SIGMA-ALDRICH CHEMIE,
, D161802),
.

7,2 / ( ) 1
30 ,
0,1 10 [16].

, 0,1
10 .
. -
. 2013. 2
, ,
2 15 / ; 10 / 5 / , ,
8 . [17].

2
1 ( 0,2 ) 100 [18].
() [19]
-
.
() (=2/1, 2
, =280 ; 1 , =254 ) [20, 21]. ()
[22], () [23]
() [24]. -
(),
() [25, 26];
()
() [22], () [27],
() () [28].
(G-SH) [29]. (-),

[30].
. ,
(multi organs failure MOF-).

, ,
, , ,
60 80 % .
,
.

,
. , ,
, .
,
2,2 ,
.

(. 1).
1.
(M m)
5
9 6
66
+,16
+,26
3456

72
5623456
!"!!6
-'-6"6--)6
- #6"6--(6
-#$6"6-- 6
12345678529
6
4579
56
7 9 566
977579 96
#$%"!#&&&6
-. 6"--(&&&6
!-)6"--.&&&6
!($6"6--#&&&6
4579
56
7 9 566
977579 966525
6
'()"!'***6
-'."--)***6
-%("--(***6
!!!"-- *6
. : 1. * ,
(* <0,05; ** <0,01; *** <0,001); 2. # ,
(# <0,05; ## <0,01; ### <0,001).

,
-, . (
40,8%) ,
, , .

(53,21,5) %, 1,8
, (98,61,9) %.

2. 19,6%
, , .
. 2013. 2
177
, ,
, ,
.
2,

-
: 37,4 %,
39,9 %.
,
,
,
: 39,0 % 24,9 % .
2. -
(Mm)
12345678529
6
4579
56
7 9 566

72
5623456
977579 96
576 5766
!6"6## $6
%$&"#$$'''6
576 57 6*4
5+6
#$,,6"##($6
#!-"###%'''6
576 57 6*
92 5+6
(&,$6"6##,!6
(#!-"##('''6
./063126*4
5+6
,(!$6"6#(&%6
(!! "##&('''6
./063126*
92 5+6
(-"#((6
$,,"##!,'''6
36 *485+6
#%&&"###-6
#&$%"##($'''6
62345
66
##%"#% 6
(#,"#$'''6
783/96*4
5+6
$-,,"!(6
&,,"#-'''6
783/96*
92 5+6
$! -"6
& ,"&$'''6
:166*4
5+6
-"##&6
(-%"##,6'''6
:166*
92 5+6
(,-"##6
#&&"##('6
16*485 +6*4
5+6
#,"###6
#((("###'''6
16*485 +6*
92 5+6
#((&"###6
##!("###$'6
1;6*485 +6*4
5+6
## !"###,6
##-("###'''6
1;6*485 +6*
92 5+6
##,-"###6
##("###('''6
<036 6*4
5+6
,(!"#(%6
-! "#&'''6
<036 6*
92 5+6
$%"##$6
!$"#-'''6
063126*4
5+6
# "##(6
,$&"##!'''6
063126*
92 5+6
#&!"##(6
($"##%'''6
5
9 6
,
34,3 % .
, .
27,8 %
, .
, - ,
, , ( 6,0 ).

178
4579
56
7 9 566
977579 96 525
6
&"#((6)))6
#%-("##(#6)))6
(%% "##,6)))6
,#"#($%6)))6
!-("#(6)))6
#%-"###&6)))6
(!$&"#%%6)))6
,!("($(6))6
%,"&!6)))6
-"##$6)))6
(%"##%6)))6
#(,"###-6)))6
#((,"###%6)))6
## ("###,6)))6
##,&"###6)))6
,%$"#(6)))6
!"#((6)))6
(("##,6)))6
#-%"##6)))6
,
.
1,8 ,
.

, (. 2).

.
,
. ,
36,02 %, 46,7 %,
, . -
. 2013. 2
, ,
: 47,8 21,9 % 28,3

41,6 % .
,
IV
,
1,2-, ,

(, , ).
2,

- .

2,2 2,8 , ,
.

.
68,5 %. : 65,5 %. ,
, , ,
- .

,
,

.
. 1. ,
, ,
.
2.

.
3.
.
1.
-2
/ . . ,
. . , . . [ .] // . 2010. . 82, 4. . 6977.
2. 1,2- / . . ,
. . , . . [ .] // . 2012. 1. . 2934.
3. Ravnic-Glavac M. Animal model in the study of colorectal carcinogenesis / M. Ravnic-Glavac, A. Cerar, D. Glavac //
Pflugers Arch. 2000. Vol. 440, 5. P. 5557.
4. Perse M. The dimethylhydrazine induced colorectal
tumours in rat experimental colorectal carcinogenesis /
M. Perse, A. Cerar // Radiol. Oncol. 2005. 39 (1).
. 6170.
5. . . / . . //
. 2000. . 6, 8. . 3338.
6. Onose J. Rapid induction of colorectal tumours in rats
initiated with 1,2 dimethylhydrasine followed by dextran
sodium sulfare treatment / J. Onose, T. Imai, M. Hasumura //
Cancer Letters. 2003. Vol. 198, . 2. P. 145152.
7. Hayward R. Doxorubicin cardiotoxicity in the rat: an in

vivo characterization // R. Hayward, D. S. Hydock // J. Am.
Assoc. Lab. Anim. Sci. 2007. 46 (4). . 2032.
8. Enterosorbtion as a method to decrease the systemic
toxicity of cisplatin/ L. . Sakhno1, O.V. Yurchenko, V. N. Maslenniy [et al.] // Exp. Oncol. 2013. Vol. 35, 1. . 4552.
9. . . : . . . . . / . . .
, 2000. 22 .
10. . .
/ . . , . . // . 2006. . 52, 4. . 7888.
11. .. : / .. ,
. ., . . . . : /, 2001. 343 .
12. .. /
. . , . . // . 2011. 1. . 3541.
13. . . . .
// www.pediatric.mif-ua.com.
. 2013. 2
179
, ,
14. -
/ . . , . . , . . , ..
. : , 2002. 156.
15. European convention for the protection of vertebrate
animals used for experimental and other scientific purposes.
Council of Europe, Strasbourg, 1986. 56 p.
16. . .
()
/
. . , . . , . . //
. 2009. 1. . 3338.
17. . . , (
) / . . // . . .
. . , 2008. 22 .
18.
/ . ., . .,
. . [ .] // . : . 2010. 56 .
19. ..
/ .. , .. , .. // . . 1988. 9. . 2224.
20. /
.. , .. , .. [ .] //
. . 1991. 10. . 1318.
21. .. / .. ,
. . // . . 1984. 3. .138140.
22. /
. . , . . , . . , . . // . . 1988. 1. . 1618.
23. .
/ . , . //
. 1971. 10. . 8993.
24. . . / . . , . . . :
, 1976. 312 .
25. . .

/ . . , . . ,
. . // . 1984. 9.
. 540546.
26. . . / .. ,
. . . . : , 1972. 252 .
27. .
/ . , . , . // . 1985. 11. . 678681.
28. . .
/ . . , . . // . 1976. . 68, 2. . 223228.
29. Ellman G. L. Tissne sulfhydryl groups / G. L. Ellman //
Arch of Bioch. and Biophys. 1959. 82. P. 7077.
30. . / . , . , . // . 1991. 3. . 913.
FACTORS OF OXIDATIVE STRESS DEVELOPMENT IN INDUCED CANCEROGENESIS

AND ITS ABSORPTION CORRECTION
Yu. V. Soroka, Yu. O. Kovalchyuk, O. M. Oleshchuk
SUMMARY. The introduction of cytostatics Doxorubicine and Methotrexate in experimental 1,2-dimethylhydrazine neoplastic
endotoxicosis is characterised by free radical lipid oxidation, disbalance of antioxydant enzymes and non-enzymes elements,
development of toxemia. Application of enterosorbent Karbolayn in simulated pathological conditions and antineoplastic
therapy conduces the reduction oxidative stress signs in rat liver and kidney and indexes of endogenous toxicity.
KEY WORDS: 1,2-dimethylhydrazine, cytostatics, oxidative stress, liver, kidney, enterosorption.
180
. 2013. 2
, ,
616.155.3-008.85+616.12-005.4

. .
. .
. i
()
(). NV+- +- , +
, . NV+-, + +-, , NV+-.
: , , , .
.
() .
,

,
, , , ,
[10, 12].
,
,
[4]. ,
[11].
() [14].
. .
[2], , ,
,

[6, 16]. , ,
[7]. ,
[15] [8] .

[9].

. , -

, , () [13].
, , ,
, .
:

.
. 86 ,

. () 24
(27,9 %) , () 19 (22,1 %), ()
23 (26,4 %) () 20 (22,2 %)
. 68
(79,1 %), 18 (20,9 %)
. 45 76 (
(59,43,7) .).
(60,02,4) , (67,11,9) .,
(63,83,7) . (61,12,8) . 2 : 41 (47,7 %)
45 60 ., 45 (52,3 %) , 60 .
55,8 %, 44,2 %.
, 24
. :

( 9
10 ) (- ,
).

() (Astelon 4, Toshiba).
. 2013. 2
181
, ,

NIHSS 1, 7
14 . 1 25 (29,1 %),
37 (45,2 %), 16 (18,6 %) 8
(9,3 %) .

Epics XL (Beckman
Coulter, C). ANNEXIN VFITC-kit (Bender Medsystems, ),
5, (Annexin 5-FIT), (PI) . V , (NV+-). (PI)
(PI+-) [5]. FSC ( ) SSC ( ),
Dot Plot.

(1024 ).
( ANV+- PI+ ).
(-)
(Sigma Aldrich, USA), . 20- 200

.
,
FL1- Epics XL (Beckman Coulter, C) [1].

( (+-)
).
() 34 ,
.

Statistica 8. : (M), (m).

(t).
. ,

(. 1).
NV+ +
(<0,05)
3,92 6,92 . +-
(<0,05) , 2,53 .
1. NV+, + + (Mm)
123456738
13
767 8!8
()13
767 8!8
+91,3
767 8!8
926
2 648488
" #$%# #8
& #%& &8
#$ #%$ &8
285888
$" "%$ &#'8
# *%& #$'8
& "*%$ &'8
. * .
,

,
+-
. +-
- (r=0,675,
p=0,003), + +- (r=0,571, p=0,002) .

(. 2). NV+
( (<0,05) ,
). , -

. , .
, . ,
, [3]
. , ,
, .
2. NV+, + +- (Mm)
6789
284
18 22!4"4
()18 22!4"4
*1+8 22!4"4
182
544
#!$%!4
!#%!&4
!#%!4
1544
!%!4
!$%!4
$!%!$4
1234554
544
&!$&%!4
!'%!4
#!&%!#4
544
!'%!''4
!&&%!4
#!$'%!&&4
. 2013. 2
, ,
+
(<0,05) , ,
.
V- PI+- . N+ PI+
12,86, 14,0,
15,71, 11,67. ,
,
.
( , ).
, ,
,
. +-
5 (42,61,17) %.

, . ,
,
.

2 (. 3).
3. 1, 7 14 NIHSS
67859
5
55
!"5
$%5
'5
585
5
5
5
5
123445
585
5
##5
5
5
585
5
##5
##& 5
5
. * NISS 1 .
3,
(p<0,05) 14 ,
(p<0,05) 7 .
,
7 ,
, 14
1 , .
NV+-,
PI+- +-

, (. 4).
, NV+-
, .
(<0,01) , .
, ,
+-
(<0,05)
(<0,01) .
4. N+, + +- (Mm)

68
%&'1(526)8*8
0118(526)8*8
%231(526)8*8
88
")+$,")#"8
")-,+)"8
/),")-+8
123456789
2588
658 8
2!8"#8
)-",")".8
#) ,")+.8
")$,+)"8
)"#,+)+.8
)##,)+"8
")"#,).8
382!8$8
/+)+",+)$.8
)+/,+)" .8
),")$/.8
. * .

N+, + + -, 1
.
PI+ - NIHSS 1 (r=0,525, p=0,040),
NIHSS 7 (r=0,415, p=0,036) 14 (r=0,470, p=0,040).
NV+-
1 .
7
(r=0,495, p=0,045) 14 (r=0,470, p=0,037). ,

, NIHSS
7 .

1 +-
(r=0,512, p=0,042).
- .
: 1.
,
-
. 2013. 2
183
, ,
, . +
NV+- +-.
2. NV+- +- , + .
3.
NV+-, +-
, ,
NV+-.
4.
PI+ - 1, 7
14 , NV+- NV+- 7 14 , + 1 .
1. . .

/ . . , . . , . . // .
2001. 6. . 5861.
2. . .
2 //
. 2010. 5. . 1213.
3. . . V- / . . , . . ,
. . // - . 2008. . 11, .1. . 1423.
4. . .
: / . . , . . //
. 6 (36).
2010. .
5. Annexin V-affinity assay: a review on an apoptosis
detection system based on phosphatidylserine exposure /
van Engeland M.,Nieland L. J.,Ramaekers F. C. [et al.] //
Cytometry. 1998. Vol. 1, 31(1). . 19.
6. Baird A. E. A three-item scale for the early prediction
of stroke recovery / A. E. Baird, J. Dambrosia, S. Janket //
Lancet. 2001. 357. . 20952099.
7. Baird A. E. Blood genomics in human stroke /
Baird A. E. // Stroke. 2007. 38. . 694698.
8. Broughton B. Apoptotic mechanisms after cerebral
ischemia / B. Broughton, D. Reutens, C. Sobey // Stroke.
2009. 40. . 331339.
9. Induction of DNA fragmentation after 10 to 120 minutes of focal cerebral ischemia in rats / Li Y., Chopp, M. Jiang N.,
Zhang Z. G., Zaloga C. // Stroke. 1995. 26. . 1252
1257.
10. Mechanisms of neural cell death: implications for
development of neuroprotective treatment strategies /
A. G. Yakovlev, A. I. Faden // NeuroRx. 2004. Vol. 1.
P. 516.
11. Apoptosis after experimental stroke; fact or fashion? /
J. P. McManus, A. M. Buchan // J. Neurotrauma. 2000.
17. . 899914.
12. Modulation of Apoptosis in Acute Ischemic Stroke
as Treatment Challenges /Joaquin Jordan, Laura MorenoParrado, David Anton-Martinez [et al.] // Current Immunology
Reviews. 2012. Vol. 8 (11). P. 3949.
13. Love S. Apoptosis and brain ischaemia / S. Love //
Prog Neuropsychopharmacol Biol Psychiatry. 2003.
27. . 267282.
14. Roles of Oxidative Stress, Apoptosis, PGC-1 and
Mitochondrial Biogenesis in Cerebral Ischemia /Shang-der
Chen, Ding-I Yang, Tsu-Kung Lin [et al.] // Int. J. Mol. Sci.
2011. 12. P. 71997215.
15. Sairanen T. Apoptosis dominant in the periinfarct
area of human ischaemic stroke-a possible target of antiapoptotic treatments / T. Sairanen, M. L. Karjalainen-Lindsberg,
A. Paetau // Brain. 2006. Vol. 129. P. 189199.
16. Predicting functional outcome and survival after
acute ischemic stroke / C. Weimar, A. Ziegler, I. R. Konig,
H. C. Diener // J. Neurol. 2002. 249. . 888895.
APOPTOSIS OF THE WHITE BLOOD CELLS IN DIFFERENT SUBTYPES

OF ISCHEMIC STROKE IN ACUTE PERIOD
N. R. Sokhor
SUMMARY. The content of leukocytes in blood in apoptosis and necrosis and the level of leukocytes with high level of
reactive oxygen species (ROS) by flow cytometry in patients with acute period of ischemic stroke (IS) were studied. The
highest content of ANV+- and PI+-cells were found in patient with atherothrombotic IS and ROS+-cells with cardioembolic
IS, the lowest level in patients with lacunar IS. In severe and very severe IS was significantly higher content of ANV+-, PI+and ROS+-cells compared with mild stroke, with moderate only level of ANV+-cells.
KEY WORDS: acute period of ischemic stroke, apoptosis, necrosis, reactive oxygen species.
184
. 2013. 2
, ,
616.438-002-085.276-092.9

. . , . . , . .

.
. ,
, .

, , , .
: , , , .
. , , , -
[1].
[2].
( , - , ), (, -, ) ,
, ,
.
.
. 108 -
180200 .
, 5 -
(Sigma, ) 1 [3]. ,
3 10 , 56 . - [4]. , .

( ), 2 /
15 [5].

.
.

. -
,
, .
( I
III). I II , I III . 510

, I .
, ,
10 (. 1), , ;
,
,
, ,
.
, ,
; ,
.
.
, , .
.
, , .
. , .
. 2013. 2
185
, ,
, %
81
71
61
51
41

31

21
1
9
23

2

3

, %
4

6

21

76755
, %
3
726
725
724
723
7
126
125
124
123
89
9
9 89
9
. 1. .
, - -
, .
,
,
186
, .
,
,
,
,
, , -
. 2013. 2
, ,
, , , .
,
(
, ,
,
) [2].
, , , .
,
,
[6]. , ,
.
.

, , , .
1. . . . . // . . 1998.
. 44, 12. . 112122.
2. . .
/ . . ,
. . . . // . 2009. 3.1 (35). . 270274.
3. . . / . . // .
. . 1993. . 116, 9.
. 249253.
4. . . / . . . . : , 1961. 340 .
5. . / . . , . . . . : - . -, 1992. 276 .
6. Holaday J. W. Cardiovascular effects of endogenous
opiate system / J. W. Holaday // Annu. Rev. Pharmacol.
Toxicol. 1983. Vol. 23. P. 541594.
ACTIONS NONSELECTIVE BLOCKER OF NALOXONE OPIOID PEPTIDES

ON THE STATE OF THYMUS ON THE BACKGROUND OF INFLAMMATION
I. O. Sulkhdost, N. A. Shutova, M. O. ucheryavchenko
SUMMARY. The morphofunctional state of thymus is studied on the model of carrageenan induced acute aseptic inflammation
with the use of unselective blocker of opioid peptides naloxone. It is shown that opioid peptides limit functional activity of the
immune system, migration of lymphocytes into the blood at acute inflammation. Inhibiting action of opioid peptides on the
immune system at inflammation is associated with inhibition of cellular and further increase in role of humoral immune
reaction, by the further increase in helper and, especially, in suppressor activity.
KEY WORDS: inflammation, immune system, opioid peptides, naloxone.
. 2013. 2
187
, ,
547.913 : 581.45 : 582.998.4

SCORZONERA HISPANICA
. .
, .
. Scorzonera hispanica .
17 , .
: , , Scorzonera hispanica.
. ,
,
. , , Scorzonera
hispanica Asteraceae.
27 % , ,
, 50 % , 10 %
, ,
, , ,
( 4 /100 ), , 1, 2, (320 %), (23 %), (53 %),
(75 %), (3 %) [14].
, , , ,
. . .

.

,
. , , . - .
,
- [57].
, , , ,
[8, 9].
,
, .
.
,
.
.
(/) 188
Agilent Technologies 6890 5973. DB-5

0,25 30 . 1,2 / 0,2 .
- () 1,2 /. 250 . 50
320 4 ./.
- (50 ) 2 ,
(), 50 , .

splitless, ,

1020 . 1,2 / 0,2 [1012].

, NIST05 WILEY
2007 470000
AMDIS
NIST.

.
.
.
Scorzonera hispanica 17 , 16 (. 1).
, , , .
17 (. 1).

. . -
. 2013. 2
, ,
, , , , , , -
, 2-, .
.
. 1. .
1.
123432
567289
6 22
2
"2
!2
&2
2
2
2
2
#2
$2
2
"2
!2
&2
2
2
2
2
#!2
$2
&"2
2
2
"$2
""&&2
"!2
""&2
"!2
"!2
"##2
!!2
!#2
&$2
&"2
3862
98 6 2
"98 6 2
% "9 6 2
2
6 6279622
"97& ' 2
37( 2
3 96 6 2
) 6* 6273862
76 6 2
396 6 2
96 6 2
76
'6
)6+9 2
6 6 2
396)6 2
76 2
6)6 2
,
;
() (, ). R- 20 ,
. ( ) , .
(2--4-), ,
.
--
792
42
!"!2
!"2
&2
""2
$$2
$2
&#2
"2
&2
"2
&&2
$2
#2
"$2
!!2
2
!#2
,
.
(/) : >
> > > 5- > > > > 1-2- > > > 2- > > > 2--4- > --.
: 1.
.
. 2013. 2
189
, ,
2. 17 , 16 .
3.
.
. , , ,
.
1. . . / . . , . . . . V. : ,
2002. 222 .
2. . .
// . . , . , . . //
. : . .-. . .
. , 1920 , 2012 . . : -
, 2012. .1. . 68.
3. . . - / . . // . . 2009. 2/3. . 2729.
4. . .
- / . . , . . //
, . 2004. 4. . 3234.
5.
.
. :
, 2004. 240 .
6. Direct resistively heated column gas chromatography
(Ultrafast module-GC) for high-speed analysis of essential
oils of differing complexities / C. Bicchi, C. Brunelli,
C. Cordero [et al.] // J. Chromatogr. A. 2004. Vol. 1024,
12. . 195207.
7. Identification and Quantification of Flavonoids and
Phenoli Acids in Burr Parsley (Caucalis platycarpos L.), using
High-Performance Liquid Chromatography with Diode Array
Detection and Electrospray Ionization Mass Spectrometry /
A. Plazonic, F. Bucar, Z. Males [et al.] // Molecules. 2009.
Vol. 14, 1. P. 24662490.
CHROMATOGRAPHIC-MASS-SPECTROMETRIC DETERMINATION OF VOLATILE

COMPONENTS OF LEAVES OF SCORZONERA HISPANICA
M. F. Tkachenko
National Pharmaceutical University, Kharkiv
SUMMARY: Volatile compounds of leaves of Scorzonera hispanica were defined by chromatographic-mass-spectrometric
method. Detected and defined 17 compounds including dominant hexahydrofarnesylacetone and squalene.
KEY WORDS: volatile compounds, leaves, Scorzonera hispanica.
190
. 2013. 2
, ,
616.34 097:616.4] 092:599.324.2
RORt-
-
. . , . .

. RORt-
Wistar. ,
RORt+- Rort+CD8+- LFV
RORt.
: , RORt-, .
. () , , ,

- () [1]. ,

, , 1 , . [1, 2].
, ,
-

80 % ,
.
()
50 ,
,
, .
orphan- (. orphan ,
). orphan-
(Retinoic acid-relatedorphanreceptors, RORs) : ROR,
ROR ROR ( RORA, RORB RORC).
ROR2 (RORt)
TOR (thymus
orphan receptor).
RORt
, , .
RORt 560
, 63 ,

Th17-
(Innate lymphoid cells, ILCs) RORt-.
RORt- .
. 45 Wistar.

(, 2001)

, (, 1985). 1 (),
,

,
[3]. 2
(20 ) 3 ,
.
, ( , ) .
.
RORt-

. MICROM HR-360
(Microm, ) 5-
, ,
, (100 %,
96 %, 70 %), 0,1
(p =7,4) () RORt.
RORt- -
. 2013. 2
191
, ,
.
RORt
Santa Cruz Biotechnology ()
CD8 Beckman Coulter
(), FITC 18 = 4 . 0,1 60 ( = 37 )
1:64.

IgG , Texas Red (Santa Cruz Biotechnology, ).
0,1
(1:9)
.
ImageJ (NIH,
). ,
AXIOSKOP (ZEISS, ) 390 (FITC) 595
(TexasRed),
AxioCam 5c (ZEISS, )
,
AxioVision 4.7.2 (ZEISS, ) .
,
, RORt CD8.

. , RORt CD8. (Lymphocyte-filled villi, LFV),
[4]. , LFV
(diffuse guthymus) [4], -,

.

EXCEL
MS Office 2010 (MicrosoftCorp., ), STATISTICA 6.0
(Stat-Soft, 2001).
(), (m).
(t),
()
.
192

0,05.
.
50 % . ,

, , , , , / , [3]. ,
- ,
,
, ()
. [3].
Wistar,
RORt+, ,
RORt+
LFV 8271 2 (. 1).
RORt+- RORt+-
, , RORt+- (. . 1).
1
RORt+- LFV 2,1 (<0,05),
,
() RORt+- ( 78 %, <0,05)RORt+-
( 2,9 , <0,05),
RORt+-.

RORt+-,
RORt, : 1

RORt+- 3 (<0,05), RORt+- 2,3 (<0,05) RORt+- 31 % (<0,05),
. 2 , RORt+- LFV
( 94 %, <0,05).
RORt+- RORt+- ( 2,3 ,
<0,05). 2 RORt-
RORt+- ( 2,8 , <0,05), RORt+ ( 2,5 , <0,05) RORt+ ( 27 %, <0,05),
.
. 2013. 2
, ,
1. Rort+ Rort+D8+- LFV Wistar (m)
123456
3 6
13266
1326"6
123456
3 6
13266
1326"6
789
1 4 6
!6
""#! $#!%6
& "6
'#' #&%26
"" !6
&#' "#%6
789
16+,1
4 6
& &6
&$#* #"%6
"$ '6
&#( (#)%6
"$ *6
&)#" '#%6
789
123246
46
"& !6
"'# $#!%6
! '26
"&# !#"%6
&$ $6
"# &#"%6
789
1+,123246
46
( "6
"*# $#$%6
"" *23
"#( '#&%6
" $23
"$#* *#%6
789
1 46 46
! !6
!(# $#$%6
") !23
*#$ #&%6
)" 26
*!#$ '#"%6
789
1+,1 46
46
! "6
&#& '#"%6
&) '23
&(#" #(%6
&' (23
!!# )#'%6
1364 46
789
1 446
" '6
'! "&26
$( (26
364 46
789
1+,1 446
&* '6
'' (26
& (26
: Rort+ Rort+CD8+ ( 1 2),

; <0,05 (1).

, -
RORt CD8-, MHCI.
, 44 % RORt+-
CD8,
RORt+CD8+-
LFV 367 1 2 (. . 1).
1, 2
RORt+CD8+- LFV ( 2,1 2,3 , <0,05)
RORt+CD8+- ( 2,32,4 ,
<0,05) RORt+CD8+- ( 2,1
2,6 , <0,05), ,
(. . 1).
RORt
() . ,
, RORt CD4+-
Th17-; IL-17
. [5]. ,
RORt+ Th17-, RORt+ IL-17 [5].
Th17-
, , , ( ) [6]. Th17
,
. -, Th17 [5,6]. -, IL-23R ( Th17)

[6]. -, RORt
Th17 [7]. ,
invitro invivo Th17 [7]. , Th17- .
Hong M. t al. (2013), ,
-

Th17- Th17/
Treg- [8]. Schmidt D. t al. (2010)
, , Th17- Th1- ,
-
- [9].
, Th17- . , Beurel E. et al. (2012)
, Th17-
,
RORt SR1001,
anti-IL-17 [10]. ,
Th17- ,
,
. 2013. 2
193
, ,
, , , (-Th17).
Th17 ,
,

.
, ,
Th17
( rTh17),
, Treg [6].
Th17-
,
; ,
, ,
,
.
T-, . , , , Th17
,
- (segmented filamentous bacteria, SFB) [6].
Th17- I-17A, I-17F, I-22
, Th17
. I-17A
I-17F , - , . I-22,
(),
, [6, 7].
, RORt Th17- ,
. ,
(, Innate
lymphoid cells, ILCs) [11],
.
Th17-, Rort-, , - CD4
[11].
. ,
194
- , MHC-,
-
, ,
, , -, ,
[12].
, 3 : 1
(NK) , , , T-bet, IFN
,
Th1; 2
GATA3, I-5
I-13, , , GATA3 Th2 , , , 3 LTi- (lymphoid tissue inducer), ILC17,
NCR22 I-17, I-17F I22- , (-),
RORt,
Th17 [13].
, RORt Th17 . - RORt CD8, ,
- - , ,
I II ,
, , , , [14].

TNF, IFN , , , , ,
, , ,
-, , NK-, [15].
, , RORt RORt+CD8+
I-17- (Tc17cell), IFN,
, - (1 2), , Th17-, [16].
. 2013. 2
, ,
: 1. RORt+- LFV,
, .
RORt+- Th17, I-17- , -, (Tc17cell).
2. RORt+ ( 94 %, 2,1 ) Rort+ CD8+-
( 2,12,3 ) LFV
RORt. RORt
.
.

.
1. Mays J. Stress and the anti-influenza immune response: repeated social defeat augments clonal expansion of
CD8(+)T cells during primary influenza A viral infection /
J. Mays, N. Powell, J. Sheridan // J. Neuroimmunol. 2012.
Vol. 29. P. 3442.
2. Reber S. O. Stress and animal models of inflammatory
bowel disease-an update on the role of the hypothalamopituitary-adrenal axis / S. O. Reber // Psychoneuroendocrinology. 2012. Vol. 37. . 119.
3. . . , /
. . // . . . . . . . 2003. . 89, 7. . 858867.
4. Hitotsumatsu O. Identification and characterization of
novel gut-associated lymphoid tissues in rat small intestine /
O. Hitotsumatsu, H. Hamada, H. Ishikawa // J. Gastroenterol.
2005. Vol. 40. P. 956963.
5. Maddur M. Th17 cells: biology, pathogenesis of
autoimmune and inflammatory diseases, and the rapeutic
strategies / M. Maddur, P.Miossec, J. Bayry // Am J. Pathol.
2012. Vol. 181, 1. P. 818.
6. Huber S. Life, death, and miracles : Th17 cells in the
intestine / S. Huber, N. Gagliani, R. Flavell // Eur. J. Immunol.
2012. Vol. 42. P. 22382245.
7. Kanai T. RORt-dependent IL-17A-producing cells in
the pathogenesis of intestinal inflammation / T. Kanai,
Y. Mikami, T. Sujino// Mucosal Immunol. 2012. Vol. 5,
3. P. 240247.
8. Hong M. Imbalance between Th17 and T-reg cells
may play an important role in the development of chronic
unpredictable mild stress-induced depression in mice /
M. Hong, J. Zheng, L. Wang // Neuroimmunomodulation.

2013. Vol. 20, 1. P. 3950.
9. Schmidt D. Chronic psychosocial stress promotes
systemic immune activation and the development of
inflammatory Th17 cell responses / D. Schmidt, S. Reber,
A. Lechner // Brain Behav Immun. 2010. Vol. 24, 7.
P. 10971104.
10. Beurel E. Inflammatory T Helper 17 Cells Promote
Depression-like Behavior in Mice/ E. Beurel, L. E. Harrington,
R. S. Jope // Biol Psychiatry. 2012. Vol. 19. P. 32103223.
11. Wojno E. Innate Lymphoid Cells: Balancing Immunity,
Inflammation, and Tissue Repair in the Intestine/ E. Wojno,
D. Artis // Cell Host & Microbe 2012. Vol. 12. P. 445457.
12. Spits H. Innate lymphoid cells: emerging in sight sin
development, line a gerelation ships and function / H. Spits,
T. Cupedo // Annu. Rev. Immunol. 2012. Vol. 30.
P. 647675.
13. Spits H. Innate lymphoid cells a proposal for uniform
nomenclature / H. Spits // Nature Rev. Immunol. 2013.
Vol. 13. P. 145149.
14. Sutton C. IL-17-producing T-cells and innate
lymphoid cells/ C. Sutton, L. Mielke,K. Mills// Eur. J.
Immunol. 2012. Vol. 42. P. 22212231.
15. Born W. Diversity of T-cell antigens / W. Born,
K. Aydintug, R. OBrien // Cellular & Molecular Immunology.
2013. Vol.10. P. 1320.
16. Yaochite J. N. Dynamic changesof the Th17/Tc17
and regulatory T cell population sinterfere in the experimental
autoimmune diabetes pathogenesis / J. N. Yaochite, C. CaliariOliveira, M. R. Davanso // Immunobiology. 2013. Vol. 218,
3. P. 338352.
INFLUENCE OF SOCIAL STRESS ON THE DISTRIBUTION OF RORT-EXPRESSED

CELLS OF THE INTESTINE-ASSOCIATED LYMPHOID TISSUE OF THE RATS
. O. Topol, O. M. Kamyshny
SUMMARY. It is investigated the influence of chronic social stress on the distribution of RORt-xpressed cells in the own
lamina of mucous membrane of the fibres of the ileum of the rats of Wistar line. It is established that the development of CHSS
results to the enlargement of quantity of RORt+- nd Rort+CD8+-lymphocytes in LFV and t is accompanied by increasing of
transcripted factor RORt concentration.
KEY WORDS: stress, RORt-lymphocytes, rats.
. 2013. 2
195
, ,
615.272+612.82+612.44+616-092.9+616.441-008.64

. .
-
. ,
.

.
,
.
: , , , ,
.
. .

. () .
,
, [1, 2, 3].

, [4].

.
. - 150180 ,
[5].

() 10 /100 30 [6].

: 3, 4, ()
(3/4) /4 [7].
() ()
,
[8].
() [5],
[9], [9],
[9].

, .
.

(. 1). , 3
75,23 %
(<0,001), 4 70,68 % (<0,001),
. 3/4
44,56 % (<0,001), .

2,09 (<0,05), -
1. (Mm)
1234567589
8
27
24789
88
'
7 8( 8''26 4 8
)
*24548"8
18
2448
8
"" %+8
28
2448
!"##8
"%& %+8
8
48
$%8
&&$$%&%38
128
28
8
#&8
"$+8 &$$$!++8
. * <0,001; ** <0,01; # <0,05,

.
196
. 2013. 2
, ,
. /4
2,95 (<0,01).
. , ( 2,45 ), ( 91,66 %), ( 3,43 ).

: 27,92% (p<0,05),
81,74% (p<0,05).
,
,
, .
( 3,43 , p<0,05),
50,76 % (p<0,05) ,
. , , ( ,
), (
)
.

,
.
. , 3 (r=0,64,
<0,05); 4 :
(r=-0,63, <0,05), (r=-0,94, <0,01); 4 :
(r=-0,84,
<0,01),
(r=0,86, <0,001);
(r=0,65, <0,05).

(. 2).
(. 3).
, . , 76,29 %
(<0,001), 56,29 %
(<0,05),
26,31 % (<0,05) .

27,95 % (<0,01).

4
(, r=0,90, <0,001), (, r=-0,83, <0,01),
(, r=0,81, <0,01), (, r=0,61, <0,05).
. .
(,
, ). .
.
2.
(m)
1894 54

2884 544
!4"4#$4
-34.64894
6/84!"#&4
12345674897
64 44
34668
64 44
84
864 889 4 84 864 889 4
84
6884
84
84
6884
84
%3&'$3$&4
$3()$3$&4
$3#*$3$)4 (3)+$3%%4 $3&,$3$+4
(3(*$3$+4
%3*+$3$)14
$3)*$3$(04
$3+%$3$*04
)3)+$3'%04 %3**$3$)04
%3)+$3$&04
3. (M+m)
2 6878
"26264848#$%8&'(8
04767813782778
34528#$%&.(8
9
88
)&*+'',8
-,'.''.28
12345673789
8
64 76 846 768
34445488
54528
6828
828 1128
-&&+'.*8
'-)''-8
.*.'+328
'-+''-48
. 2013. 2
!24568
28 3128
&//*-&*8
*,/)-+'228
197
, ,
.
.
( ,
) .

.
.

- .

.
1. . . - / . . , . . // . 2004. 1. . 2427.
2. . . / . . // - . 2004. . 7, 1. . 140142.
3. Roles of hydrogen peroxide in thyroid physiology
and disease / Y. Song, N. Driessens, M. Costa [et al.] // J. Clin.
Endocrinol. Metab. 2007. Vol. P. 37643773.
4. . .
/ . . , . . , . . // . 2011. . 8, 2. . 6265.
5. Martinez-Galan J. R. Early effect of iodine deficiency
on radial glial cells of the hippocampus of the rat fetuset /

J. R. Martinez-Galan, P. Pedraza, M. Santacana // J. Clin.
Invest. 1997. Vol. 99. P. 27012709.
6. . .
- / . . , . . , . . // . . . 1998.
4. . 6165.
7.
: . . , 2003. 430 .
8. . .
/ . . // . 1989. 7. . 810.
9. . . / . . .
1968. 53 c.
METABOLIC CHANGES IN TISSUES OF CEREBRUM AND THYROID GLAND

IN RATS WITH EXPERIMENTAL HYPOTHYROIDISM
O. I. Tuchak
SUMMARY. Thyroid hormones are able to change the activity of antioxidants and pro-oxidants thus their deficit could be a
reason of initiation of uncontrolled process of lipid peroxidation. The research of the mechanisms of relationship between the
systems of peroxidation-antiperoxidation and metabolic changes in the structures of cerebrum and thyroid gland of animals
with experimental hypothyroidism has a scientific interest. The results of carried out researches confirm the increase of free
radical reactions in blood serum, in the tissues of diencephalon and thyroid gland on the background of mainly suppression
of the antioxidant defense.
KEY WORDS: hypothyroidism, diencephalon, thyroid gland, free radical oxidation of lipids, antioxidant system.
198
. 2013. 2
, ,
616.316-001-07:616.316-008.8-07

. . , . . , . .
.
. 1, 6, 10, TNF, Ig A, G
.

.
: , , , .
.
, [4, 6, 14]. , [4, 5, 11].

, [2, 8, 9, 10].
IL-1,
IL-6, IL-10, TNF- Ig A, G .
. - 50
.
. 18
50 . ,
20 . IL-1, 6, 10, TNF
Ig A, Ig G.

Diaclone .

- . m,
,
-,
STATISTICA 6.0 (StatSoft, USA) [1].
.

(. 1).
1. 1
793 65

7 56
41
"#$%&6
6
"#$,6
6
"#$% 6
/01$26
7
276 1
!' ( ')6
,' ( ')1
'. ( '6
)'3( '1
123456789
51
79 7 62346! 1
*+'**(',6
2- ' !6
%%,' (%'6
2- ' !6
!'( '.6
2- ' !6
,'!*( '36
2- ' !6
: .
IL-1 ,

[2].
IL-1 . IL-1 57,4
(<0,05).
IL-6 ( 8,5 D) -, -
. , -, - [3]. IL-6 19
(<0,05). IL-6 :
- .
IL-6

: 1
7 , -
. 2013. 2
199
, ,
, .
TNF- 5,4
(<0,05). TNF- ,
. TNF-

. TNF- .
TNF- , ,
[2, 3].
IL-10
2,2 , (<0,05).
IL-10
,
[2, 3].
,

.

IL-10
.

[6, 10].

, .

.

.

2.
2. 1 (+m)
8
23789

!329
"#$%
.224/
"#*%

4
%&'()%&%*
+%&%$
%&-0)%&%-
123456789
55 82428454

3
3
329
2
%&,,)%&%,
%&'-)%&%,
%&*-)%&%*
+%&%$
+%&%$
+%&%$
%&*,)%&%-
%&%%-)%&%%%-
%&%')%&%%*

%&(-)%&%$
+%&%$
%&-%)%&%-
: .

Ig A

153 % (0,480,02 /, <0,05). Ig A 43 % (0,330,03 /, <0,05).
, Ig A , , .
60 %
Ig A , 40 %
.
Ig A 1 % .
5,2
(0,210,02 /, <0,05)
.
Ig G 60 %,

0,100,01 /. Ig G 8
(0,810,05 /, <0,05). Ig G
200
, .
80 % .
, Ig ,
G
. Ig
.
. 1. , , , , , -

.
1
,
.
2.
Ig , G, .
.
. 2013. 2
, ,
1. . STATISTICA: . / . . : , 2001. 656 .

2. . . / . . // Russian Journal of
Immunology. 1999. Vol. 4 (Suppl.l). C. 4652.
3. /
. . , . . , . . . . :
, 2009. 342 .
4. . .
/ . . , . . // .
2004. 1. . 8891.
5. . . - / . . // . 2004. 2. . 4042.
6. . .
-
/ . . , . . ,
. . // . 2005. 4. . 46.
7. . . , -1, -6
- (
) / . . // . . . 2003. 2. . 310.
8. . . - / . .. ., 2004. 1062 .
9. . . , - / . . // .
2002. 4. . 4245.
10. . . / . . , . . . : -, 2005. 481 .
11. - . . : . .
. . . , 1995. 19 .
12. Dinarello C. A. Immunological and inflammatory
functions of the interleukin-1 family / C. A. Dinarello // Annu.
Rev. Immunol. 2009. Vol. 27. P. 519550.
13. Strieter R. M. Cytokine in innate host defense in the
lung / R. M. Strieter, J. A. Belperio, M. P. Keane // J. Clin.
Invest. 2002. Vol. 109. P. 699705.
14. Tnantafyllou A. Ultrastructural observation of arteriolar
calcification in a submandibular salivary gland / A. Tnantafyillou, J. D. Harrison // Ultrastruct. Pathol. 2005. Vol. 22,
4. P. 305307.
NONSPECIFIC IMMUNE PROTECTION IN THE MUCOUS AT THE UNCOMPLICATED

FRACTURES OF THE MANDIBLE
S. V. Ushtan, N. E. Lapovets, L. Ye. Lapovets
Lviv National Medical University by Danylo Halytsky
SUMMARY. There were studied levels of interleukins 1, 6, 10, TNF, Ig A, G in saliva of the patients with uncomplicated
fractures of the mandible. Revealed clear changes in the levels of the studied cytokines and immunoglobulins can expand
the understanding of pathogenesis of healing fractures of the mandible and promote the development of new methods of
diagnosing and treating this type of injury.
KEY WORDS: fracture of the mandible, salivary gland damage, cytokines, immunoglobulins.
. 2013. 2
201
, ,
613.32:546.81:546.32/33-06:612.015:11]-092.9

. .
. .
. ,
(1/250 50)
(), , ()
() . , .
, .
: , , , , .
. (II) ( , Plumbi acetas) ,

. : Pb(CH3COO)2.

,
[1, 2].
, ,
.
.
( 40 70 % ), , , ,
[3]. 10 %, 20 %.
70400
, 16 .

(90 %), .
120 ,
, .
: 3,96 / 13,09 /. .
, , , , ,
. , ( ) [4].
,

,
. 202
, , ()
().
.
-
150200 , 7 .
,
. , , 2832 .

2.2.4171-10 , [5]. .
.

(+b). (StNa+b)
(StK+b)

1/250 50. 40-
7 /. . ,
[6]. Microsoft Excel. .
.
.
,
[7]. , -
. 2013. 2
, ,

.

, ,
.
. . , , ,
, .

.

2- ()

=532 . , ,
() [8].

,
(. 1).
72
89

9
5
4
3
2
12345267
829

. 1. ( . ./).
* , : * <0,01).
2 ,
,
4,5 .
3 ,

5,2 , 4 -
52
6 , . 3 4 ,
2 , : 1,1
1,3 .

, (. 2).
51
42
645
43 41
12 32
1
31
2
1
12345267
829

. 2. ( /)
.
2,

,
.
.
,
6 , , 5,05 ,
. 2013. 2
203
, ,
.
3 4 , 2 , , 1,1 .
3 4 ,
,
.

,
(. 3).
, 3 4 ,
, 3,6 . 2 , , 0,91, 3,6 ,
.
4,

.
9

237
236
235
234
2
12345267
829

. 3. ( . ./)
.
634
7879

6
534
5
234
2
12345267
829

. 4. (/)
.

,
, .
, 2 , , 3,14
.
3 4 ,
, 3,3
3,4 ,
. 2 , , 1,05 1,1 , 3 4 ,
.

(. 5).
204
2, 3 4 ,
: 1,6, 1,5 1,9
(. 3). 4 , ,
1,2 , , 3 ,
. 2 , , ,
4 , ,
1,1 , 3 ,
, 1,08 .

, .
6,

. 2013. 2
, ,
239
238

237
236
235
234
2
12345267
829

. 5. ( . ./)
.
634
6
7879

534
5
234
2
12345267
829

. 6. (/)
.
. . 2 ,
, 2,8
, .
.
, 3,42 , . 3 ,
,
3,29 ,
. -
. .
: 1.
1/250 50 , ,
, .
2.
, , .
.
, .
1. / . . , . . , . . , . . // . 2011. 5. . 4041.
2. . . () /
. . , . . , . . //
. 1992. 56. . 69.
3. . . - - -
/ . . // . 2003 . 34,
. 1. . 170190.
4. Immunotokxicity of co exposures to heavy metals: In
vitro studies and results from occupational exposure to
cadmium, cobalt and lead / D. Jung, U. Bolm Audorff,
A. Faldum [et al.] // EXCLI Journal. 2003. 2. P. 3144.
5.
, ( 2.2.4-171-10).
. 2013. 2
205
, ,
6. . . : / . . , . . .
. : , 2006. 216 .
7. :
/ . . , . . , . . [ .] :
2008. 192 .
EFFECTS OF LEAD ACETATE ON THE BACKGROUND OF DRINKING WATER

CONTAINING POTASSIUM AND SODIUM STEARATES ON LIPID PEROXIDATION
IN THE BODY OF EXPERIMENTAL ANIMALS
O. Ye. Fedoriv
SUMMARY. In the course of conducting research it has been found that the insertion of the lead acetate in doses (1/250 50)
in the background of drinking water usage, water with potassium and sodium stearates into experimental rats was accompanied
by a trustworthy increase of products of lipid peroxidation (LP) in particular, diene conjugates (DC) and malondialdehyde
(MDA) in animals bodies. These parameters were determined in blood serum, liver and kidney tissues. Higher concentrations
of products of lipid peroxidation (LP) were observed in the group of animals that consumed water with potassium stearate.
KEY WORDS: lead acetate, drinking water, potassium and sodium stearates, lipid peroxidation.
206
. 2013. 2
, ,
612.33:612.014.484/.015.111] : 615.276

NO-/
. . , . . , . . , . . ,
. .

. NO/ () ()
- . , NO-
(NOS) , ; .
-1/-2, -2 -2/5- NOS NOS.
: , , .
. , [9, 11].
,
,

() , [11, 13].
, () , [5, 14].
NO-/
. , NO- (NOS) (nNOS) (NOS) , (NO) . NO
, , ,
, , ,
[3]. L- NO-, , , NO ,
.
,
,
NO- (NOS) NO,
[8, 12].
NO-
(iNOS), -2 (2), 5- (5-), , ,
, 2 ( B4) [4].
.
NO-/
.
. 58 180200 ,
, , .
, .
20 .
- () [6]. .
, - , .
:
() (0,1
0,9 % );
, ;
, -1 SC-560
10 /; ,
-1/-2 10 /; , -2 10 /; , -2/5- 2--5(3,5-4-)--4 (25DHT) (10 /),
.
NO-/
NO- [1]; - [8], [7].

- [2].
. 2013. 2
207
, ,

ANOVA Statistica. <0,05.
. ,
NOS (4,910,94 3,260,9 / ),
iNOS . 0,380,08 /.
-
17,61,3 /, -
240,75,0 /,
107,210,3 / (. 1).
, iNOS 4,6 6
(<0,01) NOS (
65 % 34 %, ) (
42 % (<0,05,) 16 % );
- 1522 % (<0,05),
. , .
1. NO-/

123456789
472 6
838
6
896
6
9
%868'(6
56%868'(6
78166
9
%868'(6
56%868'(6
7819":/1+6 9
%868'(6
56%868'(6
78169638926 9
%868'(6
56%868'(6
781696
9
%868'(6
;2
289'6
56%868'(6
781696)$/<=>6 9
%868'(6
56%868'(6
46
3876
8
1
)*+,-./6
0+-,).0+,26
)--,*.16
020./6
)3*.2,/6
0)3,).-,46
)--,0.-,26
0)4,1.2,/6
)3),-.1,16
0)*,/./6
)-1,/.1,26
0)3.2,/6
436486
8
1
0-,1.0,26
01,/.0,0-6
)+,/.0,06
04,0.0,0)6
)+.),*6
04.+,36
03,).0,-6
03,1.0,036
03,/.0,26
03,*.0,)6
0-.+,36
03.0,/36
-1
iNOS 22 %
(<0,05), 50 % (<0,05);
NOS .
-1/-2 iNOS
49 % (<0,05), 57 % (<0,05).
NOS
81 % (<0,05). , - , .
-2 iNOS ,
NOS . -
.
-2/5-
- , , , iNOS
,
.

NO208
!"6
8
6
#1
+,)2.+,+36
+,03.+,+*6
0,+/.+,)6
0,+-.+,036
+,3+.+,016
+,/*.+,+46
+,/*.+,)26
+,*1.+,0)6
0,).+,)*6
0,*0.+,)26
+,3).+,2/6
+,-).+,0*6
9 !"6
8
6
#1
+,*4.+,+46
+,22.+,+46
+,0-.+,+16
+,)).+,+46
+,24.+,+26
+,)2.+,+)6
+,2+.+,+46
+,)*.+,016
+,*3.+,036
+,*/.+,006
+,*-.+,)26
+,**.+,016
$34%6
8
#&6
+,23.+,+36
+,20.+,+)6
+,03.+,+26
+,)1.+,+16
+,20.+,+/6
+,)).+,+26
+,)).+,+*6
+,04.+,+-6
+,)*.+,+/6
+,)*.+,+36
+,)-.+,+36
+,)1.+,+36
/
.
. 1. iNOS ,

.
2. -1/-2
iNOS,
.
3. -2

iNOS, ,
NOS ,
-2/5- iNOS, -2 .
.
NO-/
.
. 2013. 2
, ,
1. . .
, /
. . , . . // . . . 2000. 3. . 37.
2. . . / . . , . // . 1981.
4. . 209211.
3. Changes in distribution of three isoforms of nitric oxide
synthase in ulcerative colitis / P. Vento, T. Kiviluoto, H. J. Jarvinen [et al.] // Scand. J. Gastroenterol. 2001. Vol. 36.
P. 180189.
4. Cyclooxygenase 2 is induced in colonic epithelial cells
in inflammatory bowel disease./ Singer I. I., Kawka D. W.,
Schloemann S. [et al.] // Gastroenterology. 1998.
Vol. 115. 2. P. 297306.
5. Interaction between selective cyclooxygenase
inhibitors and capsaicin sensitive afferent sensory nerves
in pathogenesis of stress-induced gastric lesions. Role of
oxidative stress / S. Kwiecien, P. C. Konturek, Z. Sliwowski
[et al.] // J. Physiol. Pharmacol. 2012. 63, 2.
. 143151.
6. Gastric mucosal damage in water immersion stress:
Mechanism and prevention with GHRP-6 / Shu Guo, Qian
Gao, Qing Jiao [et al.] // World J. Gastroenterol. 2012.
Vol. 18. N 24. P. 31453155.
7. Geyer J.W., Dabich D. Rapid method for determination

of arginase activity in tissue homogenates // Anal. Biochem.
1971. Vol.39, N 2. . 412-417.
8. Green L.C. Analysis of nitrate, nitrite and (1515) nitrate
in biological fluids / L.C. Green, A.W. David // Anal. Biochem.
1982. 126. . 131138.
9. Konturek P.C. Stress and the gut: pathophysiology,
clinical consequences, diagnostic approach and treatment options / P. C. Konturek, T. Brzozowski, S. J. Konturek // J. Physiol.
Pharmacol. 2011. Vol. 62. N 6. P. 591599.
10. Lanas A. Role of nitric oxide in the gastrointestinal
tract / A. Lanas // Arthritis Research & Therapy. 2008.
Vol. 10, 2. P. 16.
11. Larauche M. Corticotropin releasing factor signaling
in colon and ileum: regulation by stress and pathophysiological
implications./ M. Larauche, C. Kiank,Y. Tache // J. Physiol.
Pharmacol. 2009. Vol. 60, Suppl 7. P. 3346.
12. Lundberg J. O.,Weitzberg E. Biology of nitrogen
oxides in the gastrointestinal tract. // Gut. 2013. Vol. 62.
4. . 616629.
13. Scaldaferri F. Inflammatory bowel disease: progress
and current concepts of etiopathogenesis / F. Scaldaferri,
C. Fiocchi // J. Dig. Dis. 2007. Vol. 8. P. 171178.
14. Wallace J. L. NSAID gastropathy and enteropathy:
distinct pathogenesis likely necessitates distinct prevention
strategies / J.L.Wallace // Br. J. Pharmacol.2012. Vol.165.
N 1. P. 6774.
INFLUENCE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS ON THE STATE

OF NO-SYNTHASE/ARGINASE IN THE COLON UNDER CONDITIONS OF STRESS
I. S. Fomenko, V. Yu. Yemelyanenko, N. B. Panasyuk, L. P. Biletska,
O. Ya. Sklyarov
SUMMARY. The influence of different nonsteroidal anti-inflammatory drugs on the state of NO-synthase/arginase system and
lipid peroxidation processes in mucosal and muscular layers of the colon under conditions of water immobilisation stress was
investigated. It was shown that stress induces the increase of inducible NO-synthase (NOS) in the mucosal and muscular layer
of the colon, at that arginase activity decreased; simultaneously processes of lipid peroxidation decreased. The blockage of
COX-1/COX-2, COX-2 and COX-2/5-LOX revealed the peculiarities of changes of iNOS and cNOS activity.
KEY WORDS: stress, uncerative colitis, nonsteroidal anti-inflammatory drugs.
. 2013. 2
209
, ,
661.718.6:591.481.1:57.043

-3
. . , . .

.
(-3)
-
(). , -3
, . -3
(). ,
-3
, .
: , -3, , .
. ,
,
. 75
80 % . ,
,
, [1, 2].
,

,
- , ,
, , ,

[3, 4].
,
. , ,
[5, 6], .. (-3),
, ,
() [7, 8] .
,

210
,

. ,
, , .
,
, , , -,
,
,
-3,
.
. 47
190230 , ( )
[9], .

[10],
(10 3) 30 .
4 : , (), ( + -3) ( + ). -3
1 % : 49 / 36
[11]. (, ), 100 /
36 [12].
. 2013. 2
, ,

.

, () .
,

- ().
[13], ,
n-- .
- () [14]:
=/,
;
.
,
,
Microsoft
Excel,
95 % (P0,05) t [15].
.

-3
1.
, () 1

38 % . 6 ,
25 % , .
.
, ,
, , ,
, , ,
,
(. . 1).
-3
, :
1 1,8 ,
6- 1,5 ,
. ,
, -3,
, -
1. -3 (n=6)
123456789
59 2668
8
976858
832
72658
8
!8
123456789
522 8
&'()8
*'+(8
/')+8
/'+&8
*' (8
*' 08
2*'*&8
1*'** 8
&'*/8
4'!08
*'/*8
*'4&8
2*'*&8
2*'*&8
1*'*&8
1*'*&8
2*'*&8
2*'*&8
4'/&8
4'+&8
*'/08
*'448
1*'*&8
2*'*&8
1*'*&8
2*'*&8
383768
8
678
"668
#8
$%8
#8
$%8
.18
#8
$%8
.12
.38
.48
#8
$%8
.12
.38
,
63
-68
3
5968
526232668
: P1 ; P2 ;
P3 .
. 2013. 2
211
, ,
,
.

, . 2.
2. -3 (n=6)
123456789
59 26688
8
976858
832
72658
8
!8
1234245673789
95
&'( 8
&'&(8
,'&-8
'(-8
&',.8
&',08
/&'& 8
/&'& 8
'2&8
&'-.8
&' !8
&' !8
/&'& 8
/&'&(8
/&'&(8
3&'&(8
3&'&(8
3&'&(8
&'- 8
',68
&' 08
&' 28
/&'&(8
/&'& 8
3&'&(8
/&'&(8
245673789
95
,- '&&8
,6'208
..'&&8
,,&'(&8
,6'& 8
62'2.8
/&'&(8
3&'&(8
,0&',(8
,. ',(8
0'6!8
0'068
3&'&(8
3&'&(8
/&'&(8
3&'&(8
3&'&(8
3&'&(8
,2!'0(8
,0-'&&8
( '-(8
(-'0&8
3&'&(8
3&'&(8
3&'&(8
3&'&(8
383768
8
678
"668
#8
$%8
#8
$%8
+18
#8
$%8
+12
+38
+48
#8
$%8
+12
+38
)
63
*68
1
5968
425232668
"668
)
63
*68
1
5968
425232668
#8
$%8
#8
$%8
+18
#8
$%8
+12
+38
+48
#8
$%8
+12
+38
, ,
(<0,01) ( 4 )
, ,
(1 ) . 6 , 3
, . ,

-, [16].
212
-3

. ,
,
,
(>0,05).
,
, , . ,
-3, , ,
- ,
.
. 2013. 2
, ,

,
(<0,01)
35 % 24 % 1- 6-
, .
, ,
.
. , ,
, ,
.
, , .
-3

(<0,01-<0,05) . , 6 (>0,05)

.

,
, , . ,
3, ,
1 6,3
(<0,001) ,
. ( 6 ) ,
3,4 (<0,01) , . ,
, .
3. -3 (n=6)
383768
8
678
"668
#8
$%8
#8
$%8
,18
#8
$%8
,12
,38
,48
#8
$%8
,12
,38
*
63
+68
0
5968
526232668
1
2,3 , 6- 1,9
, . ,
, -3,
.
. -3
-
123456789
59 26688
8
976858
832
72658
8
!8
&'&& (8
&'&&&)8
&'& -8
&'&&! 8
&'&& 8
&'&&/&8
.&'&& 8
.&'&& 8
&'&&128
&'&&-/8
&'&&&38
&'&&&/8
.&'& 8
.&'&/8
.&'& 8
.&'&/8
4&'&/8
4&'&/8
&'&&3(8
&'&&-38
&'&&)!8
&'&&&(8
4&'&/8
4&'&/8
4&'&/8
.&'&/8
, ,
.
.

-3 .
1.
/ . ., . ., . . [ .] //
: - . 2002. .11. . 4352.

2. . .
// .
. 2013. 2
213
, ,
1998. 10. . 3336.

3. . .
: . .
. . : .
14.03.05 . , 1999. 36 .
4. . . : / . . , . . // . 1998.
4. . 7279.
5. / . .,
. ., . . [ .] // . 2012. . 18, 1. . 120125.
6. / . . , . . , . . ,
. . // . 2002.
6. . 110114.
7. / . ., . ., . . [ .] //
. .. . 2013. 1. . 8184.
8.

/ . . , . . , . . [ .] // . . . .
2008. . 9, 4. . 123126.
9. : / . . .
. . . . : , 2002. 567 .
10.
: /
. ., . ., . ., . . . : , 2002. 28 .
11. . . / . . //
2526 2013 . -.
. 1112.
12. -
/ . . , . . , . . [
.]. // . 2010.
4 (17). . 6469.
13. / . . , . . //
. 2000. 2. . 4647.
14. / . . , . . , . . [ .] . : , 1974. 264 .
15. . - /
. ; . . . : , 1999. 459 .
16. . . /
. . , . . . , 1985. 194 .
PHARMACOLOGICAL CORRECTION OF CARBOHYDRATE METABOLIC

DISTURBANCES BY VITAGERM-3 IN ANIMALS WITH HYPOXIC SYNDROME
K. O. Shebaldova, K. M. Mishchenko
SI Luhansk State Medical University
SUMMARY. To research the influence of coordination compounds of germanium with dietylentryaminpentacetic acid and
potassium (VITAGERM-3) to carbohydrate metabolism in rats with hypoxic syndrome concentrations of glucose and its metabolic
products pyruvic acid and lactate levels were measured and redox potential was calculated. It was discovered that the use
of VITAGERM-3 elevated pyruvate level and reduced lactate level compared with controls at all study terms. In that regard,
VITAGERM-3 was not inferior to the reference preparations (mexydol). Thats a reason to supposed one of the VITAGERM-3
antiischemic mechanisms the ability of the compound to enhance adaptation response of the body to hypoxic hypoxia by
activating of gluconeogenesis, while preventing the development of metabolic acidosis.
KEY WORDS: the germanium compounds, VITAGERM-3, carbohydrate metabolism, hypoxic syndrome.
214
. 2013. 2
, ,
616.34-007.272-099]-092.9

. .
. .
.
.
, ,
-
. ,
.
, , .

.
: , ,
. , ,

. C , [1, 2].

,

[3, 4, 5].
,
[6, 7, 8].
: ,

.
. 72 -, : (8 ) . (32 )

5 . (16 )
48 -
,
. (16 ) 48
,
1 ,
,
,
, [9]. .

[4, 5]. , , ,
(, , , ),
,
.
,
[10, 11].

. .
. [12], , 12,
24, 48 72 .
12 24 -
. 2013. 2
215
, ,
.
(): , ( 280 ) , (
254 ) [13].
() . . [14].
1,0 3,0 0,025 %
.
30-
1500 ./ 10 . , 1,0 , -2
630

10,0 . , , (), :
(%) = 100 Eon 100/Ek,
Eon ;
Ek .
. ,
.

.

Microsoft Excel.
.
.
. , 12- -
,
,
.
.
.
.
24 48 . . ,
. ,
,
. ,
. .
.
72

-
.
.
, ,
. , ,
. ,
, .

(. 1).
12
, 24 -
1.
(Mm)
9232
653886372 68
5
5374568
63 8
7)
28
&8'78
53*68 8'778
8'78
"8'778
-553./08
&8'78
8'778
-553./08/8 &8'78
35
348
8'778
188
!"#$ 8
!#"$ "8
!$ "(8
!$ %((8
&&$ &&((8
%$ #((8
#&$ &((8
""$ %((8
!"$ (+(,81(28
1232456378
188
!"$ "8
!#$ &8
!$ #(8
#!$ &((8
"$ #((8
!%$ ((8
$ &%(8
%$ #((8
!$ "(+(,8
37637623785
8
! %%$ "8
$& &8
% $& !((8
" $& &((8
"# "$ %((8
! $& "((+(,8
"! #$& !((8
" &$& &((1(28
%& &$&5!(+(,1(28
: * <0,05; ** <0,01 ; (*) <0,05 48- ;

[*] <0,05 .
216
. 2013. 2
, ,
, 1617 %
61 % .
48 2732 % 88 %,
(72
) 3536 % ,

.

48-
. ,
.
12

. .
24

.
, 12
,
, 3944 %
116 % 48- 89 % 15 % .
24

.
, -

12 ,
.

.
12
. 24
,
,
,

. , 12

910 % 13 % , 24
1113 % 18 % . ,
, .
,
, , [15].
.

.
.
.
1. Norifumi N. Regulation of the Endocannabinoid

System in Endotoxicosis of Conscious Guinea Pigs /
N. Norifumi, N. Kayo, K. Masahito // Jouenal of Japanese
Asociation for Acute Medicine. 2005. Vol. 16, 5.
. 218226.
2. ,
/ . . ,
. . , . . , . . // . 2008. 6 (22). . 38.
3. . . : , / . . , . . // . 2006.
1 (25). . 252256.
4. . . /
. . , . . // . 2011. 1 (25). . 38.
5. Duntau A. P. Mechanismus of endotoxicosis in pulmonary tuberculosis / A. P. Duntau, A. V. Efremov, V. V. Bakaev //
Probl. Tuberc. 2000. 10. . 3739.
6. . . :
/ . . , . . .
: , 2005.
7. . .
/
. . , . . , . . // .
2007. . 6, 2. . 5760.
. 2013. 2
217
, ,
8. . . / . . // . . . . 2007. . 16, 1. . 3234.

9. . ., . ., . .
;
99805 6117/00.
. . . 201200675 .
23.01.2012; . 25.09.2012, . 18.
10. . . / . . , . . // . . . 2003. 10.
. 36.
11. Symonyan A. V. Evaluating cycvalon activity under
conditions of chronic endotoxicosismodels in rats / A. V. Symo-
nyan, V. V. Novochadov, N. A. Symonyan // Pharmacevtical

Chemistry jornal. 2007. 9. . 911.
12. . . / . . , . . ,
. . // . 1981. 10.
.3843.
13.

/ . . , . . , . . , . . // . 1988. 9. . 1518.
14. /
. . , . . , . . , . . // . 1988. . 2224.
15. . . / . . :
, 2005. 39 .
LEVEL OF ENDOGENOUS INTOXICATION IN EXPERIMENTAL ACUTE ILEUS

SIMULATION AND IN APPLYING OF A NEW METHOD OF ITS CORRECTION
L. V. Shkrobot
SUMMARY. In the experiment on rats examined the level of endogenous intoxication at blood levels middle-molacular
peptides and the sorption capacity of red blood cells at the dynamics of progression of low intestinal obstruction. The received
data were compared with the results of morphological studies, as well as data obtained after the restoration of patency of the
gastrointestinal tract without correcting exposure and applying new original method of correction. There was estimated that at
low intestinal obstruction the level of endogenous intoxication gradually increases in all indexes. The restoring of patency
without correction primary does not lead to decrease of endogenous intoxication, but on the contrary deepens it. The
application of new original method of correction allows due to the gradual and smooth restoration of patency of the small
intestine to reduce the intensity of morphological changes on the part of the vascular route and thereby to prevent the rise
of the level of endogenous intoxication in the reperfusion period.
KEY WORDS: intestinal obstruction, endogenous intoxication, reperfusion.
218
. 2013. 2
, ,
616-002.1-076-092:612.112.92

. .
, .
. , , , . ,

. .
, ,
.
.
: , ,
.
-, - ,
, -, -. ,

- . ,
, , , .
, [16].

,
, , [7].
,
- , . , , [8, 9]; ,
, , [10, 11]. ( (),
), [12],
, , .
: .
: 157 - Wstar
180200 .
, -
5 - 1
NaCl. 3, 6, 12 , 1, 2,
3, 5, 7 10 [13].

() ,
() ,
,
. , [14].

(), [15].
.
t-
[16].
.

, , , , , .
6
1,7 , . 1
4 , 1 10
3
7 . .
1 , 6 , ,
1,8 .
-
. 2013. 2
219
, ,
3 7 , 10
.
3 10 2
7 . 2
,
, 7
, , , [3].
7 .

1 . 3
, 6 12
12 , , , - , . 3
, 6 12
, , 6 .

3 ,
6 12 ,
11
1, 3 5
7 . 3 1
, 3 7

. , 3 - , 1 3 , 7 10 .

530 . 12

, 3 , 2 .

12

. 3 10 , 5 ,
,
(. 1).
123
524
11
523
526
525
5
124
123
89
39
159
19
59
89
19
. 1. .
* p<0,05, ** p<0,01 .

.

3, 12
1 , 3
7 ,
(. 2).
. ,

, ,
.
.
220

.

,
-
,

,
.

- .
. 2013. 2
, ,
1 123
723
11
72
729
728
727
721
7
126
125
124
123

17
1
7
8

4
1
. 2. .
* p<0,05, ** p<0,01 .
,

, , .
,
[17], [18].
.
,

,
,
.

,
.
, , , ,
.
, , -
,

, , , ,
.
.
, ,
,
, .
, , , , ,
.
, , ,
, , .

,

, , ,
.
1. Mast cell-mediated airway remodelling / Y. Okayama,

S. Okumura, N. Yamashita et al. // Clin. Exp. Allerg Rev.
2006. Vol. 6. P. 8084.
2. . . / . . , . . // .
. . 2001. 3. . 67.
3. . .
/ . . , . . // . 2003. 4.
. 1215.
4. . . // . . . 2001. 1. C. 610.
. 2013. 2
221
, ,
5. Peter A. Nigrovic, D.M. Lee Mast cells in inflammatory

arthritis // Res. Ther. 2005. Vol. 7. P. 111.
6. . . - / . . , . . // . . 5,
2. 2008. . 61.
7. . .
- / . . , . . //
. 2005. 9
C. 6364.
8. Accuracy of eosinophils and eosinophil cationic protein
to predict steroid improvement in asthma / R. J. Meijer,
D. S. Postma, H. F. Kauffman et al. // Clin. Exp. Allergy.
2002. Vol. 32, 7. P. 10961013.
9. Weller P.F. The immunobiology of eosinophils //
N. Engl. J. Med. 1991. Vol. 324. P. 11101118.
10. Saito H. Editorial Overview: Allergy and hypersensitivity airway inflammation and remodeling // Curr. Opin.
Immunol. 2007. Vol. 19, 6. . 674675.
11. Matsumoto K., Tamari M., Saito H. Involvement of
eosinophils in the onset of asthma // J. Allergy Clin.
Immunol. 2007. Vol. 121, 1. . 2627.
12. Costa J. J., Weller P. F., Galli S. J. The cells of the
allergic response: mast cells, basophils, and eosinophils //
JAMA. 1997. Vol. 278. P. 18151822.

13. . . // . . .
. 1993. . 116, 9. . 249253.
14. : / . . . . . : , 1987. 368 .
15. Eosinophil peroxidase deficiency: morphological and
immunocytochemical studies of the eosinophil specific
granules / G. Zabucchi, M.R. Soranzo, R. Menegazzi [et al.] //
J. Blood. 1992. Vol. 80. P. 29032910.
16. . Excel:
, :
. . . : . 2004. 516 .
17. Gleich G. J., Adolphson C. R. The eosinophil leukocyte: structure and function // Adv. Immunol. 1986.
Vol. 39. P. 177210.
18. Adamko D., Lacy P., Moqbel R. Mechanisms of
Eosinophil Recruitment and Activation // Curr. Allergy Asthma
Rep. 2002. Vol. 2. P. 107116.
19. Fulkerson P. C., Fischetti C. A., Rothenberg M. E.
Eosinophils and CCR3 regulate interleukin-13 transgeneinduced pulmonary remodeling // Am. J. Pathol. 2006.
Vol. 169, 6. P. 21172126.
PATHOGENETIC ASSESSMENT OF THE CYTOCHEMICAL METHOD

OF DETERMINATION OF EOSINIPHILS FANCTIONAL ACTIVITY
AT THE ACUTE INFLAMMATION
N. . Shutova
SUMMARY. In the article data about the role of eosinophils in an acute non-immune inflammation was given. There was
investigated the eosinophilic reaction in a carrageen-induced acute aseptic inflammation, i.e. quantity of eosinophils in an
exudate, a peripheral blood, eosinopoiesis and functional activity of eosinophils in the locus and blood. The main functions
of eosinophils were studied, generally in pathogenesis of immune reactions where at the expense of histaminase synthesis
they regulate histamine level in the locus and blood. At the same time, active release the series of cytotoxic enzymes by
eosinophils assumes an active participation of these cells in acute non-immune inflammatory processes.
KEY WORDS: inflammation, eosinophilic reaction, eosinophilic peroxidase.
222
. 2013. 2
, ,
616.342/.37-02:616-097]-092.9

. . , . . , . .
. .
.
, .
,
,
, .
: , , .
. ,

, [1, 2].

,
.
74 %,
,
[35].

, .

,
, , .
[6].
, .
().
,
, [79].
,
. , , ,
.
.

,
.
.
40 175180 . .
,
, [10].
:
10 ;
30 , .

. . (1989). . 2, 7
14

- .
(-6000) [11]. . . . [12].

, Staphylococcus aureus -209 [13].
. 2013. 2
223
, ,
.

,
. ,
.
,
,

. ,
,
, , ,
[14].
.
,
: 2
(224,675,72) . ., 7 (197,785,11) . . 14 (97,433,11) . ., (51,851,26) . . (. 1).

4,3; 3,8 1,8 .
1.
(m)
5
9 6

75 7
678529
96
6
"#$63%%6
-./06
-16
26-/6
&'&()6
6
,&(!6
,! (!6
12345678529
6
429
75
96
429
75
96
45
257976
45
257976
656
656
6
6
!) (& 6***6
+ '(&***6
6
6
)&(!6***6
, (6***6
',!(,)6***6
&+)(6***6
429
75
96
45
257976
!656
6
+ !,(,***6
6
'('6***6
'( 6***6
. ,
(* <0,05; ** <0,01; *** <0,001).
. ,
,
, . ,
, , , .
,
, ,
[15].
= 4/3, 4 3 % 6000.
1,01,5,
.

, .
, ,

: , 224
. . , ,
, , , , , , [16, 17].

: () , (). , 2
(25,960,01) %. 7
14 (28,340,36) % (28,110,72) %
. , ,
( 1,3; 1,2 1,2 ).
2 (2,370,11),
7 (2,650,04) 14 (2,810,08),
1,4, 1,3 1,2 , (. . 1).
. 2013. 2
, ,

, ,
, [18].
.

,
.
.

,

, .
1. . . : / . . // . 2008. 239.
. 67.
2. . .
/ . . // . 2006. 4. . 3741.
3. . . / . . , . . // . 2006.
1. . 4550.
4. Bennett G. L. Pancreatic ultrasonography / G. L. Bennett, L. E. Hann // Surg. Clin. North. Am. 2001.
Vol. 81(2). P. 259281.
5. . . , /
. . , //
. 2002. 1. . 105106.
6. . .
/ . . // . 2000. 4. . 3740.
7. . .
/ . . // .
2000. . 62, 6. . 5658.
8. . .
-
/ . ., . . // Terra
Medica. 2003. 4. . 2831.
9. . . -
/
. . . . : 2002. . 156.
10. . . / . . ,
. . // . 1981. 8.
. 493495.
11. . .
/ . . //
. 1991. 6. . 2832.
12. . .
/ . . , . . . . : , 1978. 159 .
13. . . / . . , . . // . 2000. 1. . 6164.
14. . ., . .

/ . . , . . // . 2001. 3. . 3739.
15. . . /
. . , . . . : .
2006. . 267275.
16. . .
/ . . // . 2003. 6. . 3639.
CIRCULATING IMMUNE COMPLEXES AND THEIR ROLE IN THE OCCURRENCE

OF CONCOMITANT PATHOLOGIES OF THE DIGESTIVE SYSTEM
O. Ya. Shuturma, N. Ye. Lisnychuk, . . Dovhalyuk
SUMMARY. In the experiment on white rats with simulated experimental pancreatitis the content and size of circulating
immune complexes and mononuclear phagocytic activity were studied. The results of this investigation indicate an increase
in the number of circulating immune complexes, particularly, small and medium ones, as well as the pronounced disorders
of leukocytes functional activity caused by the reduction of phagocytic leukocytes and their absorption capacity.
KEY WORDS: circulating immune complexes, functional activity of leukocytes, experimental pancreatitis.
. 2013. 2
225
, ,
616.311.2-002-018.25-085.242]-092.9

. . , . . , . . 1

. .
.
. .
: , , .
. ,
.

[5, 20, 23].
, 80 %
, [3,
4, 11, 13, 26].
[8, 13, 22, 25].

[10, 14, 16,
18, 19, 24].
.

.
.
,
[12].
,
. , . ,

,
[1, 2, 6, 7, 9].

:
( 60 / 5 )
(1 / 2
3 ) [21].
226
40 % ,
1:1,5, 1:2 1:3, 4
.
5 :
( ,
), , ,

1:1,5, 1:2 1:3 ,
( ,
).
10 % , , -.
[17].
Mikros 400 (), Nicon Cool Pix 4500.
Pentium 2,4 GHz Nicon Viw 5.
.
,

,
. ( ), , .
.
.
.

.
. . ,
, (. 1).
-
. 2013. 2
, ,
.

,
().
(. 2).

.
, .
(. 3).
. 1. : , . .
-. 200.
. 2. : ,
. , , . -. 250.
. 3. : ,
. . -. 250.
. 2013. 2
227
, ,

(1:1,5, 1:2 1:3)

. ,

,
(. 4).
1
1
1
1
1
. 4. ( , ),
1:1,5 (, 1), 1:2 (, 1) 1:3 (, 1).
, , . -. 200.
. , , , ( )

,

.

(1:1,5, 1:2, 1:3)
, .
,
.
.
.
1. . .
/ . . // .
2010. 2. . 2.
228
2. . . : / . . . . : . , 1999. 167 .
3. . . -
. 2013. 2
, ,
( ) / . . // . 3.
4. . , , / . ., . ., . ., . . . : , 2004. 320 .
5. . . // . .
1996. 2. . 2122.
6. . .
/ . . , . . . . : , 1981. 288 .
7. /
. . , . . , . . , . . // . . . 1993. . 39, 3.
. 5357.
8. , , : : / . . , . . [ .].
.-., 2007. . 7080.
9. . . ( ) /
. . , . . // . 1997.
4(6). . 313.
10. . . , / . . ,
. . // . 1998. 8. . 617.
11. . . / . . // . 1994.
1. . 1721.
12. . . -
/ . . , . . // .
. . . : -,
2003. . 9144.
13. : / . . , . . [ .]. . : , 2000.
251 .
14. . .
/ . . , . . , . . // . 2006. 4. . 3840.
15. . . / . . , . . , . . -
// .
1997. . 7. . 7376.
16. / . . , . . , . .
[ .] // . 2008. 4. . 2627.
17. . .
/ . . . . : , .
-, 1969. 424 .
18. :
/ . . , . . ,
. . , . . // .
2007. 2. . 6266.
19. . .
, / . . , . . , . . // .
2008. 3. . 68.
20. / . .,
., . ; . .
, 2003. 287 .
21. . 31011 .
/ . ., . ., . ., . ., . .; .
25.03.2008. 2008, . 6.
22. . . / . . , . . // . 1996. 1. . 2325.
23. / . . . . . : ,
2001.
24. . . / . . , . . // . 2002. 3 (24) . 3337.
25. . .
/ . . //
. 2007. 1. . 7780.
26. . . / . . //
. . . 2008.
3 (11). . 7075.
27. . .
/ . . , . . , . . // . 2002. 1. . 2224.
THE MORPHOLOGICAL STUDY OF THE INFLUENCE OF TINCTURE KASDENT

ON THE STATE OF THE MUCOUS MEMBRANE OF THE ORAL CAVITY IN RATS
ON THE MODEL OF GINGIVITIS IN EXPERIMENT
L. V. Yakovlyeva, Yu. B. Laryanovska, I. V. Stefaniv1
National Pharmaceutical University
SUMMARY. The main morphological changes in the vestibule of mouth on the rats on the model of gingivitis are considered.
Applications of tincture Kasdent contributed to the disappearance of signs of inflammation.
KEY WORDS: inflammatory disease, oral cavity, gingivitis.
. 2013. 2
229
, ,
616.329+611.018.82+616.8
-

. . , . . , . . , . .
-
. 20
( ) . (
) .

. ,
, -.
: , - (), (),
().
. . , , (),
- , .
- () , [1, 2] [3].
. . .
, , .
.
,
().
.
, . 90-

.
[4, 5, 6]. -
70 ,
.
Skinner [7], Gill [8] ,
.
[9].
230

.

( ) .
.
20 (Felis domestica)
,

. , ,

[10, 11]. 1, 7, 30 90 .
( , )
.
, [12].
.
10 .
.

,

. . ,
.
. 5
8 ( 63,9 % 53,2 % ). ,
. 2013. 2
, ,
.
. , .
.
.

.

. 15 -
.
,
90 (. 1).
1. -
(Mm, n=5)
5296
32
6356
+389 326
$6
.6
/%6
1%6
896!"#6
,')$-'.'6
,)0.-/'06
/0/$-/),6
/%'.-)%%6
'$'$-/,)6
1234567389579
68 396 83363 87566752 56716
$%&$'676
$(&)%676
)$&)'676
*)'676
/$'%-/,06
/),0-/0%6
,'0/-'%,6
($(%-,)/6
338376
).$/-,(06
/(.%-,%%6
/$$.-(,'6
)0%%-))'6
/,0.-'/%6
,($,-($'6
338376
$1%0-$1$6
)1)0-)%06
)$,/-))/6
338376
),$/-)(%6
/,',-/1%6
/$/'-/,.6
338376
,
2125
. , -
.

25 . , .
,
( 25 )
, ,
, .
, .

. , ,
-
,
.
. 1.

.
2.

-.
.

,
.
[13].
. .
1. . .

// . ., . . , 1972. . 6667.
2. . . // . . . , 1975. . 105107.
3. . .
: .
. . . / . . . , 1973.
32 .
4. - / . . ,
. . // . . 1984. 6. . 5458.
5. Bennet J. Esophagus motilitat // Z.Gastroenterol.
1986. Vol. 24, 2. . 716.
6. Ogorek C.P., Cohen S. Gastroesophageal reflux
disease: New concepts in pathophysiology // Gastroenterol. Clin. Nord. Amer. 1989. Vol. 18, 2.
P. 275292.
. 2013. 2
231
, ,
7. Skinner D. B. Pathophysiology of gastroesophageal

reflux // Ann. Surg. 1985. Vol. 202, 5. P. 546556.
8. Gill R. C., Bowels K. L., Murphy P. D., Kingnay I.
Esophageal motor abnormalities in gastroesophageal reflux
and effects of fundoplication // Gastroenterology. 1986.
Vol. 91, 2. P. 364369.
9. Mittal R. K., McCallum R. W. Characteristics of transient
lower esophageal sphincter relaxation in humans// Amer.
J. Physiol. 1987. Vol. 252, 5, Pf1. P. 636641.
10. . .
// . -. . , 1967. . 4. . 5962.
11. . . / . . // , . , 1977. . 516.

12. . . - / . . , . . , . . // . . 1970.
2. . 5867.
13. Edwards D. Dysphagia // Potgrad. med. Jorn.
1984. Vol. 60, 737 742.
CHANGES IN MICROCIRCULATORY BED OF MUSCULAR-INTESTINAL NERVOUS

INTERLACEMENT OF GULLET AFTER THE RIGHT SIDE TRANSECTION OF TRUNCUS
VAGOSYMPATICUS
Z. M. Yashchyshyn, L. M. Zayats, O. D. Svystak, V. H. Rohuzhynska
Ivano-Frankivsk National Medical University
SUMMARY. Experimental study was performed on 20 adult cats under ester anesthesia in the sterile conditions performed
high vagotomy at right part of the neck. Blood vessels of the musculo-intestinal nervous interlacement (MN) was injected by
mini mixture of such paints as paris blue or black flourish with next impregnation of nervous tissue by Bilshovsky-Gross
method. The results of experiment showed the reversible changes in the condition of the microcirculation of mini MNs
ganglions and the destruction changes in structural units neurocytes. There was made a conclusion that during thoracal
surgery its very important be careful and do not to damage vagosympathical trunk to prevent such complications as refluxesophagitis.
KEY WORDS: esophagus, musculo-intestinal nervous interlacement MN, microcirculation, n. vagus (NV).
232
. 2013. 2
-

31 1 2013 .
.
. 2013. 2
233

. . , . . , . . , . . , . .
. .
() .
.

. , () ,
.

, , .
,
,
.

() . , , .
.
(
).

() .
Bergman
Loxley . . .
114 1861 ,
24 90 . 80 ,
34 (,
,
, ). 1 . 10 (28,96,5) .
, ,

,
.
20 .
234
89 (78,07 %) Ig M
() Ig G , , 69,6 % ( 40,4 %
, 21,3 % 7,9 % ,
).
, ( 1,6
1,8 , ),
14,7 % (<0,05), . ,

. -
Ig M 18,9 % (<0,05) ,
- Ig M Ig G, 29,5 % (<0,05)
, Ig G
. , .
,
[ 10 ],
[ 1 2-3 ;
1 2 ] [
0,001 2 ] ,

,
43,3 % (<0,001). ,
.
,

(
200 5 1012 ) (
50 // 30 )

25,6 % (<0,05). , ,
,
-
, , ,
.
. 2013. 12
,
63,3 % ,
2550 % ( SCORAD),
2530 %, 4550 %. 2025 %
.
,
.
, .

. .
. .

. .

,
. .

.

.

180200 .

Siegers C. P. et al. (1982) .
.
. . . .
(2008). 1, 3 7

,

, , . , -
.

STATISTICA 10.0 (StatSoft, Inc., ).
, 13 ,
,
, . 7
, .
.
,
,
. 7
.
,

, .
.
,
,

.
. 2013. 2
235

. . , . . , . . , . .
. .
, .
.
18

0,6:100,0
, (47 %), (44 %), (8 %)
(1%) 25 . () -
()
umalyzer ().
, 2,1 , 1,6 (<0,001).
,
, .

.
- ,
,

. . , . . , . .

. - () ,
IL6, IL1. , , .
:
- () ,
.
. 16 ,

() 1 .
(n=18),
(2 ).
.
15 .
1 , 2-5 236
,
(ELISA), - ().
.
, ,
(21,65,0) /, (<0,05),
(9,44,1 /)
(5,52,1 /, (<0,001)).
25
(27,35,0) /,
(<0,01)
(16,85,9 /) (<0,001).
. - , ,
,

.
. 2013. 12
NO-

. . , . . , . . , . .

. (
) ,
. -- , : (
, ()) . , ,
i NOS (NOS)
, , - (NO). ; ,
,
- .
. - () - () NO- , L-
.
. - 180 200
4 ( 8 ): 1 ; 2 ,
3 ; 3 , 5 ; 4 ,
(, 2 / ).
NO- ; NO,
L- .
. NO- NOS (0,480,92 /) NOS
(0,120,19 /), . NO (17,70,67) /, (0,310,03) /. L-
(38,65,7) /.
3 NOS 4 (<0,05),
NOS 2,5 (<0,05),
23 %. NO
L-
( 18 %).
5
NOS 6
(<0,01), NOS 3
(<0,05) .
29 %, L-
20 % (<0,05).
NOS
11 (<0,01), ( 42 %, <0,05). NOS
, .
NO 26 % (<0,05), 23 %
(<0,05) L-
.
. 1. NO-
. 2. 5
NOS 6 ,
NOS ( 3 ) ( 29 %), L- 20 %. 2. ,
NO-
: NOS 11 ,
NOS 1,5 ,
, 4
5 ; NO
20 %, 42 %, L-
23 %. 3. ( ) ,
,
.
. 2013. 2
237

. . , . .
. . . ,
,

. .
-
30 2967
. () ( , +),
( , Toshiba140), .
.
-
() . 10 5315 (
12815 759), 9
(11611 11112 ), 11 5310 ( 729 12517). 10,12,1 %
: X 5914 , HRVTI
4,01,2 ., SDNN 134 , HF 860379 2.
6,32,0 %
X 659 , HRVTI 11,00,8 .,
SDNN 104 , HF 418239 2.

( . . ., 2005),
: =0,1332PmSV/EDVET, Pm
, SV , EDV
,
. ,
6,81,5 /
238
( 27,71,3 20,81,3),
6,31,1 / ( 20,21,0
26,51,7), (26,01,0 26,11,0
). SV (
286 %), EDV ( 142 %),
Pm ( 7,24,3 %) . SV
( 2211 %) EDV ( 94 %),
Pm ( 4,71,7 %)
( 7,13,9 %).
. forward stepwise 12 , .
78 % (r=0,29), (r=0,20) (r=0,08) (r=-0,29), HRVTI (r=-0,19), Mg- (r=-0,11) - (r=-0,06) , / ,
,
/ ,
.
( 22 %
)
SDNN (r=0,40),
(r=0,24) (r=0,13)
(r=-0,57). ( ) ,
,

.
.
. 2013. 12
-NO-

. . , . . , . .
.
()
.

.

,
- . NO, ,
NO-,
L-,
. L-a .
NO-
. -
.
, 106,06,7
/ . 3,8 . NOS
74,66,38 NADH(+)/ , iNOS . NOS 4,1 .
eNOS NOS. ,

, NO L-.

. . , . . , . . , . .

, , ,
4245 % .

. 30 3- - ,
, 15
,
( , )
( , ) , , , , . ,
,
, ,
, , ,
.
,

.
,

.
. 2013. 2
239

. . , . . , . . , . .
-

(),
20 92,8 %,
,
.
().
.

.
78
, 3 : 1,
(n=10), 2 (n=10),
1 100 .
58 .
10 %
1 100 . 1, 12, 24 48 . () ().

12- ,
. 24

39,92 % (<0,05) 12 .
24 ,
1,7 (p<0,05).

,
, .
616-099.616.142-071.31-092.9

. . , . . , . .
. .
,
,
. ,
.

.
- , 4 . 240

. , , ,
10 % , . 57 , -, , . (
51125 ) (
2650 ) . ,
.
,
. 2013. 12
,
, , , , , . -
,
.
, , , ,

.
.

. ,
.

,
. ,
,

. ,

, , . , , ,
.
, ,
,
, ,
.
.
615.224/355-035:[616.36+616.61]-02
-

. . , . . , . .
. .
, , - .

, .

6 : ,
, .
,
- : .
- . , -
, . , .
. , , ,
.
.
, -
.
. 2013. 2
241
- -

. . , . .
- , ..

,
, , .
, , -- .
:
, ,
,
. .
.

643 16 60 .
, ;
; ; . , , , ,
.
, , . .
. (31,72 %)

. , (), , .

. (46,97 %)
.
,
. , , , 10 % .
(39 %) . :
35 %, 7 %, 25 %.
21,31 % . , ,
,
. 19 %, 7 %, 14 % .
, 44 % (283 .)
. 3,1 % . 88 % .
. , , ,
.
, ,
-- .
-

. .

, ,
. .

242
. 2013. 12
, .

, .

(). ,
.
80
220240 .
() ,
.
,
(), --
. ,

43 % (<0,05). 78 % (<0,05). ( )
55,6 % (<0,05).
-
,

.
,
. , , , .
, , 4,
- , , . - .

. . , . .
. .
150200
. . .
4 :
(n=10), () 5 (n=6), 15 (n=6), V ,
(n=6).
. ,
5 -1
17,1 % (<0,05), -6 23,3 % (<0,05), -10
20,1 % (<0,01), - 92,0 % (<0,01),
. 15
-1
31,9% (<0,01), -10 30,6 %
(<0,01), -
28,5 % (<0,05), 5 . -6
15 23,3 % (<0,05) . 5- ,
100 /, -1
10,6 % (<0,05), ,
, .
-6.

( 1,31 ; <0,05), 5 . -
25,1 % (<0,05), -10 28,3 % (<0,01),

5 . , ,
,
,

.
. 2013. 2
243

. . , . .
. .
.

, - . , ()
.
- .

.
33 4
4,5 . (100 /), 10 (0,5 /). -
, 10 1 .

, ,
. . ,
, . ,
,
.

-
. .
. .
,
,
, .
,
, .
, ,
, . .
- 180200 ,
, . . 244
per os
(, )
25 / 21 ( . .,
. ., 2009).
, ,
. , . ,
.
(30 /)
ART () 60
. 2013. 12
: 50 , 1,2 2. 14 . 1 8 (50 /).

. . D
.
, .
, ,
D 18 % .

1,8 1 ,
-
. 8 139 % .
1 D
, 30 %
, 1,5
.
, 8 8 % 1 , D 29 %.
.
168 %
138 % .
. , 1
121 % , 39 % , , 8 111 %
( 24 %
).

. . , . . , . . , . .

,
, . - ,
.
- , .
,

. -,
: .
(n=20), .
(n=15) .

, 10 . 24 ,
, - - ,
.
, - -.
,
. , -
. 2013. 2
245
10 ()
,

.
, ,
, , - .

.
-

. . , . . , . . ,
. . , . .
, .
, ()
,
, .
15- ().
.
30 . 6
15 ( 6000 ,
pO2=9,8 %).
Bcl-2 53,
- 7-
5 .
.
56 %,
- 68 %, . 10

, -
26 % . - ,

-, .
. 1.
- .
2. 10
.

2

. . , . .
,
. . . ,
, ()
.
246

() 2 (- --, 10,7 /).
41
60 -
. 2013. 12
(3 /, ) ( , 10, 20, 30, 45 60

), (
, 20, 40 60 ) ( , 30 60 ).
5 .
11 () 10
90 % (27,24,9 ),
, (66 %)
30 (69 % 45
71 % 60 ).
7,10,1 1,500,14, 1,380,09 1,900,23.
- () 367124 11224 30 ,
(12327) 60 .
6 (31,01,2 )
20 ,
30 95 %, 60
72 % .
1,970,16 5,40,4 20 ,
2,650,23 2,500,25 40 60 .
30 (34072 35790
30 ), 60 24472.
8 (30,72,4 ) 10
62 %, 30 53 %,
, 86 %
45 119 % 60 . -
: 16943 8823 34086.

(2,140,17, 2,570,23 1,990,15),
60 (7,30,1).
9 ,
.
(27,12,0 ) 104 % 10 112 % 60
1,520,03
2,330,12 ( 20 ), 1,960,16 ( 40 )
1,910,09 ( 60 ).
: 11336,
13646 14937.
, 7
, . ,
14,81,3 128 % 30
122 % 60 , 2,250,36 5,450,44,
7,10,1 7,30,1. 8022, 16234 16759 .
,

( Wilks): , -,
, , -, ,
, , ,
, , Hb, .
: 612.172+612.67

. . -, . . , . . ,
. . , . .
. . .
, () ()
.

5 . () 25 . ().
- 100 /,
32 /.
5 . ,
, 4 , , 2 . .
.
TUNEL-.
, , ,
, , -
. 2013. 2
247
,
. (): ( ); ( , , 1 ).
, 3, 4 ; ,
.
, .
, 0,1
0,24 . 1,17, 1,03.

, ;
. ,
, -
0 %, 0,039 %;

0,98 % 0,62 %.
.
. ( ), , .
. ,
: , .
. , . , , .
, ,
, .

2
. . , . . , . .

, 2 ()
,
, ,
.

() .

(),

(), .
. - ( 10 ) (,
, ) 56 , 3984 .
(72 %) , . ,
(n=24). 12
12 6312 .
3 , .
248
7 (5 2 ),

.
. /
Z , .

, .
, , . .
, Z-.

. 2013. 12
.
. .
,
. .

.
, , -
.
. (
),
,
.
. 2
,
, , ,
.

. . , . .
-
, ()

, . .

.
:
20 - 180220 .

Sigma ()
60 / .

.
6 .
- 6
.
, . , .
.
.

.
,
.
. 2013. 2
249

. . , . . , . . , . . , . .
. .
,
,
,
.
()
,

, .

HCl- .
HCl, pH 1,2 1,0 / .
EDTA
- 1,077 /3.

(FL-1 ) Epics
XL (Beckman Coulter, ).
,

(71,620,57)% (40,460,78) % (<0,01),
24 .
,
,

. ,
.

. . , . . , . . , . .

. .. ,
(),
(Tracey K. J., 2007). ,
, . , (insular, dorsal and ventral
anterior cingulate cortex) - (Oppenheimer S. M. et al., 1996; Matthews S. C.
et al., 2004).
()
(Ohtake Y. et al., 2007; Prinsloo G. E. et al., 2013; Subhani
A. R. et al., 2013; Popovych I. L. et al., 2013).
, - (Tracey K. J., 2007; Sternberg E. M., 2006).
250
,
.
32 16 (- -
-, ) II .
() ( +
-).
( , ),
( , ) (
)
Staphylococcus aureus.
. 2013. 12
,

. - : (r=-0,74), LF/HF (r=-0,66), LFnu (r=-0,51),
AMo (r=-0,38),
: (r=0,77), RMSSD
(r=0,32), VLF (r=0,37). (ULF%)
(r=-0,54),

(r=0,40). ULF
.

VLF (r=0,28). , , (-- , ,
),
, ,
.

,
: R=0,89; 2(24)=60; p<10-4.

(
R) (R=-0,88), LF/HF
(R=0,75), LFnu (R=0,56), VLF (R=-0,45), AMo (R=0,44),
ULF (R=-0,42), RMSSD (R=-0,38) ULF% (R=-0,09),
, ,
(R=-0,988),
(R=-0,15) (R=0,14).
- () - 5 (r=-0,58).
15 - r -
-0,57-0,43. - 4 (r=-0,50) 1 (r=-0,50);

6 (r=-0,46),
2 (r=-0,44), 3 (r=-0,41), 4 (r=-0,40), Fp2 (r=-0,38),
T4 (r=-0,37) Fp1 (r=-0,35). - 3 (r=-0,47),
1 (r=-0,42), Fp1 (r=-0,40), P4 (r=-0,39), T3
(r=-0,37), Fp2 (r=-0,35), C3 (r=-0,35), F4 (r=-0,34)
F3 (r=-0,34). - 4 (r=-0,38) 3 (r=-0,37).
: R=0,77; 2(12)=22; p=0,038.

- 4 (r=-0,36)
3 (r=-0,34) - F4 (r=-0,33) - 2 (r=0,34). :
R=0,52; 2(3)=8,8; p=0,031.

- F8 (r=-0,42), T6 (r=-0,38),
O2 (r=-0,35) O1 (r=-0,35) - F8
(r=0,37). R=0,45; 2(4)=6,3; p=0,18.

: R=0,89;
2(48)=63; p=0,05.
- F4 (r=-0,53), 5 (r=-0,51), T4
(r=-0,48) Fp1 (r=-0,48), - 2 (r=-0,54)
F8 (r=-0,37) -
6 (r=0,52), F8 (r=0,49) 4 (r=0,49).
(r=0,54) (r=-0,54) (r=-0,52).
,
.

SHR
. . , . . , . . , . .
,
.
40 % . -
, . ,
. 20
. 2013. 2
251
Wistar 47 SHR 56 .
, , , ,
. .
,
SHR
32 % , 38 %
30 %
.
SHR , , -
90- .
SHR
62
75 %,
,
HOMA, , .
. SHR , 2- .
,

. . , . . , . .
. .
8090 %
.

. ,
,
- .
- , ().
E. Coli (1 /)
2 . 15
- -1 -4 -10.
, - , -
252
,
. -1
, , , -.
-4
, , .

-10.
, ,
, -
. , ,
,
, iNOS,
.
/ ,
,
.
. 2013. 12
-

. .
. .
.

,
, - .

.

,
, .
,
.
- (, ), . ,

.
-

.

-
180200 .

5 -1
. 14 -
(40 -1 ) . .
- (60 -1
) 1, 3 7
. - ,
- ()
- .
. STATISTICA 10.0 (StatSoft, Inc.,
).
,
,
.
3
7 .
1 ,
3
,
7 .

- . 1

,
.
.

, , 3 7 .

.
. 2013. 2
253

. . , . . , . . , . . , . .
, .
,
(NO)
( )
NO

( . . ., 20082012). ,
NO- (NOS) (
, NOS, iNOS)
,

NO, , ,
, .
()
,
B (NF-B)
NO -
iNOS (
, ), NO-.
, (10 /, 30 ) -
, ,

. ,
iNOS ()
nNOS 7-.
, -

NO, de novo iNOS, NOS,
, .

. .
. .
() - ().
34 58 % .
, ,
.
.

.
- 200
254
220 .
.
G. Matute-Bello. (40 /).
1,2 1,0 / .
12, 24, 48 72 .
-
. . .
,
.
.
. 2013. 12
,
-
40,2 % (p<0,001) 12
42,7 % (p<0,001) 24 , . . 48
- , 12 24 ,
23,8 % (p<0,001) 27,0 % (p<0,001).
72 - , , 12, 24 48
4,2 % (p<0,001), 42,7 % (p<0,001), 45,1 %
(p<0,001) 24,8 %( p<0,001).
, 12 36,3 % (p<0,001),
. 24
12,0 % (p<0,001), 12 . 48 .
,
12 24 21,5 % (p<0,001), 23,8 %
(p<0,001) 27,0 % (p<0,001) .
72
62,0 % (p<0,001) 13,9 %
(p<0,001), 48 , 12
24 .
12
40,5 % (p<0,001)
. 24 12,0 % (p<0,001)
12 . 48 . ,
, 12 24
67,4 % (p<0,001), 45,2 % (p<0,001)
51,8 % (p<0,001). 72

80,0 % (p<0,001) 48 , 28,5 %
(p<0,001) , 10,9 % (p<0,001)
12 5,8 % (p<0,001) 24 .
, - 12 24
, .
.
-
-
.

. . , . . , . . , . .

, - ,

, .

,
. ,
.

( 75
200300 ,
5 ) 17 (10 7 , 55,610,98 )
15 (6 9 ,
58,221,27 ), .

. .
(
12 . ) 2
.
- Cormay Diana ().
- - , () . . .

.
( <0,05).

, ,
. 2013. 2
255
120
( 1,210,19 /
1,210,34 / ).
120

(
2,83 %, <0,05) ( 3,44 %, <0,05),
( 17,45 %, <0,05). , 120
.
,
, , -
. , 120
(5,360,14 5,690,11 /) ( 4,15 %).
(3,870,20
3,260,33 /)
. ,
, , .
,
,
.

. .

,
() , ()
.
(), .
.

, .
.
40 () 0,350,40
. 4 10
. I , II, III
IV 1, 14 21 . -
256

. . (1970). . . , . . (1988).
R. Fried (1975).
.
, 1
14,1 % (<0,05) .
, 14 21
18,9 % (<0,05)
48,1 (<0,05). ,
, 14
21 .
.
, , 14 21
.
. 2013. 12
-

. . , . . , . .
-
, - , .
(
) ( )
- .
, , . , ,
.
,
(80100 %
) -
,
(),
(), .
() 70 %

-.
5060 % , :
-- /. (), ,
,
, .

. .

.
66 -
Wistar. c

0,1 . , 6 28 .

,
,

, .
( 2 )
,
, 2128 , -
.

, 2128 .

, ,
14 , 2128
, 10- , .
.
, ( 2 ) (2128 ) . , -.

.
. 2013. 2
257

,
- -
. . , . . , . .
.
() , .

(), .
. -- ,

.
,
, , . 28 18 1 79
- .
.
.
50 ().
: (),
(), (), - -
(), (),
(-), (), (), - ().
,
, 33 %,
21 %, 12,3 %,
11 %, 11 %, 10 %, 13 %.
-
.
() 11 %.
-
,
9 %,
7 %, 11 %.
- 12 % .
, .
,
,
, ,

, ,
, .

-
. .
. .

.
, .

.

- .
258
, ,
, ,
.

.
, -
,
.
. 2013. 12

180200 , . -
(40 -1 ).

, . -
. . , . . (2008).
.
, , 1, 3 7 . ,
.
, , , , .
, -
. 7
.

, ,

,
, .
, .
.
, -

, -
.
, - ,
, - ,
.
616.839 053.2:612.273.2

,

. .
. . .

()

(). 20 ,

. (I)
12 611 . (II)
8 1217 . - .

- , . . 710 4560 . 2
106 . . 2 -
, 2 7672 . .
(, , ) 14,3 % I 30 %
II . ()
() I 23,3 /,
21 ./ II
22,8 ./, 19,1 ./. .
I
18 ./, 15,8 ./. II
17 ./, 21,4 ./.
. 2013. 2
259
,
24,3 %, 2,9 %.

.
,
, .

. . , . . , . .
,
. .. ,
, - . , ,
.
50 Wistar.
( ), ( ), ( Nakamura),
, , II . 4-
- ( Nakamura
). (), ,
.
5 (2 3 )
,
(1,020,01). ST ,
.
4
, 1,120,02, - .
9 (6 3 ) 1,310,03, -
260
1,70,2
12811
5515 ( 43%) ST 6110
2714 ( 44%),
.
23 (9 14 ) (
1,680,04 4,50,3 ),
, 1306 2611
( 20 %) ST (495
437 ).
4 9 ( 2,780,25,
9,00,4 ) .
14410 12230
( 85%) ST 5510
-614 .
,
11 , ( Wilks):
,
, , , , , ,
R, ,
. 100 %- .
. 2013. 12
-

. . , . .
. .
,
- ,
, . ,
,
- .
- ,

, .
, ,
, , . ,

.

.
60
190210 , 5 .

()
280 / 10 10 .
1 /,
. 1 24 ,
.
-
, ,

.
,
, ,
,
,

. ,
, . ,
24 .
.
,
.
, , .
,
. , .
-
. , ,
1 16,0 % ,
1 9,5%, 1,7
.

,
- .
. 2013. 2
261

. .
.

.
,
Ca2+,
K+, Na+ - (Na+:Na+, K+:K+,
Ca2+:Ca2+) (Na+:Ca2+, K+:Ca2+, Na+:K+)
( (), , ).

()
() ,

.
- (C) - -.
,

1,91 0,52 8,92 1,52 ,
16,3 37,8 . C K+:Ca2+ 2-6:1, Na+:K+ 2-24:1,
Na+:Ca2+ 6-73:1;
7-53:1, 6-38:1, 28-100:1, 34 .

() Ca2+, K+, Na+ ; Ca2+ K+ Na+ .

- Ca2+, K+, Na+ . Ca2+, K+, Na+ ;

Na+ K+ Ca2+ .
HELICOBACTER PYLORI

. .
. .
H. pylori .

( )

.

,
. H.pylori
-
.

, 262

.
H.pylori. . ,
H.pylori
23,8 %,
4,8 %.
H.pylori . , -
, H.pylori
(94,4 %). ,
-
. 2013. 12
H.pylori

. -
-

. . , . .
.
()
, ,
. , , . ,

.
.
. ,
. , , -
. , .
, ,
Na+, K+- +--
.

-. -
Na+,K+-- , 1 . +-- , NaN3.

, ,
, (36 %).
, , 19 % , - 19 % . ,
Na+,K+-- 6,320,24,
3,240,14 / ,
-
51,3 %. +-- 3,630,28,
2,080,24 /
, 42,7 % .
, , , ,
Na+,K+- +- . Na+ , .
: 612 : 599. 323. 4 : 616 005. 4
M. GASTROCNEMIUS

. . , . .
,
, , .
. 2013. 2
263
, ,
, .
, (, 1985)
. 24
Wistar 2 -
: (12)
(12).
.

.
m.gastrocnemius (cap.lat.) 37 .
:
30 , 5000 , 1 . 3 : F1 ,
F2 , F3 . rigin 7.0.

, . , .
.
.

(F2)
, (F1) (F3) , .
, . , (F2)
,
. 19,850,002%
. , , 17,380,003 % ,
2,470,002 % ,

.

. ,
. , ,

.
,
.
.

, ,
,
.
616.831-001-06:616.379-008.64]-06:612.015.11-092.9

-

. .
. .

. 264
, ().
-
. 2013. 12
- ()
-
().

-, :
(), , ,
, IV ,
.
- GLP. .
14/. . 3 24 , 5 14 - .

.

- V (AN),
, ().

.
Epics XL.
,
1 AN 35,4%,
5 (150,5% ).
5 14 46,2 30,8%
.
110, 140,1 101,6% 3, 24 5
. ,
, 32,7%
,
.
61,5%.
71,8%.
, AN - 32,8, 39,8, 61,3 86,1% 3, 24 ,
5 14 .
91,7, 107,1, 89,5 123,5%, .

100,9, 97, 121,8 93%,
.

14 ,
, , V
, .
, , , , .

.
,
-
. .
. .
.
, .
.

. -
,
.

, -
.

, - .
-
. 2013. 2
265
,
,
.
- (40 -1 ).

1, 3 7 .
,
, ,
- ,
. .
,
, ( ), , ,
.

.
- , 3 , 7
, . , , .
.
. , ,
. 7
.
,
.

, ,

, , .

,
.

. .
. .
,

,

, . ,
5
12 %. , 10 15 , 15 %, , 15 42 %.

5 15 %,
10 31 %, 15 2,1 . ,
266

,
.
, , .
, . 5
63 %, 10 3 , 15
3,9 .
15 .
39 %. -
. 2013. 12
, ,
,
, ,
. 5 2,1 , 10
3,8 , 15 4 , .
,
, , , . 2,2 ,
5 2,3 ,
10 2,6 , 15 3,2 .

.
,
,
-
.
, , . , (), 5
2,4 , 10 4,3 ,
15 3 .
.
, 5 , ,
13 % ,
, 10 2,9 , 15 2,3 .
,

.
,
, ,
.
616.8-008.615.1-02:616-005.1/-005/6
-
. .

, -
( ),

. ,
, :
; (); - , , .
.
, (), . ,
, .

, - () , .
,
.-, ,
( )
( ) , 1979 -
(). -, ,
, , , , .
. 2013. 2
267

(--) (-).
,
- ,
,

. , ,
-() ,

.
(-) :
-
(-),
, -, - .

.
, , , , , .

, - , , , ,
-
. 28.10.1997
00290.
,

. .
. .

. , . , - .
, . , , .
10 - 44
, . . 15 21 . ( ) 10 10 ,
( )
12 . -
268
- .
- , , , .
, ,
, .

.
,
,
.
, .
. 2013. 12
616.62-008.224-003.93-02

. .
. .
. ,

12 -
, . 5
56 , 2 7
.

.
.
, , , , -
12 .
.
.
, . .
, , , .
, , ,
. .

. . , . . , . . , . .

() .

-.
. (
10 ) : (1 .), 1- (2 .), 2- (3 .).
.
.
(),
(<0,001)
( 10,8 % 1 . 40,5 % 3), - 21,6 %, 29 % 30,6 %
- 25 %, 28,4 % 31,5 %
1, 2 3 .,
- -, , -
,
(<0,001) 2
3 . ( 25,5 % 41,2 %).
(<0,001) (
10,1 % 12,8 %)
( 32,9 % 27,5 %,
12 % 25,7 %). , ( 94,5 % 92 %
) (
2 2 . 1,2 6,5 3).
,

,
( )
,
.

.
. 2013. 2
269

. . , . .
. .
,
.

, , .
, , .
.

.
() () .

.

.
57
,
:
, .

, (-).
(), , (), () ().
,

. 1,6 , -
270
1,2 .

, , . , -
.
,

.

.

.

,
.
.
,
,
, , .

,

. , ,

.

.
. 2013. 12

. . , . . , . .

()
, 40 .
1
[. . , 2009; , 2010].

(37,8 100 . ),
58,8 100 . .
17,9, 29,9
100 . [. . ,
2009; . . , 2010].
,
.
, ,
,
[ , 2011].
,
. . ,

, .
, .
,
. [ . ., 2007].

: , , ,
, . (NK- ,
, ).
[.. , 2009; .. , 2010].

.
ATF 3. ATF 3 (activating transcription factor 3)
, , , . , , ,

ATF3.
ATF3
,
[ , 2010 ].

, ATF3 ,
,
, , , ,
, .
, ,

.
. 2013. 2
271

. .
,
() .
-
35 ,

( D+) 58
( D-).
20 , ( C).

CIWA-Ar. , -
(- ). , ().
( forward stepwise) 7 ,
. 83 % (r*=0,92; Wilks=0,08; 2=275; p<10-6), - (r=0,43) (r=0,35) SDNN (r=-0,50), VLF (r=-0,42)
HF (r=-0,15). ,
D+ (CIWA-Ar=421)
(101375 .) (1182 -)
SDNN (16,10,7 ),
VLF (598 2) HF (11111 2). D- (CIWA-Ar=241) / :
43520 ., 972 -, 22,80,6 , 20119 2
272
16416 2 , : 9711 ., 812 -, 53,95,7 ,

851145 2 883450 2 .
17 % (r*=0,72; Wilks=0,48; 2=78;
p<10-6), (r=0,49)
VLF- (r=0,35).
D (99,31,5 Hg 443%),
D+ (90,11,4 Hg 293%)
(82,82,4 Hg
364% ).

(). ,
Mahalanobis D+ D-
6,8 (F=19; p<10-6), D+ : 45 (F=73; p<10-6), D- : 32
(F=61; p<10-6).
(: -7-3; :
-4,8) (: -1,5+0,5; : -0,5). D (: -2+2; : +0,6) (: -1+2;
: +1,0), D+ ,
, (: 0+3; : +1,8) (: 0-5; : -1,3).

83 % (6 35 ),
95 % (3 58 ), 90 % (2 20 ). 7 90 %.
. 2013. 12

. .

.
.
.

.
() ().
40
-, 5
8 .
.
1 7 . ,
14 24 .
. ., -
. . (1985). R. Fried (1975).

(),
(m),
t.
0,05.

22,6 %, 1 . 7 .
14 24 24,9 % 29,7 % .
,

(1 ),
(),
( 14 24 ) , .
: 612.015:57.032:576.535

4BL
. .
. . .
(H2S)
. H2S : -, -- 3-, L-. H2S ,
, .

4BL. 4BL
, .
DMEM 10 % 37 2-.

(NHS) 2,5 .
50 . 35

. , NHS
82,5 . /,
165 . /. 96

231 . /,
313,5 . /.
, 4BL 1,42 2,5 NHS. .
. 2013. 2
273
- -

. . , . . , . .
-
. . . ,
49 -
(), 10 (),
7 . , (), () (), 41 (),
(Ad), .
Statistica 5.5
.

: R=0,79; 2(30)=77; p<10-5.

(r=-0,72) (r=0,72) (r=0,74).
,
- (r=-0,57), (r=-0,37), (r=-0,33) (r=-0,26) (r=-0,26);
: (r=0,36), (r=0,31), (r=0,27) (r=0,22) (r=0,21).
, .
, -
(r=0,62),
(r=0,62) (r=-0,57)
(r=-0,32),
(r=0,41), (r=0,31),
(r=-0,22) (r=-0,21)
. , -

/ (r=-0,76), , , (r=-0,27) (r=-0,31) /. (r=0,31)
(r=-0,26). - -, , ,
274
-
: R=0,96; 2(120)=244; p<10-6. , ,

92 %.

, ,
( ), ,
. ,
.
, ,
. ,
: R=0,89; 2(112)=146;
p=0,017. (r=0,49),
(r=0,63), (r=0,44) (r=0,36) , 17- (r=0,34), (r=0,49),
(r=-0,14).
,
(r=0,51) (r=0,38), (r=0,38) (r=0,37),
(r=0,45)
(r=0,51) (r=0,27) .
(r=-0,47),
(r=-0,48) (r=-0,42) , (r=-0,50) (r=-0,23)
, NK- (r=-0,47),
(r=-0,40), (r=-0,40) (r=-0,22)
.

: R=0,93;
2(60)=162; p<10-6. (r=0,97), (r=0,56), (r=0,28),
(r=0,26) , , (r=0,09). (r=0,39) (r=0,34)
(r=0,26), (r=0,36)
. 2013. 12
(r=0,28)
(r=0,29), 0- (r=0,26).
(r=-0,92), (r=-0,47) (r=-0,50)
(r=-0,38) .
,
-
,
, , ,
, .

, , , ,
. - .

. . , . . , . . , . .
,
. (. . , 56 ,
, ) 3 (. . ) 4
16 (- - -, ),
3
... ..., . 7
.
(. . )
()
(- , ., ).

Statistica-5.5.

, 4 , ,
() .
, , 4 .
7 .

() 16 .
28 .

-.
1 (+9731 %,
1723385 2/ 2572480 2/; t=3,13;

p<0,01),
T5 (+8330 %; t=2,77; p<0,01) P3
(+7027 %; t=2,59; p=0,01). ,
4 (+4419 %; t=2,32; p<0,05), 4 (+4721 %;
t=2,24; p<0,05), 4 (+4421 %; t=2,10; p<0,05), 6
(+4116 %; t=2,56; p=0,01) 2 (+3616 %; t=2,25;
p<0,05) 3 (+5421 %; t=2,57;
p=0,01), F7 (+3514 %; t=2,50; p<0,02) Fp1
(+5021 %; t=2,38; p<0,02). F8
, (+8950 %; t=1,78;
p>0,05). Fp2, F4, C3 F3
- 10887 %
. -
125 % ( 434 484 ; t=2,40; p<0,02)
- .
, 184 % (
35,13,7 29,02,5; t=4,50; p<0,001).
- , : Fp1
(+4318 %, 13,31,1 18,41,7; t=2,39; p<0,02),
F7 (+299 %; t=3,22; p<0,01), F8 (+2814 %; t=2,00;
p=0,05) , , F4 (+2413%; t=1,85;
p>0,05). (
115 %, 4,90,1 Hz 5,40,2 Hz; t=2,20; p<0,05),
1034 %, 938 % .
- : F3 (+3410 %, 603 786;
t=3,40; p=0,001), F4 (+3010 %; t=3,00; p<0,01), Fp2
(+299 %; t=3,22; p<0,01) Fp1 (+2710 %; t=2,70;
p<0,01), C3 (+299 %; t=3,22; p<0,01) 3
(+258 %; t=3,13; p<0,01). , , .
. 2013. 2
275
,
- , 1 ( 93 %, 694 623; t=3,00;
p<0,01), T6 (-83 %; t=2,67; p<0,01), 3 (-63 %;
t=2,00; p=0,05) 3 (-63 %; t=2,00; p=0,05),
12
96106% .
104 % ( 13,91,3 12,21,1; t=2,50; p<0,02)
- 31 % ( 8,50,2
8,20,1 ; t=3,00; p<0,01) , (+54 %).
,
,
, , ()
. 84 (
4 ,
, , , 16 ) 56 (28 28 ). forward stepwise. 15 (
): - 14 -(4),
-(4), -(3) -(3) . ,
82,4 % , ,
(R=0,908;
Wilks =0,175; 2(15)=81; p<10-6).
Mahalanobis 18,8
(F=12,6; p<10-6).

7 .
( ),
. , ()
-4,5-0,3.
,
401 , ,
+1,7+4,0. , 792
,
(+0,1+3,1),
. 1214
+1,0+3,3,
.
(+1,3+2,4) 1667 . -
276
, 15 ,
-2,130,20
+2,130,17.
, (n=4) . , I : -1,60,8 +1,30,5
(p<0,02); II: -2,00,3 +1,80,3 (p<0,001); III: -3,10,4
+2,80,4 (p<0,001); IV: -2,30,7 +2,70,5 (p<0,01);
V: -1,90,3 +1,80,2 (p<0,001); VI: -1,70,3 +2,20,2
(p<0,001); VII: -2,40,8 +2,30,7 (p<0,01).

,
.
,
(
). ()
,
( )
.
100 %.
- ( )
12 % 7 % .
. , VI (), , ,
,
,
. , VII (),
, , 0,13 . ( -0,13 0,00). , ( -0,09 +0,03) II (), ,
I (: )
( 0,10 0,02).
, ,
,
, 3
,
.
VII ( ).
. 2013. 12

. .

-
.
-
. ,
, .
.
: . .
.

,
.
, 0,3800,400 .
()

() 500 / (F. J. Dixon
., 1961). ()
11 . () (3,5 %; 5 %;
7 %).
()
() (Horost H.J.,
1965).
,
(, 2001).
.
(<15S; <0.01),

. ,

.
, , 13 % (<0,05),
70 % (<0,001). ,

,
. , .

.

, .

, ,
.
,
. -,
.
. 2013. 2
277

. .
. .
- ,
, / , ,
,
. , , ,
. ()
. ,
, , , .
,
, .
.
, , .

. ,

.
, ( , ) (), . : 0,5 /,
5,0 /
278
. ,

.
, , ,
,
.
.
.

.
, ,
. .
,

, ,
.
,

. ,
, , ,

.
. 2013. 12

. . , . . , . .

(3, 4) , , ,
, .

.
L-, .
,
, 10 /. , ,
10 /, 140 /. (4),
5 .
().
() .

.
-
.
1,74 (<0,01).

, .
() 49 ,
N/r 46-41 . 49 ,
, .
(49 )
,

.
, ,
. ()

, , .

. .
. . .
,
- (-)
- .
4 : ,
,
, 15 -
-
, , ,
. , . ,
, ; -
. 2013. 2
279
,
,
,
, -
. ,
, .
15,9 % 144 %,
16,5 %
. (
1,41 %) 23,8 %,
41,8 %, 25,53 %,
25,71 % .
6,75 %, 38,15 % - 38,71 %
,
.
,

5,9 %
15,8 %, 28,8 %, 5 %, 15,66 % . 11,44 %
.
9,96 %, 10,46 %, --
33,53 %
.
.
- :
,
10,8 % 41,07 %, 10,3 %
6,16 %,
18,07 % 11,24 %,
10,13 %, -
39,59 %
32,24 %;
11,4 % 43,38 %,

11,38 % 6,29 %,

19,6 %
11,48 %, 9,92 %,
-
43,7 % 36,84 % ,

.
-

. .
. .
-

, .

- .

,
.
280

.
-
.
,
- ,
, . -
. 2013. 12

. ,

.
,
.

,
.

. .
. .
,
-. ,
.
,
.

() .

-, HCl, pH 1,2 1,0 -1
. 2, 6, 12 24
.

- ,
(254-280) ().
10 % . .
.

, -
. 12 ,

12,6 % (<0,05). ,
6 ,
12 , 24 , .
12 . .
, , , ,
.
.

, ,
. .
,
, 3,3 %

.
12 , .
. ,
, ,
2,5 %.
.
. 2013. 2
281
,
, -
, - .

. .
. .
-

, , .
, . ,
. , , , , , , ,
.

--

.
62 180210 .
0,5 /
7 ,
5%
1,0 100 .

7, 14, 30
- .
,

, . , ,
.

.

. .
. .
.
,
.
282
: .

- 200300 .
. 20
, 17
(),
. 2013. 12

, 16 ,
.
,
0,9 % , 12,5
40 % 1 .
- .
() . .
(1975 .).
. .
2
( 0,6350,036 0,5260,020 . .),
17,2 % (<0,05), 7 0,5740,004 . ., (<0,05) (>0,05).
,
2
7 , - .
612.015.11:616.712001.36
. .

, , ,
.
.
73
20 68
,

. . . .
12 (10,75-33,5 ) . ()
- , ()
.
,
,
. . 5 , 3 .
. ROC- -

.
, 20 % 50 % . . 100 %

.

,
, . ,

,
ISS, , RTS.
,

.

, , ,

,
-
. 2013. 2
283
, , ,
, .

.
,
50 %

.
. -
,

. 12
. ,

.
12
, , .
-

. . , . .
, .
. ,

. ,
, , , ,

.
, , .
- ,

, , ,
- .

, ,

.
-
.
-. ( , ) 284

.
,

(NO),
,
.

. ,
NO -
.
-
.
- ( ), ( )
( ) .

2 .

1, 3.
1 2 ,
3 .
. 2013. 12

,
2,7
2,3 .
,
.
,
.

:
. . , . .
Pomeranian University, Supsk, Poland
L- /
.
NO-
- .

(30 /, 2 ).
L- (600 /)
, N--L- (L-NNA, 35 /),
30 - .
-
0,200,22 , :

. . (1975). .
0,35 () 1 - (),
3 , 3 , 2,5
( ) (10
2 , ). 200 A. : ( 3 , V3)
( 4, V4)
, (V3/V4),
(A/)
(V).
,
, ,

.

. L-

,
NAD-
. NAD- FAD-
L- ,
NO (), ,
.
NAD- , . - :
.
NO
.
N--L-
, L-, . , /,
, , , -
. 2013. 2
285
,
. , .

.

NAD- ,

.
, - . -
, NO, .
, - ,

NO-. NAD-
.
NF-KB

. . , . .

()
,

- () - () NF-B. ,

-. NF-B

(). ,
NF-B
Wistar
() .
. 70 Wistar, 7 :
( 1); ,
1 ( 2);
, 2

( 3);
286
1 2,
() (Can) ( 4 5,
); 1 2, () (Lb) ( 6 7, ).
Nf-kB+-
NF- (SantaCruzBiotechnology,
). () () , (),
.
. Nf-kB+
: 1,82 (<0,05);
5291% (<0,05); 8992% (<0,05),
Nf-kB .
Nf-kB+- (
Can 26 %, <0,05; 33 %, <0,05;
27 %, <0,05 1; Lb
46 %, 1 50 %, 2;
. 2013. 12
17 %, 2), ( Can 2
Nf-kB+- 54 %, <0,05;
Lb 1 29 %),
Nf-kB
.
. , -
Nf-kB . , , ,
, - .

. . , . .
. .
-
. , , .

.

.
.

. .
150180 .
1 /.

1
.
,
32 %.
,
.

. . , . . , . . , . . ,
. . , . .

,
()
.
.
, .

, .
,
. 34
36 50 .
.

Tanita 600B ()
,

. 2013. 2
287
.
().
LF (2), HF(2), VLF(2).
-
LF/HF
(, 2).

.
, VLF
VLF% (r=0,37, p<0,05 r=0,41, p<0,02),
HF (r=0,31, p<0,05 r=0,45,
p<0,01) LF(r=0,29, p<0,05).

. , HF,
LF, VLF TP : 0,59 (p<0,01),
-0,61(p<0,005), -0,55 (p<0,01) 0,73 (p<0,001).
,

.

. . , . . , . .
. .. ,
()
.
58 -
Wistar 240290 , 10
, ,
6
1,5 % .
.
.
Ca (Ur)
Mg (Cr),
(L) : L=(CaUr/
MgCr)0,25. , ()
L 1,220,08 (0,901,66).
, L 42 %
701% (8062 %) , 826 % Ur 664 %
Mg 16012 % Cr 1185 % .
, 33 % L ,
82118 % , 25 %
1375 % (121176 %) , Ur 15517 %
Mg 408 %
Cr. L Mg
(r=-0,74), Ur (r=0,58)
(r=0,33) Cr (r=-0,30) . 288
L Ur (r=0,34) (r=-0,35) () (r=-0,67).

() : CTA=(CauPu/
CapPp)0,25. 3,380,41 .
L
923,6 % , L
12813,7 % , ,
1197 % L.
L
(r=0,56).
, L
4655 / 60739 / , 771 %
,
2,650,05 / 2,090,16 / ,
1272 % . , L 18911 %
3 912 % .
L 903 % , 1051 % .
(r=0,90) (r=-0,90) .

-

. 2013. 12
. , 25 % - Selye.
42 %
- , 33 %
.
,
- - .

80100 %.

NO-/
. . , . . , . . ,
. . , . .

, . ()
, . NO-/ .
46
180200 ,
. - () .
: (); ,
; ,
-1/-2 10 /;
, -2
10 /; ,
-2/5- 2--5-(3,5--4-)--4- (25DHT) (10 /),
.
() () NO-;
, . - .
ANOVA Statistica. <0,05.
, iNOS 4,6 6
(<0,01) NOS (
65 % 34 % )
( 42 % (<0,05) 16 %, ; -
- 1522 %
(<0,05). -1/-2 iNOS 49 % (<0,05),
57 % (<0,05). NOS 81 %
(<0,05). ,
-
. -2
iNOS
,
NOS . -
.
-2/5-
- , -, , iNOS ,

.
. 1. iNOS ,
.
2. -1/-2
iNOS,
. 3. -2 iNOS,
, NOS
, ,
-2/5-
iNOS, -2
.
. 2013. 2
289
616.441-008.61-036-055]-092.9

. . 1, . . 2
. 1,
. . 2

,
,
(
), . ,
,
. -, ,
,
.

,
.

.
L- ,
,
,

, . , ,
,
, . ,

. ,
.

.
, ,
, ,
.

. . 1, . . 2
.1,
.. 2
, ,
,
1015 . , .

.
(1, 2, 3 .) (50 /)
.
290
()
.
, ,
.
,

. - - , .
. 2013. 12
,
,
. .

, .

. . 1, . . 2, ..2
. 1,
. . 2
, , , . ,
,
. , , .

.
.

.
150180 .
1 /. (80 /),

(
)
(40 /). (0,1 /) + (0,5 /.)
(2 /)
.
(50 / )
10 , 50 , 1 , 1 .
, - (
L-arginin)
( L-NAME). , ,
, . ,

.
, ,
, ( ).
, L-arginin .
. 2013. 2
291
616.12:577.175.522-06:616.12-008.318-085.357]-092.9-055

. . 1, . . 2, . . 2, . . 2
.1
. . 2
, ,
, . , .

.
- . ,
. , , .

.

.
1 .
1, 24 , 3 7

. ( , ), (% ,
), ( ) ( ,
). ,
, .

, .
.
,
.
.
,
- .
. . -, . .
. .
. 50 % .

,
.
,
.
, stratum corneum
292
, .
. ,
,
, .

. ,
. 2013. 12

. ,
NO-
.
, NO-,
.
615.065+615.21
,
, -
2007-2012 .
. .
-
344
() (),
,
()
- 2007
2012 ,
-
, .
(42 %)
, 17 % , 14 %
, 5 % 5 % , .
, (64 %)
36 % , ,

. 64,5 % ,
31 60 (52,6 %), 1,8 .

,
, (
1111,6 %),

( )
.
, , 17,6 % 34
.

. . , . . , . .
. .

,
(),

.
.

, -
.
2-
40 (1 /) E. Coli (SigmaAldrich, ).

, :
, -
. 2013. 2
293
,
, , ,
, , , , .
14 .
, -
,
,
.

.
, ,

.
. . , . .

. ()
,
.

. ,
. ,
.
, ,
. ,
/ ,
, .
: .
.
56 .
51 5 , 57,011,4 .

(,
). .
294
. , 12
(21,4 %) (, , , : , , , ). (n=7, 12,5 %)

( 350
5 ).
(n=16, 28,6 %)
. 6
(10,7 %) (1
2 ). 12 (21,4 %) , . 3 (5,4 %) .

(83,3 %), (85,7 %).

(65,3 %).
. , .
.
. 2013. 12

. . , . . , . . , . .
. .

.

.
, - ,
.
, , , .
, , , .
- , -
. ,
, , . .
: 1.

; 2.
; 3.
. ,
,
, , , ,
,
.

. . , . . , . .

()
, . ,
, , .
.

( , , ),
(, , , , ), ,
, .
,
.
.

().
. , (), , ,
. , ,
. () .
, , , .
.
. 2013. 2
295
,
0,3800,400 . . . , . . (1985):
0,2
. 0,2
. ()
24 ( ).
()
() (). , .
,
(, 2001).
.
, , 95 % (<0,05),
65 % (<0,001).

. ,
296
72 % 59 %,

40 %, . ,

. , ,
,
, , ,
.

. , . , --, ,
.
,
.
. 2013. 12

1. , , , , , , , .
, , , , ,
, , .
2.
, . : ,
: , , , , , ,
, , (-ml) , .
3. , , , , , 8 , , , 12 , ,
5 , 3 .
4. 4 18002000 (: 2,5 , 3 , 1,5 , mes New
Roman 14 ). 2
CD *.doc, *.docx, *.rtf.
JPG, TIF, CDR, ,
. 300 d.
. ,
, .
. , . .
.
, soft . .
Microsoft Equation.
5. 3008-95 .
. ( ,
, , , , ):
( )

. ( ,
, , ,
, )
.
. ( ,
.
, , , , , . )
. ( , , ,
, )
.
. 2013. 2
297
. (
, )
( )
( , )
( )
( )
( )
( )
, 2 . (
).
6. , ()
3651-97 . , .
7.
.
8. ,
( ,
, ). 3 .
: , ( ), , , , , , .
.
9. , , .
10. , , .
, , .
11. . 31 1800 (1 .).
, .
12. :
, .. , , 1, 46001, ,
.
13. :
: ..
02010830
/ 31252273210444 .,
838012
.
298
. 2013. 12

Zkem 2 2013

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Zkem 2 2013

Uploaded by

Copyright:

Available Formats

. . .

SHEI Ternopil State Medical University

O. Ya. Shuturma, N. Ye. Lisnychuk, . . Dovhalyuk

1. 2012 focused update of the ESC Guidelines for the

A.J. Camm, P. Kirchhof, Y.H. Gregory [et al.] // Eur. Heart J.

24. Mauro Biffi. Atrial Remodeling: Evolving Concepts

STRUCTURAL HEART REMODELING IN ATRIAL FIBRILLATION PATIENTS

(SIGMA Chemical, ) 50/.

: p<0,05 (*), 2- (#).

6. Dietary fat stimulates endogenous enkephalin and

FUNCTIONAL STATE OF LEU-ENKEPHALINERGIC SYSTEM OF HYPOTALAMIC

7080 % [4], 6490 %,

Gastroenterol. 2009. Vol. 15. 2. . 8694.

ASPECTS OF DIAGNOSIS OF ACID DISEASES

5. The quality of in-house medical school examination /

SUBSTANTIATION OF EFFICIENCI TEST EXAMINATION AS AN IMPORTANT STAGE

8. Serum and hair levels of zinc, selenium, iron, and

. 2012. 2 (42). . 1824.

MICROLEMENTS BALANCE IN CASE OF IRON-DEFICIENCY ANAEMIA

3 NOS 4 ( < 0,05),

and inhibition / W. K. Alderton, C. E. Cooper, R. G. Knowles //

CHANGES OF LIPID PEROXIDATION PROCESSES, NO-SYNTHASE SYSTEM

: 1. * p<0,05; 2. ** p<0,01; 3. *** p<0,001, .

FEATURES OF CARDIOINTERVALOGRAPHY WITH CARDIOMYOPATHY

1 22 = 234 2 8 + 467 2 8 234 5

1 243 42 = 234 8 467 8 (9 234 )5

M1(Z34), M2(Z34), M3(Z34) M4(Z34) .

  91 89 89184 9861

. 2. N(Z34=1)1 "-" Z34 -

  91 89 89184 9861

  91 89 89184 9861

geneous surface and layers / A. O. Agelskaya, Yu. A. Ushenko,

DIAGNOSTICS OF ACUTE CORONARY INSUFFICIENCY BY MEANS OF THE METHOD

616.895.87 085.214.2] 036.8

- (35,3 %) , (92,4 %),

(82,4 %), ( (84,1 %), (75,5 %), (72,2 %)

INFLUENCE OF COGNITIVE DEFICIT ON SOCIAL FUNCTIONING OF PATIENTS

. [6; 9; 13; 14]. . , , .

USE OF MODERN ANTIMICROBIAL AND ANTI-INFLAMMATORY TOPICAL

EFFECTS OF ANTHROPOGENIC POLLUTION ON MUCOSAL IMMUNITY

ULTRASTRUCTURAL ENAMEL AND DENTINE FEATURES OF HUMAN PREMOLARS

CLINICAL AND LABORATORY STUDY OF EFFICIENCY LICORICE ROOT

11. Donald D. A. The distribution of blood to the

FEATURES OF BRAIN CIRCULATION IN RATS IN NORM

MORPHOLOGICAL AND FUNCTIONAL STUDY OF POLISORB PREPARATION

26 2648 488

CYTOKINE PROFILE IN PREGNANT WOMEN WITH METABOLIC SYNDROME

PROSPECTS OF QUERTIN USE UNDER CONDITIONS OF CHRONIC DRUG

(2-4<0,001) , 5 fT3 ( , 2-5<0,02)

CHANGES OF INDEXES OF LIPID METABOLISM IN RATS WITH HYPOTHYROID

(m). Excel (Microsoft, ),

FEATURES OF CURRENT FREE RADICAL PROCESSES AND ANTIOXIDANT SYSTEM

616-056.5: [616.12-008.331.1 + 616-056.52 + 616.13.002.2-004.6 + 616.379-008.64]

(), (), (),

8 73 893

1. . . 2 / . . , . . , . . // Consilium medicum. 2006. . 8. 5.

I. Lughetti [et al.] // J. Clinic. Endocrinol. Metabolic. 2005.

[et al.] // J. Clin. Rheumatol. 2004. Vol. 10.

Standing Committee For International Clinical Studies

MORPHOLOGICAL AND FUNCTIONAL CHARACTERISTIC OF THE MYOCARDIUM

1. Wetzel M. A. Sediment pollution in the Elbe estuary

RELATIONSHIP BETWEEN PARAMETERS OF SMALL INTESTINE PEYERS PATCHES

EFFECTIVENESS OF COMBINED USE OF ABSORBENT POLYURETHANE AND

: 1. * p<0,05; 2. p<0,01; 3. * p<0,001, .

91 89 891849861

91 89 891849861

91 89 891849861

26 2648 488

8 73 893

32983298

32983298

!

96592 96

1894 54

793 65